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ABSTRACT
FIBRINOGEN-CONJUGATED GOLD-COATED MAGNETITE NANOPARTICLES
FOR ANTIPLATELET THERAPY
by
Evan Krystofiak
The University of Wisconsin-Milwaukee, 2013
Under the Supervision of Professor Julie Oliver
Ischemic stroke is the world’s second leading cause of death and accounts for 2-4% of
total worldwide healthcare costs. Ischemic stroke is caused by the occlusion of arteries
responsible for supplying blood to the brain, which can result in disability or death.
Arterial blood clots consist of aggregates of activated platelets wrapped in a mesh of
fibrin. Tissue plasminogen activator, the only current FDA-approved treatment for
ischemic stroke, functions by lysing fibrin in a blood clot. Unfortunately, tissue
plasminogen activator significantly increases bleeding risks, which restricts its use.
Alternatively, targeting and disrupting platelets within a clot could improve stroke
outcome. To test this hypothesis, we have developed a targeting system utilizing
fibrinogen to specifically target nanoparticles to activated platelets. Human fibrinogen
was evaluated for targeting both human and murine platelets under conditions that are
similar to an in vivo blood clot. Our results indicate that human fibrinogen conjugated to
gold nanoparticles was capable of targeting activated human and murine platelets.
Further, human fibrinogen conjugates bound to preformed platelet aggregates while in the
presence of plasma levels of unconjugated fibrinogen. To disrupt platelets, we developed
a system to cause localized hyperthermia to the platelet surface by utilizing inductively
heated magnetic nanoparticles. Magnetic gold-coated magnetite nanoparticles were
synthesized and characterized. The morphology of the gold-coated magnetite product
ii

differed substantially from the expected core-shell structure often reported for such
nanoparticles. Despite the unexpected morphology, the nanoparticles could still be
functionalized with protein and targeted to activated platelets. Localized hyperthermia
was created when platelet-bound, fibrinogen-conjugated, gold-coated magnetite
nanoparticles were exposed to an oscillating magnetic field. The effects of the
hyperthermic treatment to surface-activated and aggregated platelets were evaluated by
electron microscopy. The treated platelets demonstrated considerable structural damage,
with the cell membrane showing significant disruption when compared to controls. A
method to quantify platelet damage was developed and utilized to refine the length of
exposure to the oscillating magnetic field and dose of nanoparticles. In the future, it may
be feasible to use fibrinogen-conjugated, gold-coated magnetite to target and disrupt
platelets in a thrombus in vivo, thereby restoring blood flow to ischemic brain.
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Chapter 1: Development of a novel treatment for ischemic stroke
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Statement of the problem: Impact of stroke:
A stroke can be defined as a disturbance in blood supply to the brain that causes rapid
loss of brain function. The result of most strokes is the infarction of tissue in the brain
that can quickly lead to permanent brain damage which can cause disability or death (1).
Stroke is the fourth leading cause of death in the United States (2) and the second cause
of death worldwide (3). Many stroke survivors develop permanent physical and/or
mental disabilities, including loss of mobility, speech, and emotional control. Strokes
account for an annual cost of $25 billion in the United States (4) and 2-4% of the total
healthcare costs globally (5), with large long term costs to society caused by disability
and loss of work hours (6, 7). Despite the enormous impact of stroke, current treatments
are extremely limited and new approaches to therapy are profoundly needed.

The majority of strokes are ischemic (see Pathology underlying stroke) and caused by an
arterial blood clot that blocks delivery of oxygen and nutrients to tissue downstream of
the vascular occlusion. Arterial clots are composed of a combination of platelets and
fibrin, both of which are potential targets for stroke therapy.

Platelets as a target for stroke treatment:
Blood clots form when an activation event triggers the blood coagulation cascade
proteins and activates platelets. The blood coagulation cascade produces the serine
protease thrombin which converts the plasma protein fibrinogen to fibrin. Activated
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platelets stick to one another at the injury site to form a platelet aggregate in a fibrinogendependent process. The blood coagulation system works with platelets to form an arterial
blood clot, shown in Figure 1. Under pathological conditions, inappropriate activation of
the coagulation cascade (fibrin generation) predominates on the venous side of the
vasculature, while inappropriate clotting on the arterial side depends on a combination of
platelets and fibrin (8, 9). The majority of ischemic strokes occur in arteries within the
brain and thus consists of a blood clot that contains both fibrin and activated platelets.
The current ischemic stroke therapy lyses the fibrin component of the blood clot to
attempt to dissolve the occlusion and restore blood flow.

Targeting the platelet component of the blood clot may provide an alternative and
possibly superior method of disrupting blood clots in ischemic stroke. Inhibition of
platelet activation is used successfully to prevent further thrombotic events in patients
who have already had previous complications such as ischemic stroke or myocardial
infarction. Platelet activation inhibitors such as acetylsalicylic acid (aspirin) (10) or
clopridogrel (Plavix®) (11); or preventing platelet aggregation by blocking the platelet
fibrinogen receptor (12, 13), have been shown to be effective in preventing heart attack.
The use of aspirin to inhibit platelets, together with warfarin to inhibit the blood
coagulation cascade, has been shown to reduce embolic risks in patients fitted with
artificial heart valves (14). The effectiveness of these preventative treatments
demonstrate that anti-platelet therapy can be a powerful tool in precluding arterial blood
clotting.

4

Normal platelet physiology:
Platelets are circulating cell fragments that primarily function to maintain normal
hemostasis. Platelets are derived from the bone marrow where they fragment from
resident megakaryocytes and are released into the blood (15-17). Mammalian platelets
normally lack a nucleus and much of the cellular machinery found in other cells but
retains membrane, granules, and mitochondria that originated in the parent
megakaryocyte. The lack of a nucleus results in the platelet having very limited ability to
synthesize new protein during its entire lifespan. As a result, irreversible inhibitors such
as acetylsalicylic acid can permanently impair the platelet proteins they bind to, having
long lasting effects.

The morphology of resting platelets in circulation is discoid. This morphology is
maintained by a ring-shaped bundle of microtubules at the platelet periphery, known as
the circumferential band of microtubules. The platelet interior is filled with two types of
granules. Degranulation occurs during platelet activation, allowing the contents of the
granules to participate in hemostasis and wound healing. Platelet alpha granules contain
growth factors and proteins important for blood clotting such as thrombospondin, von
Willebrand factor, and fibrinogen (18). The adhesion molecule P-selectin (CD62P) is
sequestered in the membrane of the alpha granules, and is exposed to the surface only
upon membrane fusion that occurs during degranulation. CD62P recruits leukocytes
expressing P-selectin glycoprotein ligand-1 to the site of platelet activation as an
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inflammation response (19). Additionally CD62P can be used as a marker for platelet
degranulation to determine platelet activation level (20).

Platelet dense granules are named based on their appearance in electron micrographs, and
contain soluble mediators such as serotonin, adenosine diphosphate (ADP), and calcium
(21). Platelets also contain a network of membrane invaginations that extend throughout
the platelet interior, known as the open canalicular system (OCS) (22). The OCS is
continuous with platelet surface membrane, increasing the platelet surface area that is
available for interaction with its outside environment and acting as a reservoir of platelet
plasma membrane. These features in resting platelets are shown in Figure 2.

Upon exposure to a stimulus the platelets become activated which causes a myriad of
changes in platelet physiology. The platelet cytoskeleton undergoes extensive
rearrangement causing the shape of the platelet to change from discoid to a rounded ball
and creating pseudopodial extensions (23). The extent of the shape change and extension
of the pseudopodia is directly dependent on the platelet activation pathway (24). Platelets
exposed to an activating surface will spread over that surface, flattening out and greatly
increasing the apparent size of the platelet (23, 25). Strong activation signals will elicit
platelets to release their granules into the extracellular environment (20). The granule
contents can then recruit other platelets into an activated state (26), promote the blood
coagulation cascade (27), and promote healing by release of growth factors (28). The
platelets also become competent to bind fibrinogen which allows platelets to crosslink to
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one another, forming a platelet aggregate (Figure 3); this process is described later in this
chapter.

Platelet activation pathway:
Platelet activation can be caused by a variety of agonists or contact with a charged
foreign surface. Physiologic agonists include adenosine diphosphate (ADP) (29-31),
epinephrine (30, 32), thombin (30, 31, 33) and collagen (30, 31, 34, 35), with the latter
two being the dominant platelet activators in vivo.

Platelet activation pathways make extensive use of G-protein coupled receptor signaling
with the Gi, Gq, and G12/13, subunits. Gi functions by blocking adenylate cyclase
activity within the platelet, preventing production of cAMP. Gq activates phospholipase
C- which cleaves membrane phosphatidylinositol 4,5-biphosphate into inositol
triphosphate and diacylglycerol; these molecules then cause calcium to be released into
the cytoplasm. G12/13 activates the small GTPase Rho which goes on to cause
cytoskeletal rearrangement. The signaling via G-protein couples receptors for common
platelet activation and inhibition pathways is depicted in Figure 4.

Each platelet activation pathway has its own unique receptors and pathways but converge
into a single common activation pathway (36). In the common pathway phospholipase
A2 cleaves phospholipids in the platelet membrane to produce arachidonic acid. The free
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arachidonic acid is converted to proinflammatory thromboxane A2 (TXA2), prostacyclins
and prostaglandins in a cyclooxygenases COX-1 and COX-2 dependent manner (37).
TXA2 then binds to the G-protein coupled thromboxane receptor. Activation of the
thromboxane receptor activates Gq and Gi (38, 39). The resulting drop in cAMP
production and calcium influx triggers many cellular responses, including the
cytoskeletal rearrangement and degranulation discussed above, and the conformational
change of receptors on the platelet surface.

Thrombin signals through a family of G-protein coupled receptors called the protease
activated receptors (PARs) (40, 41). These receptors have a protease cleavage site near
their C-terminal. Once cleaved, the newly exposed C-terminal becomes a tethered ligand
for itself (42, 43). The primary thrombin receptor in humans is PAR1, with PAR4 acting
as a secondary thrombin receptor (41). Mice lack PAR1 and utilize PAR4 as their
primary thrombin receptor (44). When studying platelets it is often desirable to activate
the PAR receptors to promote full platelet activation but to avoid proteolysis. The PAR
receptors can alternatively be activated with synthetic peptides of the sequences
corresponding to the tethered ligand portion of the receptor. For activating platelets, the
human PAR1 peptide SFLLRN-NH2 and the murine PAR4 peptide AYPGKF-NH2 can
be used as agonists (45, 46). The PAR1 and PAR4 couple to many different G proteins
including Gq and G12/13, PAR1 additionally binds Gi (47, 48).
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Collagen signaling occurs through the platelets’ primary collagen receptor glycoprotein
VI (49) and a secondary receptor, the integrin 21 (50). Signaling events lead to
activation of phospholipase C2, which leads to increase in cytoplasmic calcium levels
(50, 51). The signaling response is most similar to the foreign surface activation pathway
in which the platelet encounters a highly charged surface that does not exist in the
vasculature. In vitro the foreign response pathway is used to create surface-activated
platelets by exposing platelets to glass, polystyrene, or formvar surfaces which is a useful
system in studying platelet/protein interactions (52-55).

Platelet degranulation releases ADP into the platelets’ surrounding environment. This
ADP recruits neighboring platelets into an activated state by signaling through the Gprotein coupled puringergic receptors P2Y12 and P2Y1. P2Y12 couples to Gi (56) and
P2Y1 couples to Gq (57). ADP contrasts with thrombin or collagen in that ADP itself
does not typically cause the initial platelet activation event, but rather supports the growth
of the secondary platelet response (26).

Platelet activation can be inhibited by preventing activation signals from propagating
through the platelet, which is of interest both clinically and for understanding platelet
function. Platelet activation can be prevented by the use of calcium chelating agents such
as EDTA and sodium citrate. These agents are commonly employed as anticoagulants
during venous blood draws to prevent platelet activation and blood coagulation cascade
activation. Platelets that have been chelated of external calcium will require the
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supplementation of calcium ions before they can become competent for activation again.
Prostacyclin (PGI2) is produced by endothelial cells using a similar pathway to TXA2 but
has the opposite effect and is thought to modulate the platelet activation response. PGI2
binds to the prostacyclin receptor (IP) which activates adenylate cyclase resulting in
cAMP production (58-60). The increased cAMP production prevents platelet activation
(61, 62). Platelet activation may also be prevented by drugs that inhibit the COX
enzymes in the thromboxane pathway such as acetylsalicylic acid and non-steroidal antiinflammatory drugs (37). Treatment with COX inhibitors results in the impairment of the
platelet activation system by physiological activating agents.

Platelets and fibrinogen:
Fibrinogen is a 340 kDa plasma dimeric glycoprotein found at a relatively high
concentration of 3 mg/mL in human blood. Fibrinogen monomers consist of three
polypeptide chains (alpha, beta, and gamma), that are connected through a series of
disulfide bonds to form a fibular protein (63). Fibrinogen is vitally important for both the
blood coagulation cascade and platelet aggregate formation. In the blood coagulation
cascade, thrombin cleaves protective peptides off the ends of the fibrinogen alpha and
beta chains (64). With the protective end cap sequence removed from fibrinogen the
newly created fibrin spontaneously polymerizes with other nearby fibrin molecules
creating a dense meshwork around a site of injury. Fibrinogen has just as significant a
role in platelet response to injury. Platelet activation leads to fibrinogen binding which
allows the platelets to become cross-linked to one another to form an aggregate, a vital
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step in the normal arterial bleeding response. As a result, fibrinogen binding to its
receptor on activated platelets has been extensively studied and characterized (54, 65-69).

Platelets bind fibrinogen through the integrin IIb3, also known as glycoprotein IIb/IIIa
(70). IIb3 is capable of both integrin inside-out and outside-in signaling. Inside-out
signaling occurs during platelet activation when interactions between talin (71, 72) and
kindlin (73) cause the cytoplasmic tails of IIb3 to separate (“inside”) causing a
conformational change on the extracellular side of the integrin (“out”), which makes it
competent to bind fibrinogen (67) in a calcium-dependent manner. This inside-out
signaling is heavily dependent on platelet activation (65). Once activated, IIb3 is
capable of binding to a single fibrinogen binding site. The second fibrinogen binding site
on the dimer is free to bind to an additional IIb3 on the same platelet or on an adjacent
activated platelet, crosslinking platelets together and forming a platelet aggregate.
Outside-in integrin signaling occurs after IIb3 binds fibrinogen and crosslinks adjacent
receptors (69, 74, 75). The fibrinogen cross-linked receptor centralizes on the platelet
membrane under the direction of the underlying platelet cytoskeletonThe final location
of the migrated cross-linked receptors is dependent on the activated morphology of the
platelet. Surface-activated platelets will centralize fibrinogen on the platelet surface to
the vicinity of the granulomere, a structure created by unreleased platelet granules often
located near the center of the platelet. Platelets activated in suspension or platelets
participating in an aggregate will use fibrinogen to produce platelet/platelet junctions
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where platelets have become cross-linked together or move bound fibrinogen within the
OCS of the platelet (76).

The binding of fibrinogen to its receptor is essential for normal platelet function.
Mutations in IIb3 that prevent fibrinogen binding or blockage of IIb3 by antibodies
prevents platelet aggregation (77-80). One such antibody, abciximab, has been shown to
be effective in preventing thrombotic events during percutaneous intervention (13, 81,
82) but has failed to show significant benefit in the treatment of ischemic stroke (83, 84).
These trials demonstrated the importance of fibrinogen/IIb3 interactions in arterial
blood clot formation but also the limitation of using an antibody to disrupt a preexisting
blood clot.

The interaction between fibrinogen and IIb3 provides a potentially powerful mechanism
to specifically target the platelets in a blood clot. IIb3 on platelets has been targeted
using arginine-glycine-aspartate (RGD) peptide sequences (85, 86). However, fibrinogen
may prove superior to RGD peptides because it is thought to only bind to activated
platelets that have competent IIb3, which creates a method to distinguish between
quiescent circulating platelets and activated platelets. This method of targeting would
also be superior to IIb3-directed antibodies like abciximab, which do not select for
activated IIb3, and have systematic effects on all platelets. Fibrinogen conjugated to
gold nanoparticles has been successfully used to study the fibrinogen/IIb3 interaction by
electron microscopy (25, 52-55, 76, 87-89), suggesting that fibrinogen-conjugated
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nanoparticles can be targeted towards activated platelets. We propose that we could use
the full fibrinogen molecule to specifically target activated platelets in a blood clot.

Pathology underlying stroke:

Strokes are classified into two broad categories, hemorrhagic and ischemic. Hemorrhagic
stroke is caused from bleeding of a vessel within the brain. In hemorrhagic stroke, a
blood vessel wall weakens to form an aneurism which can further weaken until the vessel
wall ruptures. The resulting blood leakage into the brain may increase intracranial
pressure that can lead to neural damage. Further, exposure of neurons to high
concentrations of the blood coagulation protease thrombin causes apoptosis via signaling
through PARs (90, 91). The best available treatment for hemorrhagic stroke is early
detection of the aneurism before it ruptures and to undergo a surgical repair of the vessel.
After a rupture has occurred, treatment becomes more difficult. Attempts to repair the
vessel or to reduce intracranial pressure may be taken. Prevention of the hemorrhagic
stroke can be accomplished by reducing risk factors associated with high prevalence
which include hypertension (92, 93), cholesterol imbalance (93), and head trauma.

Ischemic stroke is the occlusion of a blood vessel supplying the brain, leading to hypoxic
conditions downstream of the blockage. Ischemic strokes are the most common form of
stroke, accounting for more than 80% of all incidences (7). Types of ischemic stroke can
be further broken down by cause of the occlusion. Embolic strokes are caused by
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embolism where a piece of debris forms somewhere in the body, is swept up by blood
flow, and then becomes lodged within a brain vessel. Debris often forms within the
heart, in an unclosed foramen ovale (94, 95) or a damaged heart valve (95, 96); or in
atherosclerotic arteries (95). Thrombotic strokes occur when an occlusive blood clot
forms within an artery in the brain. The most common cause for a thrombotic stroke is
the rupture of an atherosclerotic plaque, which initiates blood coagulation (97). Both
types of ischemic stroke produce the same outcome, a blood clot restricting blood flow to
the brain. The occlusion creates an ischemic core in the brain tissue which was directly
fed by the occluded artery. The deprivation of oxygen and nutrition causes a metabolic
drop in these cells which quickly leads to cell death by deregulation of cellular K+ and
Ca2+ ion gradients (98, 99). Moving outward from the ischemic core, affected brain
tissue is referred to as the penumbra (100). This area was only partially fed by the
occluded artery. These neurons become silent due to reduced metabolism and are at risk
of degradation as the ischemic stroke progresses. The organization of the occluded
vessel, ischemic core, and penumbra tissue within the brain in depicted in Figure 5. The
penumbra tissue may be restored to normal function if blood flow is safely restored in a
timely manner (101), leading to great interest in reperfusion of the penumbra as quickly
as possible (102).

Current treatments for ischemic stroke:
The only treatment for ischemic stroke currently approved by the FDA is recombinant
tissue plasminogen activator (tPA). The first generation product on the market carries the
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generic name alteplase (Activase®, Genetech). The drug is infused intravenously, where
it catalyzes the production of plasmin from the precursor plasma protein plasminogen.
Plasmin is a protease which lyses the fibrin meshwork within a blood clot, causing the
blood clot to dissolve, and restoring blood flow to the surrounding tissue, reperfusing
ischemic neurons. The treatment has produced positive outcomes in clinical trials (103105) but has temporal limitations to its safety and effectiveness (103, 106, 107). Infusion
of tPA causes systemic fibrin lysis not only at the site of ischemic stroke, but in other
regions of the brain and body, resulting in increased bleeding risks. The primary
bleeding risk associated with tPA is intracranial hemorrhage at the occlusion site or
downstream of the occluded vessel. For this reason treatment with tPA can treat an
ischemic stroke but cause a hemorrhagic stroke. Initial studies demonstrated that tPA
administered within 3 hours of stroke onset produced a statistically significant increase in
positive outcomes (103). More recent guidelines state that tPA administration up to 4.5
hours post onset improves outcomes in carefully selected patients (108-111). Treatment
with tPA after this time window results in poorer outcomes and particularly because of
increases in the risk of intracerebral hemorrhage (103). Treatment in this short
therapeutic window is difficult because the stroke patient must arrive at an emergency
room, be diagnosed with a stroke, and have hemorrhagic stroke ruled out.

Second generational tPA drugs have been developed to improve effectiveness. The
modified tPA drugs, reteplase (Retavase®, Boehringer Mannheim) and tenecteplase
(TNKase®, Genentech), have amino acid substitutions which were introduced to increase
their half-life in plasma. The increased half-life of the drugs allows more active drug to
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reach the occlusion site and allows plasmin production over a longer time. Of tPA drugs,
only alteplase is approved for treating ischemic stroke, reteplase and tenecteplase have
undergone clinical trials to determine their effectiveness (112-114). It is unlikely that the
increase in half-life of the newer tPA drugs will ablate the hemorrhagic risks already
associated with tPA treatment, meaning the treatment window for administration of tPA
is unlikely to change.

The FDA has approved the mechanical retrieval of blood clots in large blood vessels,
using the MERCI Retrieval (115) and Penumbra devices (116). The MERCI device
utilizes a catheter system with an expandable heat activated NiTi memory wire, the wire
captures the blood clot which can then be pulled out of the artery (117). The Penumbra
system utilizes a catheter to apply suction to a thrombus, allowing for recanalization
(118, 119). These devices have less temporal restrictions than tPA and have been used
up to 8 hours after occlusion, however they are only available for blood clots occurring in
relatively large vessels and are not FDA approved for stroke therapy. The majority of
ischemic strokes occurring in smaller vessels may currently only be treated using
alteplase, with its temporal and safety limitations.

Development of targeted tPA:
Two general strategies have been attempted to overcome the limitations of infused tPA in
treating ischemic stroke. One strategy utilizes nano-systems to control tPA localization
or activity at the occlusion site using mechanical means. This strategy has utilized tPA
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that is associated with magnetic nanoparticles either by encapsulated tPA and magnetite
nanoparticles in liposomes (120), or by SiO2-coated Fe3O4 nanoparticles directly
conjugated to tPA (121). These treatments then propose utilizing an external static
magnet to direct the nanoparticles to the blood clot causing the stroke, with the intended
effect of limiting systemic effects of tPA by confining it to the desired site. A separate
system utilizing tPA conjugated to nanoparticle aggregates has also been developed.
Under normal conditions, the majority of the tPA is localized within the aggregated
nanoparticles, leaving little tPA exposed to the surrounding blood. Upon exposure to
high shear stress, such as occurs in a partially occluded artery, the aggregates break apart,
exposing tPA at the surface of the clot (122). Another method in development for
targeted tPA delivery to the occlusive clots utilizes tPA complexed to polyethylene glycol
grafted onto anionic gelatin which was reported to reduce the tPA activity. The
complexed tPA activity was restored by exposure to ultrasound at the site of the blood
clot which reportedly released the tPA from gelatin and allowed targeted therapy (123).
These studies represent innovative methods of localizing active tPA to the correct site but
may present issues with biocompatibility. Further, these systems may leave untargeted
tPA in circulation similar to the currently approved tPA therapy.

A second strategy utilizes molecular modifications to tPA that target the molecule to the
desired thrombus and/or modulate its activity. Methods to target tPA to platelets by
attachment of RGD peptide to tPA to target the platelet fibrinogen receptor (85) or
targeting blood clots by conjugating tPA with an anti-fibrin antibody (124) have also
been employed. These strategies suffer from the short half-life of tPA in vivo along with
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systemic tPA activity. More recently, attempts to target platelets with inactivated tPA
have utilized a complex system using tPA conjugated through electrostatic interaction to
human serum albumin (HSA) modified with RGD peptides to target the fibrinogen
receptor on platelets. The conjugation of tPA to HSA reduces tPA activity. Upon
addition of negatively charged heparin, the electrostatic interaction between tPA and
HSA is disrupted, dissociating the two proteins (86). The tPA is then active and free to
produce plasmin.

Nanoparticle-based targeted cell death:
While the tPA based treatments focus on lysis of the fibrin within blood clots, we propose
that targeted destruction of platelets within a blood clot may improve stroke treatments.
There has been much interest in the use of nanosystems to specifically target and destroy
specific cell types (125-130). The majority of this research has been focused on
development of anti-cancer therapies, however, the concept can be applied to any cell
types of interest that expresses unique targetable features. Typical therapies entail a two
part strategy. The first part of the strategy is to specifically target cell populations of
interest. Targeting can be performed through a variety of different targeting molecules
such as proteins, lipids, carbohydrates, or organic modifications that can specifically bind
to receptors or proteins on the cells of interest. Popular methods of targeting
nanoparticles to specific cells often conjugate antibodies directed against proteins
expressed on the cell surface or conjugation of ligands to nanoparticles that can target
specific receptors. Nanoparticle size can also be used to specifically target phagocytotic
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cells. Nanoparticles greater than 40 nm actively promote phagocytosis (131, 132).
Additionally, the size of the nanoparticle may also determine bioaccumulation sites
within the body, which is largely dependent on the ability of the nanoparticles to leave
the blood stream and whether the nanoparticles are phagocytosed (133-135). Careful
choice of a targeting strategy can allow for very specific targeting of a cell type, or even
selection between activated and unactivated cells of the same type.

The second part of the strategy relies on causing nanoparticle-mediated effects such as
death of the cells of interest. Nanosystem-based methods of causing cell death often
consist of cytotoxic agents or nanoparticles capable of causing cell death directly. By
combining cell targeting with a method of causing cell death, the nanoparticle effects can
be quite toxic or damaging as they will be confined to the targeted cells. An example of
such a system utilizes a functionalized liposome encapsulating the chemotherapy agent
doxorubicin. Doxorubicin is normally quite toxic to cardiac tissue, limiting its use as a
chemotherapy agent. Encompassing the drug in a liposome reduces the systematic
toxicity of the drug (136) and allows for targeting of cancer cells via functionalization of
the liposomes with folate (137). Other nanoparticle-based systems that can lead to
cellular destruction include the introduction genetic material to the cell, specific proteins
such as tPA as discussed above, or physical damage caused by hyperthermia.
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Inductive hyperthermia as alternative therapy:
Hyperthermia has long been recognized as a method to damage or destroy unwanted cells
or tissues. Observations that fever-like conditions could have therapeutic effects on
cancer were made as early as 1866 (138). Raising the cell temperature as little as 5o C
(from 37o C to 42o C) can have profound effects on cell survival (130, 139). The
majority of hyperthermic studies thus far have focused on anti-cancer therapy, as many
types of cancer are inherently more sensitive to temperature than normal cells (125, 129,
130, 140, 141). Many methods have been developed ranging from those that can raise
the temperature of the whole body to highly localized cell-directed hyperthermia.
Hyperthermia treatments may be performed by circulating heated liquid through the
peritoneum (142), implanting devices within tumors that are then subsequently heated
(143, 144), radio frequency (RF) based tissue heating (145), or using nanosystems that
can absorb energy from an external source and convert it into localized heat (140, 146,
147). For most applications, it is preferred to have the treatment be as non-invasive as
possible. Injected nanoparticle-based systems that can convert external energy to heat
meet this requirement. These systems utilize either near infrared light (127) or RF
electric (126, 148) or magnetic fields to cause specific heating of the nanoparticles.
Further, nanoparticles can be targeted toward specific cells via functionalization which
allows the hyperthermic damage to be confined to the cells or area of interest and prevent
damage to healthy tissue.
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For our applications, magnetic field-induced hyperthermia using magnetic nanoparticles
are of most interest due to the ability to target the nanoparticles specifically towards cell
types and the existing body of knowledge of inductive heating (141, 149, 150). Magnetic
field frequencies used for inductive heating are relatively low, and are similar to
frequencies used for magnetic charging in implantable devices. Nanoparticle
hyperthermia performance is specific to composition, crystallinity, and size of the
nanoparticles (151). Magnetic fields may transfer energy through three different, but
sometimes overlapping, mechanisms (152, 153). The simplest mechanism involves
reverse Brownian motion. Nanoparticles are caused to vibrate by the magnetic field,
imparting increased kinetic energy on their surrounding environment, in a temperatureand solution viscosity- dependent manner. In nanoparticles large enough to possess a
permanent magnetic axis, heating may also be performed via hysteresis loss caused by
reordering a magnetic moment within the nanoparticles. The third type of heating may
be performed on superparamagnetic nanoparticles that are too small to maintain a
permanent magnetic axis. These nanoparticles switch magnetic axis based on the Néel
relaxation time of each nanoparticle, which is a size- and temperature-dependent process.
The superparamagnetic nanoparticles may be heated by an external oscillating magnetic
field, which causes the magnetic axis to flip faster than the Néel relaxation time (149,
153). The RF used for heating superparamagnetic nanoparticles primarily through the
Néel relaxation mechanism is preferred for treatments in biological systems due to the
relatively simple RF circuitry required and viscosity independence, which is difficult to
control in vivo and may change over time.
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For hyperthermic applications, many types of superparamagnetic nanoparticles have been
successfully employed. Of these, the iron oxides magnetite (Fe3O4) and maghemite (Fe2O3) are the most attractive due to their highly magnetic behavior and safety for use in
biological systems. Organically coated iron oxide is used as an injectable iron
supplement known as ferumoxytol (Feraheme, AMAG Pharmaceuticals). It was clinically
used as a MRI contrast agent but has since been removed from the market due to lack of
efficacy. Magnetite- and maghemite-based nanoparticle treatments have been developed
for anti-cancer therapy (129, 149, 152, 154-156). Initial treatments proposed for tumor
metastases in lymph nodes involved injection of a suspension of sub-micron sized
magnetic particles into the lymphatic system, followed by exposure to an oscillating
magnetic field (157). Treatments were refined to use smaller (~10 nm)
superparamagnetic magnetic nanoparticles that were injected in the vicinity of the tumor
and heated by an external magnetic field; the heat generated by the nanoparticles caused
hyperthermic cell death (125, 128, 129, 140, 151, 158-162). These treatments relied on
physical placement of the particles near the tumor rather than specific targeting, and thus
were dependent on bulk heating to produce the desired effect.

Hyperthermia via bulk heating has been applied only to large solid tumors, and has
produced limited success. This is due to neighboring “bystander” cells being heated and
killed along with the cancerous cells. Further, targeting cells not localized at a single site,
such as cells circulating in the blood, requires that the nanoparticle specifically target the
cell type. Targeting mechanisms for iron oxide nanoparticles have been developed such
as imparting a positive charge to a liposome covering to make the particles pro-
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phagocytotic (128), or conjugating antibodies against cell specific surface markers onto
the nanoparticle (150, 163). The latter were used mainly for MRI imaging studies, but
demonstrate the potential for targeting magnetic nanoparticles toward cells of interest.

Nanoparticles that contain a magnetic iron oxide core with a gold shell have been
developed (154, 164, 165). The “core-shell” structure offers advantages over bare iron
oxide. The shell is thought to protect the iron-oxide core from external pH, ionic, and
oxidative conditions which can all negatively affect the hyperthermia performance of iron
oxide nanoparticles (166). The gold coating also provides a surface that may be easily
conjugated with proteins. Conjugation of proteins to colloidal gold has been established
and used extensively for immunolabeling for transmission electron microscopy (TEM)
and scanning electron microscopy (SEM) (25, 52, 167). Successful conjugation of
antibodies to the core-shell particles is expected to be very similar. While the core-shell
nanoparticle concept appears promising, in practice, synthesis of the core-shell particles
is highly variable. Synthesis of magnetite under aqueous conditions leads to variations in
size and composition of the iron oxide (151). Growth of gold on an oxide surface adds
further complications, as the growth is not well understood. Gold growth on thin films of
magnetite on the (001) and (111) surfaces has shown that gold does not easily wet the
magnetite surface (168, 169) which leads to the question of how gold growth occurs to
surround the iron oxide core in a core-shell like structure. Antibody-conjugated goldcoated magnetite nanoparticles have been successfully targeted to prostate (170) and
breast cancer cells (171), producing cell death via magnetic field-induced hyperthermia.
Using a protein-based targeting mechanism, these gold-coated magnetite nanoparticles
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should be able to target and destroy nearly any type of cell that can be targeted using an
antibody or protein, as long as nanoparticles reach the cell surface in sufficient numbers
to convey hyperthermic damage.

Main hypothesis:
We hypothesize that localized hyperthermia on activated platelets within a blood clot
could cause sufficient damage to dissolve blood clots. We propose targeting platelets
within a blood clot using fibrinogen conjugated to gold-coated magnetite nanoparticles.
We further hypothesize that conjugation of fibrinogen to the nanoparticles will allow
specific targeting of activated platelets within a blood clot and provide a means for the
nanoparticles to label the interior of the aggregate utilizing IIb3 movement after ligand
binding. Gold-coated magnetite is expected to provide a nanoparticle that is
superparamagnetic and has a gold surface that is easily functionalized with fibrinogen by
nonionic adsorption similar to that used with colloidal gold. Lastly, we propose that
using these nanoparticles will create hyperthermic conditions highly localized to the
platelet surface when the labeled platelets are exposed to an oscillating magnetic field at a
frequency used for superparamagnetic-based heating. These conditions should cause
structural damage to the platelets, causing them to break apart. The ultimate goal is to
cause enough localized damage to cause a blood clot to dissolve, restoring blood flow.
The scope of these aims is to develop the fibrinogen-conjugated gold-coated magnetite
nanoparticle for targeted platelet destruction using hyperthermia in vitro. While all
studies were performed in vitro, a strong emphasis was placed on how the methodology
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is expected to perform in vivo in anticipation of future studies using a small animal model
of arterial thrombosis.
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Figures and Figure Legends

Figure 1. A simplified diagram of arterial blood clot formation. An activation event
leads to the blood coagulation production of thrombin. Thrombin activates resting
platelets causing them to enter an activated state. Activated platelets aggregate together
in a fibrinogen dependent process. Thrombin also cleaves fibrinogen to fibrin, the fibrin
then forms a polymer meshwork. Together the fibrin and platelet aggregates form a
blood clot.
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Figure 2. Structural features of a resting platelet. (A) depicts a cross section of a discoid
platelet. Microtubules (MT) are shown in cross section near the periphery of the platelet.
Granules and open canalicular system (OCS) are within the platelet. A top down view of
the platelet is shown in (B). Ultrathin sections of platelets sectioned similar to (A) and
(B) are shown in (C) and (D), respectively. Size bars are 1 m.
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Figure 3. Structural features of activated platelets. Platelets that have experienced a
strong activation signal degranulate, releasing the granule contents into the extracellular
space either at the platelet surface or into the OCS. Fusion of granules with the platelet
membrane causes P-selectin (CD62P) expression (triangles) which can recruit leukocytes
to the inflammation site. Platelets aggregate together by binding fibrinogen (rectangles)
which crosslinks the platelets. Fibrinogen bound that has crosslinked two adjacent
receptors on the same platelet moves into the OCS of the platelet.
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Figure 4. Platelet activation signaling by G-protein coupled receptors. Thrombin signals
through protease activated rececptor 1 (PAR1) and protease activated receptor 4 (PAR4)
receptors coupled to the Gq, Gi, and G12/13 (G12) subunits. ADP signals through the
P2Y1 and P2Y12 receptors which signal through Gq and Gi, respectively. The
thromboxane receptor (TP) in the common activation pathway signals through Gq, Gi,
and G12/13. Gq activates phospholipase C (PLC). PLC produces the secondary
signaling molecules inositol triphosphate and diacylglycerol, which lead to calcium
release in the cell and ultimately to a conformational change of the fibrinogen receptor
IIb3 into its active state. G12/13 signals through Rho which causes cytoskeletal changes
resulting in platelet shape change. The Gi subunit inhibits adenylate cyclase (AC)
causing the cAMP levels in platelets to drop, which causes platelet activation.
Prostacyclin (PGI2) signals through the IP receptor which is coupled to a Gs subunit.
Gs causes AC to produce cAMP which has inhibitory effects on platelet activation.
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Figure 5. Diagram of ischemic tissues observed after occlusion of an artery supplying the
brain. Tissue directly downstream of the occlusion site becomes the ischemic core, this
tissue is deprived of oxygen and nutrients from the blood and will die. Tissue partially
fed by the occluded artery is called the penumbra. This tissue suffers from less severe
hypoxia and can recover if blood flow is restored in a timely manner.
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Chapter 2:

Fibrinogen-based platelet targeting
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Abstract:

Selective targeting of activated platelets is desirable for anti-platelet therapy as it allows
for disruption of platelets involved in blood clots to be treated but prevents targeting of
quiescent circulating platelets. We propose using human fibrinogen to target platelets
through the integrin IIB3 which is only competent to bind fibrinogen upon platelet
activation. The function and selectivity of fibrinogen-conjugated nanoparticles was
evaluated with an emphasis on potential in vivo application. While human systems are
convenient for in vitro studies, future in vivo studies would require use of a murine
animal model. The utility of human fibrinogen in a murine platelet system was examined
through platelet aggregation studies, and with nanoparticle labeling was tested using
either murine or human fibrinogen. The ability of fibrinogen-conjugated nanoparticles to
bind to preformed platelet aggregates in the presence of unconjugated fibrinogen, which
resemble in vivo conditions, was examined. To better understand the selectivity of
fibrinogen-conjugated nanoparticles, a system in which tagged, unactivated platelets and
activated platelets were mixed and labeled with fibrinogen-conjugates was developed.
No significant differences between human and murine fibrinogen in aggregation or
labeling of murine platelets were observed. Fibrinogen-conjugated nanoparticles were
found localized to the area around the granulomere in surface-activated platelets and at
platelet-platelet junctions and the open canalicular system in aggregated platelets.
Preformed aggregates exhibited a similar labeling pattern but with fewer labels present.
Fibrinogen-conjugated nanoparticles were found to be selective for activated platelets.
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The results suggest that fibrinogen is a suitable molecule to target nanoparticles
specifically to activated platelets and may function well in vivo.

Introduction:

Successful destruction of platelet aggregates will require two features to be feasible:
First, a nanoparticle capable of causing structural damage to platelets within a blood clot;
and second, a mechanism to actively localize the nanoparticles to the platelets within the
blood clot. Here we focus on the targeting mechanism we have proposed, using the
ligand fibrinogen to specifically target activated platelets through binding to the platelet
fibrinogen receptor. Ideal targeting molecules can specifically bind to the desired target,
have low binding to all other cells and tissues, and can be obtained at high concentration
and purity. Additionally, for our studies the molecule must retain biological activity
following conjugation to nanoparticle surfaces in order to perform its intended function
of delivering nanoparticles to activated platelets.

The ability of fibrinogen to bind to activated platelets is critical for platelet aggregation,
and as a result, for overall platelet hemostatic function (1, 2). The primary platelet
fibrinogen receptor is the integrin IIB3, but the receptor can also bind von Willebrand
factor and fibronectin via arginine-glycine-aspartate (RGD) amino acid sequences found
on the ligands (3, 4). The importance of IIB3 is demonstrated effectively in
Glanzmann’s thrombasthenia, a disorder in which platelets lack a functional fibrinogen
receptor, resulting in bleeding problems caused by the inability of platelets to crosslink
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and form effective aggregates (5-7). Due to the importance of integrin IIB3, it has been
studied extensively using antibodies (8-10) and small molecule inhibitors (11) against the
integrin. Of particular interest is the 7E3 antibody against IIB3 that appeared to show
binding preference for IIB3 on activated platelets (12), which was developed as a
therapeutic antibody to block platelet aggregation. The original murine monoclonal
antibody was made a chimeric Fab to reduce antigenicity of the antibody in humans (13)
and prevent platelet clearance caused by the Fc portion of the intact antibody. The
modified antibody received the name abciximab (trade name Reopro) and has since been
employed in percutaneous interventions to prevent thrombus formation (14). Abciximab
was further tested as an ischemic stroke treatment but during phase III clinical trials it
was found to increase the rate of fatal intracranial hemorrhage while failing to show
good efficacy in treatment of ischemic stroke (15, 16). However, abciximab
demonstrated the potential utility and benefit of targeting IIB3 on platelets as a means to
treat thrombotic conditions.

The interaction between fibrinogen and the integrin IIB3 has been well characterized (9,
17-20). The integrin IIB3 exists in a non-binding conformation on quiescent platelets,
unable to bind to fibrinogen. Upon platelet activation, the integrin undergoes a
conformational change that renders it competent to bind its ligands (21) providing a
useful mechanism for targeting of activated platelets. Once fibrinogen has bound and
cross-linked receptors, the receptor undergoes integrin outside-in signaling where the
receptor can signal back to the platelet that ligand has bound (22, 23). This causes the
integrin with bound ligand to centralize in the plane of the platelet membrane by moving
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along the underlying actin cytoskeleton. On surface-activated platelets, the movement
will be toward the area around the granulomere of the platelets (24-28). Platelets
activated in suspension will move bound fibrinogen along the surface of the platelet to a
final destination in the open canalicular system (OCS) (29-33). The movement of
fibrinogen-conjugated labels to the interior of platelet aggregates is desirable, as it will
allow treatments to disrupt the entire volume of platelet aggregates rather than only those
platelets exposed on the thrombus surface. The localization of fibrinogen-conjugated
nanoparticle labels is important for how nanoparticle-mediated highly-localized
hyperthermia will affect platelet structural integrity. Of particular interest is fibrinogen
labeling on platelets that have been activated and aggregated before being exposed to
fibrinogen-conjugated nanoparticles. Blood clots formed in vivo will have already
formed a platelet aggregate and bound fibrinogen from the circulation that will directly
compete with the binding of fibrinogen conjugated to nanoparticles. The feasibility of
using fibrinogen as an activated platelet targeting system needs to be evaluated under
conditions that approximate this in vivo competition.

The species of fibrinogen used for targeting is an important consideration. Nearly all in
vitro studies may be performed using freshly isolated human platelets. For in vivo
studies, an animal model is necessary to demonstrate effectiveness of targeting and
destruction before further development of human applications. For in vitro systems
human blood cells and proteins are generally preferred for their availability, purity, and
lower commercial costs. However, effectively targeting platelets in an animal model may
require a species matched, non-human fibrinogen. Many arterial injury models are
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available in a variety of organisms. For our studies, the murine platelet system has
appeal; it has been used to study effects of tissue plasminogen activator (tPA) (34) and
plasmin (35) on arterial blood clots, using a ferric chloride arterial injury model. The
injury model was originally developed in rat, and utilizes ferric chloride to denude
endothelium in the carotid artery which leads to an occlusive thrombus (36). It has since
been successfully employed in mice (34, 35, 37, 38). For our system it would be ideal to
develop a targeting system that uses human fibrinogen for targeting both human platelets
in vitro and murine platelets in vivo.

The vertebrate fibrinogen molecule is a complex glycoprotein consisting of 3 pairs of
subunits: alpha, beta, and gamma (39, 40). Fibrinogen has several possible binding sites
for the integrin IIB3. Human fibrinogen contains two RGD amino acid sequences on
the alpha chain at position 95-97 and 572-574 on the mature molecule (41), but while
these RGD sequences are capable of binding to IIB3 (42) they are not essential for
fibrinogen binding (2, 18) or platelet function (43). Rodent IIB3 lacks the ability to
bind RGD sequences (44, 45). This leads to inability of these platelets to bind human
von Willebrand factor; however, human fibrinogen is able to bind to rat IIB3 (45, 46).
The dodecapeptide sequence at the C-terminal of the fibrinogen gamma chain is the
primary sequence bound by IIB3 and is responsible for nearly all fibrinogen/platelet
physiology (2, 18, 47, 48), rather than the RGD sequences. The dodecapeptide sequences
of the C-terminus of the gamma subunits of human and murine fibrinogen differ by only
two amino acids, HHLGGAKQAGDV for humans and HHMGGSKQAGDV for mice
(differences underlined) (49, 50). A study comparing the binding of human and rat
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dodecapeptides to rat platelets concluded that their affinity for IIB3 was equal (51).
Studies have utilized human fibrinogen in murine systems successfully to analyze
fibrinogen binding to platelets (52-55). Currently no comprehensive study on the use of
human fibrinogen in a murine platelet system has been conducted. Here we will evaluate
the use of human fibrinogen for targeting and aggregating murine platelets in vitro. We
will also determine the ability of fibrinogen-conjugated nanoparticles to label preformed
platelet aggregates in competition with plasma fibrinogen, which will approximate
labeling conditions in vivo. For successful therapies, fibrinogen-conjugated nanoparticles
must bind to blood clots that have already been formed and in the presence of plasma
fibrinogen.

We further developed an in vitro platelet system that creates a population of activated
platelets along with a population of biotin-tagged unactivated platelets. This system can
create an approximation of the conditions around blood clots and demonstrate fibrinogen
labeling specificicity for activated platelets. This allowed us to observe the specificity of
fibrinogen conjugated to nanoparticles for activated platelets while in the presence of the
specifically tagged unactivated platelets. It is vitally important that unactivated platelets
are left unlabeled as they would otherwise be destroyed during treatment, thus increasing
bleeding risks, as well as acting as a sink that reduces the nanoparticle dose delivered to
the thrombus.
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Materials and Methods:

Isolation of human platelets:
Venous blood anticoagulated with 3.2% sodium citrate in evacuated blood collection
tubes (Tyco Healthcare Group, Mansfield, MA) was centrifuged at 100 x g for 15
minutes. Platelet-rich plasma was applied to a 25 mm diameter x 90 mm high column of
Sepharose CL-2B (Sigma-Aldrich, St. Louis MO) equilibrated with Tyrode’s buffer (15
mM HEPES, pH 7.4, 3.3 mM Na2HPO4, 138 mM NaCl, 2.7 mM KCl, 5.5 mM glucose, 1
mM MgCl2, 1 mg/mL bovine serum albumin (BSA)) to perform size exclusion
chromatography on the platelet rich plasma. The gel-filtered platelets were then surface
activated or aggregated as described below. Experiments were completed within 2 hours
of the blood draw to preserve normal platelet functions.

Isolation of murine platelets:
Blood was collected by cardiac puncture of C57BL/6 mice immediately following
euthanasia by CO2 inhalation. Blood was drawn into a one cc syringe containing 90 l of
3.2% sodium citrate. Pooled blood samples from 4 - 6 animals were used for aggregation
studies; pooled samples from 2 mice were used for surface activation studies. Murine
blood was centrifuged at 80 x g for 10 minutes. Gel-filtered platelets were produced
using size exclusion chromatography similar to above but on a 10 mm diameter x 50 mm
high Sepharose CL-2B column, and were subsequently used for surface activation or
aggregation experiments.

56
Preparation of colloidal gold nanoparticles:
Glassware used for preparation of nanoparticles was washed thoroughly with diluted
7X® concentrate detergent (MP Biomedicals, Solon, OH) and rinsed extensively with
double deionoized H2O (ddH2O). Preparation of 18 nm colloidal gold nanoparticles was
performed as previously described (26). Briefly, 0.2 µm filtered ddH2O was mixed with
4% tetrachlorogold (III) hydrate (MP Biomedicals) to a final concentration of 0.01%.
The solution was heated to boiling. Next, filtered 1% trisodium citrate (Fisher Scientific,
Pittsburgh, PA) was added to a final concentration of 0.02% or 0.01% for 18 nm and 38
nm colloidal gold, respectively. The solution was mixed thoroughly until a distinct red
color developed, then was refluxed for 30 minutes. Nanoparticles were air-dried onto
formvar coated TEM grids. Size distributions of the colloidal gold nanoparticles were
assessed by measuring diameters of the longest axis of the nanoparticles using ImageJ
(National Institute of Health, Bethesda, MD) to analyze micrographs acquired with a
Hitachi H-600 transmission electron microscope at 75 kV, or scanning electron
microscopy on a Hitachi S-4800 at 30 kV between 50,000 to 100,000 X magnification.
The mean nanoparticle diameter and standard deviation were determined from counting
500 nanoparticles in multiple fields of view.

Conjugation of proteins to colloidal gold nanoparticles:
Fibrinogen was conjugated to the nanoparticles by non-ionic protein adsorption (29). To
conjugate human or murine fibrinogen to 18 nm gold nanoparticles, the pH of the colloid
was adjusted to 6.8 for human or 7.3 for murine fibrinogen using 0.2 M K2CO3. The gold
nanoparticles were then incubated with 16 g/mL of plasminogen-, von Willebrand
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factor-, and fibronectin-depleted human fibrinogen (Enzyme Research Laboratories,
South Bend, IN) or 16 g/mL murine fibrinogen (Enzyme Research Laboratories) for 5
minutes. Polyethylene glycol (average MW 20,000, Sigma-Aldrich) was added at a final
concentration of 0.004% as a stabilizing agent. The fibrinogen-conjugated nanoparticles
were separated from free protein by centrifugation at 16,000 x g for 5 minutes, and the
resultant soft pellet was resuspended in Tyrode’s buffer at one-tenth the original
nanoparticle volume.

Streptavidin (Southern Biotech, Birmingham, AL) was conjugated to 38 nm colloidal
gold in a similar manner. The pH of the nanoparticle solution was adjusted to 5.5 and
incubated with 20 g/mL streptavidin for 1 minute prior to addition of polyethylene
glycol. Attempted conjugation of streptavidin using the standard protein incubation times
of 5 minutes produced conjugates that failed to form pellets during centrifugation. The
nanoparticles were pelleted and resuspended in the same manner as the fibrinogen
conjugates.

Aggregation of gel-filtered platelets:
Gel-filtered platelets were diluted in Tyrode’s buffer with BSA to give a final
concentration of 200,000 platelets/µL, and were supplemented with CaCl2 to a final
concentration of 2 mM for human and 5 mM for murine platelets. Unconjugated
fibrinogen was added to the platelets at a final concentration of 200 µg/mL. When using
fibrinogen-gold conjugates as the sole source of fibrinogen, 15 µL pelleted fibrinogenconjugated colloidal gold was added per 235 µL of platelet volume which is a
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concentration of approximately 96 g/mL, based on a perfectly efficient protein
conjugation to the nanoparticles. The total volume of platelets, fibrinogen, and calcium
was 500 L (aggrogometer) or 250 L (24 well plate) per aggregation reaction.

Aggregation of human platelets was performed on a Chronolog Dual Aggregometer
(Havertown, PA) warmed to 37o C, stirring at setting 7, mated to an ADInsturments
Powerlab 4/30 analog-to-digital converter with LabChart software (ADInstruments,
Colorado Springs, CO) sampling at 10 Hz and a 100 mV range. After 30 seconds of data
acquisition, aggregation was initiated by addition of 67 M of the peptide agonist
SFLLRN-NH2 (Bachem Americas, Torrence CA), the ligand for human proteaseactivated receptor 1 (PAR1), the primary thrombin receptor on human platelets (56, 57).
Aggregation was considered complete 5 minutes after aggregation initiation. The percent
aggregation was determined by the output voltage of the aggregometer using the equation
below, where Vout is the output voltage of the aggregometer and Vmax is an instrumentspecific maximum voltage, which is 80 mV for the Chronolog Dual Aggregometer. The
aggregometer uses a blank, consisting of Tyrodes’s buffer supplemented with fibrinogen
and calcium to determine the voltage range.

For some experiments using either human or murine platelets, aggregation was performed
in 24-well tissue culture plates with a small magnetic stir bar in each well. The reaction
wells were centered on a Corning PC-620D magnetic stirrer (14 x 18 cm surface), set at
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~70% maximum speed, which was found to produce enough shear to reproducibly
aggregate platelets, and incubated at 37C. To initiate aggregation, human or murine gelfiltered platelets were supplemented with human or murine fibrinogen and calcium prior
to the addition of agonists. The agonists included: the human PAR1 peptide SFLLRNNH2 (human platelets only), the murine PAR4 peptide AYPGKF-NH2 (Bachem
Americas) (58, 59), ADP (Sigma-Aldrich), and ionomycin (Calbiochem, San Diego CA)
(60). Reactions were allowed to proceed for 5 minutes and terminated by the addition of
1 mL of 1% glutaraldehyde in 0.1 M HEPES, pH 7.3. Aliquots of 200 µL were removed
for determination of percent aggregation (see below), and the remaining sample volume
was diluted to 5 mL in 1% glutaraldehyde for electron microscopy preparation. Samples
were allowed to fix for a minimum of 30 minutes at room temperature.

The extent of aggregation was calculated from the light transmittance (%T) of the
samples. Aliquots of glutaraldehyde-fixed aggregation reactions were transferred to a 96well flat bottom plate and the %T was measured at 595 nm in a Molecular Devices
Versamax microtiter plate reader (Sunnyvale, CA). Control samples used to define the
minimum and maximum percent aggregation were diluted in glutaraldehyde in a manner
similar to the aggregated samples. Controls included (1) gel-filtered platelets
supplemented with fibrinogen, and calcium representing baseline, or zero aggregation
(0%T); and (2) Tyrodes’s buffer with fibrinogen and calcium representing complete
aggregation (100%T), and serving as the de facto blank. Percent aggregation was
calculated as:

% Aggregatio n 

%Tsample  %Tbaseline
%Tcomplete  %Tbaseline

*100
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Dose response curve aggregation data were presented as percent of maximal aggregation
to better compare data between experiments. Percent of maximal aggregation normalizes
responses obtained from different donors/animals or on different days, defined as:
% Of Maximal Aggregation =
Statistical analysis was performed using Student’s t-test to compare samples, with
significance defined as p < 0.05.

Aggregation of platelet-rich plasma:
Human platelet-rich plasma was obtained by centrifugation of blood at 100 x g for 15
minutes. Aggregation of samples was performed in a Chronolog Dual Aggregometer, as
above, using platelet- rich plasma supplemented with 2 mM Ca2+. Platelets were
activated with the 67 M of SFLLRN-NH2 and allowed to aggregate for 5 minutes. The
resulting platelet aggregates were labeled for 5 minutes with fibrinogen-conjugated
nanoparticles derived from 6 mL of stock, which gives an approximate concentration of
96 g/mL fibrinogen. Samples were then fixed and prepared for TEM as described
below.

Fibrinogen labeling of surface-activated platelets:
Surface-activated platelets were prepared by placing 7 µL drops of Ca2+-supplemented
gel-filtered platelets onto Formvar-coated 400 mesh nickel grids (Electron Microscopy
Supplies, Hatfield PA). Human platelets were allowed to adhere and spread for 15
minutes at room temperature, while murine platelets were given 30 minutes. Nonadherent platelets were washed away by gently dunking the grids in Tyrode’s buffer.
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Grids were then floated on 7 µL drops of colloidal gold-conjugated fibrinogen adjusted to
OD522 of 0.5 just prior to supplementation with Ca2+. Grids were incubated in the labels
for 10 minutes, then washed by three, 5 minute incubations on drops of Ca2+supplemented Tyrode’s buffer. After washing, samples were fixed in 1% glutaraldehyde
in 0.1 M HEPES, pH 7.3, for 30 minutes at room temperature.

Fibrinogen labeling of mixed activated and unactivated platelet populations:
Blood was drawn from healthy adult volunteers and anticoagulated with 3.2% sodium
citrate and 5 g/mL prostaglandin E1 (PGE1, stock is dissolved in 100% ethanol, SigmaAldrich) and was centrifuged at 100 x g for 15 minutes. The resultant platelet-rich
plasma was gel-filtered as described above.

Gel-filtered platelets were split into

thrombin activated and unactivated groups. The unactivated group was washed in CGS
buffer (13 mM sodium citrate dihydrate, 123 mM NaCl, 33 mM dextrose, pH 7.4) by
centrifugation at 300 x g for 10 minutes, supplemented with an additional 5 g/mL PGE1,
to prevent activation (61), and incubated in 1 M EZ-Link® Sulfo-NHS-LC-Biotin
(Fisher Scientific, Pittsburgh PA) for 20 minutes at room temperature. Following the
biotinylation, unreacted biotin was removed by gel filtration on a second 25 mm diameter
x 90 mm high Sepharose CL-2B column equilibrated with Tyrode’s buffer with BSA.
After gel-filtration platelets, were supplemented with 2 mM calcium.

A separate group of gel-filtered platelets and a control group of biotinylated platelets
were supplemented with calcium and activated with 2 nM thrombin (Haematolgoic
Technologies, Essex Junction, VT) for 5 minutes at room temperature. Afterward the
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thrombin activity was quenched by the addition of 20 nM antithrombin III (ATIII,
Haematolgoic Technologies) and 5 units/mL heparin sodium (Elkins-Sinn, Cherry Hill,
NJ) for 5 minutes at room temperature.

The platelets were washed twice by

centrifugation at 300 x g for 5 minutes in Tyrode’s buffer with BSA to remove
thrombin/ATIII complexes and secreted platelet degranulation products.

The

biotinylated, unactivated and thrombin-activated platelet populations were mixed
together in equal proportions and labeled with Alexa Fluor® 488-fibrinogen (Invitrogen,
Grand Island, NY) or fibrinogen conjugated to 18 nm colloidal gold. The samples were
fixed in 1% paraformaldehyde for light microscopy and flow cytometry or 1%
glutaraldehyde for SEM. The aldehydes were quenched and washed in 50 mM glycine in
PBS twice at 300 x g for 10 minutes. Samples were incubated for 20 minutes with
TRITC-streptavidin (Southern Biotech) for light microscopy, phycoerythrin-avidin (PEavidin, Southern Biotech) for flow cytometry, or streptavidin conjugated to 38 nm
colloidal gold for SEM. After labeling, samples were fixed again for 30 minutes by
dilution in 1% paraformaldehyde for light microscopy and flow cytometry or 1%
glutaraldehyde for SEM.

Epifluorsecence microscopy micrographs were generated with a Roper Scientific
CoolSnap ES CCD mounted to a Nikon Eclipse TE2000-U inverted microscope using a
Nikon Plan Apo 40x objective. Brightfield images were captured using DIC optics.
Fluorescent Alexa 488-fibrinogen imaging was done using a FITC cube at 50 ms
exposure, avidin-TRITC imaging was performed using a TRITC cube with a 100 ms
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exposure. Fluorescent image channels were overlaid using Metavue software (Universal
Imaging Corporation, Downingtown, PA).

For flow cytometry, some paraformaldehyde-fixed platelet samples were stained for the
platelet degranulation marker P-selectin (CD62P) using a PE-anti human CD62P clone
AK-4 (62) (BD Biosciences, San Jose, CA). Flow cytometry analysis was performed
with a BD FACSCalibur using CellQuest™ Pro software, sampling at least 10,000 events
gated on the platelet population on log forward and log side light scatter dot plots. Data
in histograms was scaled and smoothed to better show differences between samples.

Scanning electron microscopy of platelets activated in suspension and aggregated:
Following fixation, aggregates were collected by filtration onto 0.4 µm pore size
Nuclepore® membranes (General Electric, Fairfield, CT). Membranes were post-fixed in
0.05% OsO4 in 0.1M HEPES, pH 7.3, for 15 minutes and dehydrated through a graded
series of ethanol to 100%. Samples were dried by the critical point procedure in a
Balzers CPD020 unit (Schalksmühle, Germany) using 100% ethanol stored over type 3A
molecular sieves (Grace Davison, Columbia, MD) as the intermediate fluid and liquid
CO2 as the transitional fluid. Dried samples were sputter coated with 2 nm iridium using
an EMITECH K575x sputter coater (Ashford, Kent, United Kingdom). Analysis was
performed on a Hitachi S-4800 scanning electron microscope (Dallas, TX) using 1-2 kV
for secondary electron (SE) imaging and 30 kV for backscattered electron (BSE)
imaging.
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Transmission electron microscopy of platelets:
Gel-filtered platelet aggregates were fixed in 1% glutaraldehyde, 1% tannic acid in 0.1 M
HEPES, pH 7.3, at room temperature for an hour and then 4o C overnight. Aggregated
platelet-rich plasma was fixed in 2% glutaraldehyde in 0.1 M HEPES, pH 7.3 for 10
minutes and then centrifuged at 300 x g for 5 minutes to remove agglomerated plasma
proteins that pellet above the platelet sample. The samples were fixed a second time in
2% glutaraldehyde, 1% tannic acid in 0.1 M HEPES, pH 7.3 overnight at 4o C. All
samples were washed three times in HEPES and embedded into 1% agar (Difco, Detroit,
MI) in 0.1 M HEPES by combining warm agar and 4o C platelet samples in equal volume
in small TEM embedding molds. After the agar had become dense at 4o C, samples were
postfixed in 0.05% OsO4 for 1 hour at room temperature, washed 3 times in ddH2O, and
stained with 1% uranyl acetate for 30 minutes. Samples were dehydrated in a graded
ethanol series and then transferred from ethanol to propylene oxide. Samples were
infiltrated and embedded with low viscosity Spurr’s resin (63) but substituting the
accelerant N,N-dimethylbenzylamine with 2(dimethylamino)ethanol (64) (Electron
Microscopy Sciences, Hartfield, PA). Ultrathin silver to pale gold sections were cut on a
RMC MT-7000 ultramicrotome and were stained with 1% uranyl acetate. Sections of
aggregates produced from platelet-rich plasma were additionally stained with lead citrate.
Sections were imaged on a Hitachi H600 TEM (Dallas, TX) at 75 kV.
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Results

Aggregation of human and murine platelets:
To ensure that all aggregation data could be collected within 2 hours of the blood draw,
we validated a method that allows multiple aggregation reactions to proceed
simultaneously, the 24-well plate system. We directly compared the 24-well plate system
to the standard assay performed in an aggregometer. Aggregation of gel-filtered human
platelets with the maximal dose of the human PAR1 peptide agonist SFLLRN-NH2 (67
M) in the 24-well plate system gave percent aggregation results similar to the end point
readings of aggrogometer tracings (56), following stimulation. Maximal aggregation
measured in the aggregometer occurred within 5 minutes of stimulation, as observed by
the plateau of the aggregation tracings (Figure 6A). Maximal achievable aggregation
(times varied with sample) in the aggregometer was 76 ± 5.7% (standard deviation, n=3),
at exactly 5 minutes after stimulation the platelets aggregated 76 ± 5.6%, and platelets
aggregated in the 24-well plate system demonstrated similar aggregation of 80 ± 2.8% 5
minutes after stimulation (n=4) (Figure 6B). There was no significant difference between
the two methods, indicating that the methods produce and detect a similar extent of
platelet aggregation under the same conditions. Therefore, further aggregation
experiments utilized the 24-well plate system of platelet aggregation, which allowed for
up to 16 conditions to be tested simultaneously.

The ability of either murine or human fibrinogen to support murine platelet aggregation
through different activation pathways was testing using murine PAR4 activating peptide
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AYPGKF-NH2, ADP, and ionomycin at their maximal agonist dosages. As shown in
Figure 7A, murine platelets stimulated with 100 M AYPGKF-NH2 that were
supplemented with murine fibrinogen aggregated 51 ± 14% and 51 ± 15% when
supplemented with human fibrinogen (p=0.91, n=6), showing no significant difference
between the two species of fibrinogen. Similarly, when murine platelets were activated
with 10 M ADP, aggregation supported by murine fibrinogen was found to be 46 ±
9.9% and 43 ± 9.1% with human fibrinogen (p=0.55, n=6). Aggregation with 10 M
ionomycin also did not produce a difference between murine fibrinogen (55 ± 19%) and
human fibrinogen (53 ± 16%) (p=0.93, n=2) aggregation. Murine gel-filtered platelets
that were not supplemented with fibrinogen and stimulated with 10 M ADP aggregated
to 24 ± 6% which is a 42 ± 2.6% reduction in aggregation when comparing to fibrinogensupplemented murine platelets (n=3) (not shown).

Dose-response curves of murine platelet aggregation in response to the three agonists
above, using gel-filtered platelets supplemented with either murine or human fibrinogen,
were generated. Dose-response curves were reported in percentage of maximal
aggregation, as defined in the methods above, rather than raw percent aggregation, to
correct for differences in quality of blood draws and inter-experimental variability.
AYPGFK-NH2 doses ranging from 12.5 µM to 200 µM produced a dose-response curve
with overlapping murine and human fibrinogen data points as shown in Figure 7B.
Maximal aggregation occurred at 100 M AYPGFK-NH2, with no significant change in
aggregation observed at 200 M dose. No significant differences in the percent of
maximal aggregation in the presence of murine or human fibrinogen at a given agonist
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dosage were observed (n=6). ADP dose-response curves from 0.625 µM to 10 µM
followed a similar trend, with murine and human fibrinogen data points completely
overlapping, and no significant differences between the species of fibrinogen detected
(Figure 7C) (n=6). Maximal aggregation was observed at 10 M ADP. The response to
ionomycin doses ranging from 0.025 µM to 2 µM is shown in Figure 7D (n=2). Maximal
aggregation occurred at 2 µM ionomycin. Aggregation in the presence of human
fibrinogen typically produced higher average percent of maximal aggregation than
murine fibrinogen, but there were no significant differences between the data sets.

To demonstrate that fibrinogen conjugated to colloidal nanoparticles by nonionic
adsorption retains its biological activity, the ability of fibrinogen conjugated to 18 nm
colloidal gold to support aggregation was investigated. Optimum concentration and pH
values for conjugation of murine and human fibrinogen were determined by an
adsorption isotherm. Conditions for human fibrinogen were 16 g/mL concentration at
pH 6.8 as previously reported (26). Murine fibrinogen conjugated best at pH 7.3
maintaining the same 16 g/mL concentration. Human gel-filtered platelets
supplemented with conjugated human fibrinogen and stimulated with 10 M ADP
aggregated 64 ± 15% while similarly treated platelets supplemented with unconjugated
human fibrinogen aggregated to 62 ± 18% showing no significant difference in
aggregation when fibrinogen bound to nanoparticles is used (n = 3) (Figure 8A).
Aggregation of human platelets supplemented with conjugated murine fibrinogen was 58
± 0.5%, compared to aggregation with unconjugated murine fibrinogen at 49 ± 14%
(n=3). No significance difference in aggregation supported by conjugated or
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unconjugated fibrinogen was observed. The level of murine platelet aggregation using
conjugated fibrinogen followed a similar trend (Figure 8B). Murine platelets
supplemented with conjugated murine fibrinogen aggregated to 43 ± 4.3% (n=3), while
those supplemented with unconjugated fibrinogen aggregated 43 ± 1.6% (n=2). Human
fibrinogen produced similar levels of aggregation whether conjugated to colloidal gold
(40 ± 1.6%, n=3) or unconjugated (39 ± 1.5%, n=2).

Human and murine fibrinogen labeling of surface-activated and aggregated platelets:
The biological activity of human and murine fibrinogen conjugates were compared
through their labeling to human and murine surface-activated platelets. Colloidal gold
conjugates of human fibrinogen labeled human surface-activated platelets heavily, and
displayed the typical, well characterized labeling pattern (25-27). Bound labels cleared
from the periphery and moved toward the area around the granulomere on the platelet
surface (Figure 9A). Human platelets incubated with murine fibrinogen conjugates
exhibited similar labeling to that seen with human fibrinogen conjugates (Figure 9B).

In general, murine platelets exhibited less extensive surface activation than human
platelets under similar conditions (Figures 9C and 9D). In order to find murine gelfiltered platelets with morphology comparable to that of the typical human surfaceactivated samples (Figures 9E and 9F), supplementing Ca2+ to 5 mM rather than 2 mM
was required. The majority of murine surface-activated platelets labeled weakly with
either murine fibrinogen (Figure 9C) or human fibrinogen (Figure 9D). However, the
minority population of murine platelets at advanced stages of surface activation showed
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similar levels of labeling with human fibrinogen (Figure 9E) and murine fibrinogen
(Figure 9F) to their human counterparts. As with the well-spread human platelets,
labeling of the strongly activated murine platelets was extensive around the granulomere
of the platelets and relatively clear in the periphery.

Different morphologies and fibrinogen labeling patterns are observed when platelets are
activated in suspension rather than by contact with and adherence to a foreign surface.
Platelets aggregated in suspension using fibrinogen conjugated to nanoparticles as the
sole source of supplemental fibrinogen were collected onto filter membranes and imaged
by SEM. Morphology of the platelet aggregates was observed using SE imaging at low
accelerating voltage to distinguish surface features, and BSE imaging at higher
accelerating voltage to distinguish the high atomic number nanoparticle labels from the
low atomic number cell components. Unstimulated murine platelets incubated with
murine fibrinogen conjugates were isolated (Figure 10A) and had very low levels of
fibrinogen binding (Figure 10B). Murine platelets aggregate when activated with 10 M
ADP in the presence of either murine fibrinogen (Figures 10C and 10D) or human
fibrinogen (Figures 10E and 10F) conjugates. Labels are found on the surface of the
aggregates and in some areas that appear to be internal to the aggregate. Labeling in
either species was not homogeneous, some parts of the platelet aggregates labeled more
extensively than others. Some murine platelets appear to have no labeling despite being
involved in a platelet aggregate. Murine aggregation produced in the presence of human
fibrinogen conjugates appeared more compact than those formed with murine fibrinogen
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conjugates. Fibrinogen labels can be observed using conjugates of either species of
fibrinogen.

Human platelets aggregated with murine fibrinogen conjugated to colloidal gold as the
sole source of supplemented fibrinogen and stimulated with ADP aggregated strongly, as
shown in Figures 10G and 10H, and labeled extensively in most aggregates. Labels
appeared predominately within the aggregates (Figure 10H), but were also visible on the
surface of platelets. Human platelets aggregated with human fibrinogen conjugates were
examined as a positive control, and showed robust response with large very compact
aggregates produced (Figures 10I and 10J). Human fibrinogen labeled human platelets
primarily in the internal areas of the aggregate. However, labeling was also observed on
the platelet surfaces. In general, human platelets labeled more expensively with
conjugates of fibrinogen of either species than did murine platelets.

Localization of fibrinogen conjugates within murine platelet aggregates:
Murine platelets were labeled with human fibrinogen conjugates and aggregated as
described above. The samples were prepared for TEM and ultrathin sections were cut to
further examine the distribution of fibrinogen-conjugated nanoparticles within platelet
aggregates at higher resolution than can be achieved by low magnification BSE SEM
imaging. Fibrinogen labels were found on the surface of the platelets as well as in the
OCS of the platelets (Figure 11A) in a manner similar to nanoparticles clearing the
periphery of surface-activated platelets. In sections of an aggregate with multiple
platelets visible, labels were present in platelet/platelet junctions as shown in Figure 11B.
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Labeling was very heterogeneous between platelets, similar to the SEM studies of
fibrinogen conjugates binding to platelet aggregates.

Fibrinogen binding to preformed human platelet aggregates under in vivo-like
conditions:
Fibrinogen conjugates must be able to bind to preformed platelet aggregates in vivo in the
presence of plasma fibrinogen for any strategy using fibrinogen targeting. To
approximate these conditions, platelets were aggregated with unconjugated fibrinogen
and labeled post aggregation with conjugated fibrinogen. As a positive control, human
platelets were aggregated with supplemental fibrinogen conjugated to colloidal gold,
which labeled the platelets extensively, as observed by SEM and TEM in Figures 12A
and 12B, respectively. The vast majority of labels are located between platelets at
platelet/platelet junctions as well as internally in the platelet OCS system with few labels
present on the surface of the aggregates, similar to the fibrinogen binding to murine
platelets as described above. Labels were often clustered together on individual platelets
within an aggregate with neighboring platelets labeling less substantially. To test
labeling under more challenging conditions, platelets were aggregated with unconjugated
fibrinogen and then incubated with fibrinogen conjugated to colloidal gold. These
samples displayed similar labeling patterns to those previously described, but at lower
levels of total labeling (Figures 12C and 12D). Labeling was heterogeneous with some
very well labeled platelets existing beside moderately labeled platelets within the same
aggregate, similar to the localization observed in platelets aggregated with conjugated
fibrinogen. To even better approximate in vivo conditions, labeling of aggregates formed

72
in platelet-rich plasma was tested. Platelet-rich plasma was aggregated with the addition
of 67 M SFLLRN-NH2 to maximally activate the platelets without overt production of
fibrin. After aggregation, fibrinogen conjugated to colloidal gold was added directly to
the platelet rich plasma to label the preformed aggregates. TEM analysis of these
aggregates showed that fibrinogen conjugates still bound and penetrated deeply into the
aggregate (Figure 12E). Nanoparticle labeling was readily detectable, although the
labeling density observed in the preformed platelet-rich plasma aggregates was lower
than that in gel-filtered platelets aggregated with unconjugated fibrinogen. Nanoparticles
were observed to be less clustered within the aggregate and primarily located at
platelet/platelet junctions. Fewer labels were observed in the OCS.

Selectivity of fibrinogen binding for activated platelets:
A method that allows discrimination between unactivated and activated platelets is
necessary to evaluate the ability of fibrinogen conjugates to selectively target activated
platelets in an in vivo thrombus, while leaving unactivated platelets unlabeled. Therefore,
a procedure to produce an unactivated, biotinylated platelet population beside an
activated platelet population was developed. Biotinylation of platelets without causing
activation required substantial modifications to the standard biotinylation procedure used
commonly for other cell types (65), requiring the use of PGE1 to prevent platelet
activation. The gel-filtered platelets used as the starting material for both the
biotinylation and activation procedures showed no fluorescence when labeled with both
AlexaFluor-488 fibrinogen and streptavidin-TRITC (Figures 13A and 13B). After
biotinylation, about 5% of the unactivated platelets were positive for fibrinogen binding

73
(Figure 13C) and nearly 100% were positive for streptavidin (Figure 13D). Streptavidin
staining was mostly uniform around the surface of individual platelets, indicating the
biotinylation was successful. For activated platelets, about 90% were positive for
fibrinogen binding (Figure 13E) and as expected, 100% were negative for streptavidin
(Figure 13F). Fibrinogen labeling was heterogeneous on the activated population. It was
strongest in partially aggregated platelets and some individual platelets, while other
individual platelets stained relatively weakly with fibrinogen. When the two populations
of platelets were mixed prior to labeling, they remained mostly segregated. When
labeled with both fibrinogen and streptavidin, platelets demonstrated positive
fluorescence signal for only one or the other, and showed virtually no overlap (Figure
13G and 13H).

The mixed platelet population experiment was quantified using flow cytometry. The
relative fluorescence of bound fibrinogen or avidin was determined on singly labeled
controls and compared to that in the doubly labeled mixed sample. Baseline fibrinogen
binding was similar between the starting unactivated gel-filtered platelets and the
unactivated biotinylated platelets. Activated platelets exhibited a 15-fold increase in
fibrinogen binding, as shown in Figure 14A. Biotinylated platelets were stimulated with
thrombin to assess their capacity to become activated after repeated exposure to PGE1. A
modest 3-fold increase in mean fibrinogen binding was observed as a shift in the entire
platelet population as compared to the unactivated, biotinylated sample. Avidin binding
was only detected on platelets that were biotinylated (Figure 14B). As a measure of
activation, platelets were also stained for the degranulation marker CD62P. Data
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averaged over 3 experiments showed 28% of biotinylated (n=3), 91% of activated (n=3),
and 70% of activated biotinylated platelets (n=2) were CD62P positive, compared to 5%
in the unactivated population. A representative experiment is shown in Figure 14C. Dot
plots comparing fibrinogen and avidin binding to mixed biotinylated and activated
platelets were generated. The dot plot was divided into four distinct regions: [1]
fibrinogen negative, avidin negative; [2] fibrinogen positive, avidin negative; [3]
fibrinogen negative, avidin positive; and [4] fibrinogen positive, avidin positive. The
fibrinogen negative, avidin negative region was defined by the unactivated population
that was labeled with both fibrinogen and avidin. The avidin positive population was
defined using the biotinylated platelet population labeled with avidin. When the
activated and unactivated, biotinylated populations were mixed together, 13 ± 12% of the
platelets were both fibrinogen and avidin negative, 39 ± 12% were fibrinogen positive but
avidin negative, 41 ± 3% were fibrinogen negative and avidin postive, and 2 ± 1% were
fibrinogen positive and avidin postive (Figure 14D, n=3). The remaining 2% ± 1 of
events were not within one of the four defined regions.

The mixed platelet population system was adapted to evaluate the selectivity of
nanoparticle labeling for activated platelets. Fibrinogen was conjugated to 18 nm ± 2
gold nanoparticles and streptavidin was conjugated to 38 nm ± 5 gold nanoparticles.
Platelets were isolated, biotinylated and labeled as described for the fluorescence
experiments, with gold conjugates of fibrinogen and streptavidin substituted for
fluorochrome conjugates. Specimen preparation and analysis were as described for SEM.
Gel-filtered platelets showed the discoid morphology expected for unactivated platelets
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and had only background levels of nanoparticle labeling with either fibrinogen or
streptavidin labels (Figures 15A and 15B). The biotinylated platelets were primarily
discoid but the majority of them deviated from the completely unactivated morphology
and had short, thick pseudopodia, indicating that a slight degree of activation occurred.
Thrombin-activated platelets had a rounded morphology with multiple long pseudopodia.
Similar to the starting gel-filtered platelets, unactivated, biotinylated platelets showed
little labeling with fibrinogen (Figures 15C and 15D) and activated platelets showed little
labeling with streptavidin (Figures 15E and 15F).

Biotinylated platelets labeled well with streptavidin and displayed a nearly uniform
distribution of labels over the surface of the platelets (Figure 16). Thrombin-activated
platelets labeled with fibrinogen (Figure 17) displayed two distinct labeling patterns.
Heavily-labeled platelets had labels on the platelet surface membrane as well as
numerous labels internally, most likely in the OCS. Other activated platelets exhibited
weaker labeling, with fibrinogen only present on the surface of the platelet. Nearly all
thrombin-treated platelets were in a rounded form with many pseudopodia projecting
from the platelet body, demonstrating an activated morphology. After the two platelet
populations were mixed together and labeled with both fibrinogen and streptavidin
(Figure 18), the labels nearly exclusively segregated to the thrombin-activated population
or the unactivated biotinylated population, respectively. Streptavidin consistently labeled
platelets with an unactivated or weakly activated morphology, while fibrinogen labeled
the platelets with obvious activated morphologies. The nanoparticle label types were
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easily distinguished at 13,000 x magnification due to the difference in size, brightness
intensity in BSE micrographs, and distribution on the surface and within the platelet.

Discussion
The use of fibrinogen as a specific targeting molecule to direct nanoparticles to activated
platelets was evaluated with an emphasis on the feasibility of the method being adapted
to an in vivo system. First, the utility of human fibrinogen for targeting in both human
and murine platelet systems was evaluated. Human fibrinogen performed similarly to
murine fibrinogen with no significant differences between the two species of fibrinogen
in murine platelet aggregation induced through different activation pathways. This
indicates that human fibrinogen may be used for either human or murine in vitro studies
and in future murine in vivo studies. Further studies showed that fibrinogen conjugated
to gold nanoparticles can bind to platelets that have already formed a platelet aggregate in
the presence of plasma levels of unconjugated fibrinogen. The biological activity of
fibrinogen conjugated to nanoparticles was confirmed by the ability of the conjugates to
support platelet aggregation and produce a characteristic labeling pattern. A method to
evaluate whether fibrinogen conjugates show selectivity for activated platelets in a
system containing both unactivated and activated platelets was developed. The activated
platelets approximated platelets that would be involved in an in vivo thrombus, while the
unactivated platelets reasonably represented circulating quiescent platelets. The activated
population bound fibrinogen conjugates heavily while the unactivated population
remained untargeted by fibrinogen.
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Human fibrinogen for use in the murine system:
Use of a single species of fibrinogen for targeting human and murine platelets is desirable
for both experimental and practical aspects. Fibrinogen probes may be used to study the
role of activated platelets in blood clot formation either in vitro or in vivo. For our
purposes, fibrinogen targeting provides a method to specifically deliver nanoparticles to
activated platelets involved in thrombus formation. Human platelets reproducibly
aggregated to a greater extent than murine platelets under similar conditions. The murine
blood samples were likely over-anticoagulated, when the blood collection produced less
than the expected volume of blood, as the syringe was preloaded with enough citrate to
anticoagulate 810 L blood. The lower blood volume and higher effective concentration
of citrate would lead to excess chelation of platelet internal calcium and could have led to
lower activation response. We partially compensated for this issue by the addition of
extra Ca2+ ions, 5 mM final concentration, when activating murine platelets as compared
to 2 mM for human platelets. The differences in activation and aggregation were likely
due to effects of processing the murine platelets for in vitro use rather than any true
difference in the ability of human and murine platelets to aggregate. It is also possible
that murine aggregation may be dampened when compared to human hemostasis due to
the large difference in vessel diameter and coagulation response. The differences we
observed between the species in maximum aggregation does not preclude comparison of
how well human and murine fibrinogen can support aggregation. For this analysis
murine platelet aggregates are not compared to human aggregates, but rather murine
aggregates generated with human or murine fibrinogen are directly compared to one
another. Murine platelet aggregation varied depending on the activation pathway and
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dose of agonist used. Supplementing murine platelets with murine or human fibrinogen
produced completely overlapping aggregation dose-response curves. It has been
demonstrated that rabbit gel-filtered platelets can support aggregation using granulederived fibrinogen at nearly the same level as platelets supplemented with fibrinogen (66,
67). Human gel-filtered platelets by contrast require supplemental fibrinogen to support
aggregation (68). We demonstrated that moderate aggregation (24%) occurs in our
murine gel-filtered platelet system without supplemented fibrinogen, but at a greatly
reduced level. These results demonstrate that supplemental human fibrinogen supports
aggregation similarly to murine fibrinogen regardless of whether the platelet activation
pathway is stimulated with a strong agonist such as the thrombin receptor activating
peptide AYPGKF-NH2, a moderate platelet activator such as ADP acting on the P2Y12
puringergic receptor, or by bypassing surface receptors and directly activating platelets
by increasing membrane calcium permeability (ionomycin). There was no shift of the
dose-response curves toward lower agonist doses in the presence of murine fibrinogen as
compared to human fibrinogen suggesting that there is no enhancement of sensitivity
when using species-matched protein in this model.

The aggregation data was generated using a 24-well plate system of aggregating platelets
rather than using the more commonly used aggregometer. The aggregometer is
essentially a heated stir plate and single wavelength spectrophotometer. Stirring and
temperature control allow platelets to clump together in a reproducible manner and the
spectrophotometer measures the optical density which is used to determine the percent
aggregation. The 24-well plate system essentially deconstructs the aggregometer into its
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essential elements, by using 24-well plates with a stirbar in each well and a stir plate to
aggregate platelets inside an incubator. After aggregation, the material is fixed and a
microtiter plate reader is used to measure the optical density of each sample similarly to a
96-well plate based aggregometry protocol (69). The 24-well plate system produced
similar end point aggregation values for human platelets as were obtained in an
aggregometer, indicating the two methods are essentially equivalent for end point
analysis. The advantage to the 24-well plate system is that many samples may be run
simultaneously, with our methods 16 samples could be tested at once, while a typical
aggregometer may only be able to aggregate up to 4 samples at the same time. This
ensures that the comparisons between samples are of the highest possible biological
significance as the platelet aggregation response is time dependent. Aggregation of gelfiltered platelets is especially challenging as their responsiveness decreases rapidly over
time. The 24-well plate system removes the time-dependent variability from platelet
aggregation, and is useful in experiments where direct comparison of multiple platelet
aggregation responses under varying conditions is required.

Human fibrinogen for targeting nanoparticles to activated platelets:
The use of fibrinogen conjugated to colloidal gold to label platelets has been extensively
studied in both the surface-activated system (26, 27) and in platelets activated in
suspension (29, 30). We confirmed earlier studies (70) that fibrinogen conjugated to
colloidal gold supports aggregation of platelets in a similar manner to platelets
aggregated with unconjugated fibrinogen. This suggests that the conjugation to
nanoparticles does not diminish the ability of the fibrinogen to bind to IIB3 or to
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crosslink platelets together. An individual molecule of fibrinogen on an 18 nm colloidal
gold nanoparticle may have both of its binding sites available. Alternatively, molecules
of fibrinogen may only have a single binding site available after conjugation, but the
nanoparticle contains multiple fibrinogen molecules (71). Regardless, fibrinogen
conjugates retain virtually all of their platelet-specific biological functions.

The only difference between the two species of fibrinogen observed was when murine
platelets were aggregated using supplemental human fibrinogen conjugated to colloidal
gold. In these experiments, more dense aggregates were produced than when
supplemental murine fibrinogen conjugates were used. The aggregates supported by
murine fibrinogen conjugates produced less cohesive aggregates, in that they showed less
evidence of being tightly drawn together in a manner resembling clot retraction. It is
unlikely that the structure or sequence of the human fibrinogen supports murine
aggregation better; rather, the commercially available human fibrinogen is of higher
purity which allows it to be conjugated to colloidal gold more effectively. Labeling
between the conjugates within the aggregates appeared similar.

When studying labeling of surface-activated platelets, the majority of the murine platelets
were not well spread or well labeled in these experiments, which is likely due to the
effect of excess citrate in the blood sample. The well-spread murine platelets found in
the minority of the population were used as a direct comparison to human surfaceactivated platelets, which had similar morphologies. Fibrinogen from both species
labeled the well-spread human and murine surface-activated platelets in the expected
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labeling pattern (26, 27, 72). We did not observe differences between human and murine
fibrinogen in either percent aggregation supported or labeling pattern. This indicates that
for purposes of targeting nanoparticles toward platelets and future murine in vivo work,
human fibrinogen should behave quite similarly to murine fibrinogen, and because
commercially available human products are more pure and less expensive, human
fibrinogen can serve as a suitable substitute that will work well in both human and
murine systems.

Fibrinogen conjugate binding to platelets in the presence of plasma levels of
unconjugated fibrinogen:
Fibrinogen conjugates were capable of labeling platelet aggregates when used as the only
source of supplemental fibrinogen to support aggregation, after the platelets were
aggregated with unconjugated fibrinogen, and even in aggregated platelet-rich plasma. A
population of platelets labeled intensely under all conditions tested, while other nearby
seemingly similar platelets had lower levels of labeling and internalization of the
conjugate. The difference in labeling could be due to the history of the platelet, its age,
and/or its relative health. Alternatively, these platelets may have bound unconjugated
fibrinogen released from platelet internal stores upon activation (73, 74). The amount of
labels found within aggregates generated with conjugates was enormous. Aggregates
labeled after aggregation with unconjugated fibrinogen bound less fibrinogen conjugates
but still displayed large quantities of bound nanoparticles. The platelet-rich plasma
aggregates better approximated what would occur in vivo, and showed dramatically
reduced but readily detectable binding of fibrinogen conjugates. In all cases the labels
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were observed primarily within the platelet aggregate at platelet/platelet junctions and in
the OCS. The fibrinogen labels penetrated deeply within preformed aggregates even
when high concentrations of competing unconjugated fibrinogen were present, showing
that fibrinogen conjugates have excellent potential for therapeutic targeting of the entire
aggregate, rather than just the surface of a thrombus.

Fibrinogen specificity for activated platelets:
Platelets activated with thrombin labeled strongly with fibrinogen. Labeling was similar
to that observed in platelet aggregates produced with fibrinogen conjugates, where some
platelets internalized the labels while other platelets only had labeling on their surfaces.
When biotinylated platelets were utilized, they were easily distinguished using
streptavidin conjugates. The binding patterns of fibrinogen and streptavidin make
distinguishing the labels straightforward. When thrombin-activated and biotinylated
platelet populations were mixed together, the two populations of platelets remain distinct
in morphology (75, 76) and fibrinogen labeling patterns. The segregation of the two
populations was quantifiable using flow cytometry. The method developed was
successful in preventing the activated platelets from recruiting the unactivated platelets
into an activated state, allowing evaluation of fibrinogen binding on the two distinct
populations. Fibrinogen bound only to platelets that were activated with thrombin,
suggesting that fibrinogen targeting, whether using a fluorochrome conjugate or
nanoparticle conjugate, will select for truly activated platelets.
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We tested whether the biotinylated platelets could be activated, and found they exhibited
much weaker fibrinogen binding and CD62P expression after thrombin activation. The
reduction in activation is likely due to their repeated exposure to PGE1 and its solvent,
ethanol. Diminished responsiveness of the biotinylated platelets is a flaw of this system
but was unavoidable, as without the efforts taken to prevent activation during the
biotinylation process, all of the resulting platelets would be at least partially activated,
and not representative of circulating platelets. In the mixed population experiments, the
activated and unactivated biotinylated platelets demonstrated distinctly different levels of
fibrinogen binding.

Fibrinogen appears to be a good candidate for activated platelet targeting; this model
suggests that the unactivated platelets in circulation would be left untargeted while
activated platelets involved in a blood clot would become strongly labeled with
fibrinogen. Further, it may be possible to utilize the mixed platelet population system
developed here to show specific hyperthermic damage to activated platelets using
fibrinogen-conjugated gold-coated nanoparticles while leaving unactivated platelets in
healthy condition.

Expected in vivo applications:
These results suggest that fibrinogen conjugated to nanoparticles is capable of targeting
conjugated nanoparticles to activated platelets participating in an aggregate or thrombus
while leaving unactivated platelets unlabeled. Human fibrinogen can be used as the
preferred targeting molecule for both human and murine systems. Fibrinogen conjugates
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are able to bind to platelet aggregates, even after formation with and in the presence of
unconjugated fibrinogen. However, a reduction in labeling will need to be considered
during development of any in vivo applications. The internal localization and clustering
of fibrinogen labels in platelet aggregates supports the idea that inducing hyperthermia
will be feasible. The depth to which the labels can penetrate aggregates is especially
encouraging for the predicted success of the system in disruption of in vivo thrombi.
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Figures and Figure Legends:

Figure 6. Aggregation of human platelets using different assay systems. (A)
aggregometer tracing of gel-filtered platelets supplemented with 200 g/mL human
fibrinogen and 2 mM Ca2+, and stimulated with 67 M of SFLLRN-NH2. Representative
results obtained from 3 blood donors. Aggregation was initiated at 30 seconds (arrow),
and was considered to have reached its maximal point by 5 minutes 30 seconds. The
maximal aggregation from the aggregometer and the end point from aggregometer and
the 24-well plate aggregation system (n=3) are shown in (B). Error bars are standard
deviation. No significant difference in maximal aggregation was observed between the
aggregometer and 24-well plate systems.
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Figure 7. Aggregation of murine gel-filtered platelets supplemented with murine (open
bars) or human (closed bars) fibrinogen. (A) Aggregation with maximal doses of
AYPGKF-NH2 (100 M), ADP (10 M), or ionomycin (2 M). (B-D) Dose-response
curves of murine platelet aggregation in the presence of 200 µg/mL murine fibrinogen
(open triangles) or human fibrinogen (closed circles). Data are expressed as a function of
the aggregation observed with the maximal dose of the indicated agonists. Error bars
represent standard deviation, n = 6 (B, C) or n = 2 (D) for each data point. No significant
differences between murine and human fibrinogen were detected at any dose of any
agonist tested.
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Figure 8. Direct comparison between unconjugated (open bars) and colloidal goldconjugated (closed bars) fibrinogen in the aggregation of gel-filtered platelets in response
to 10 M ADP. (A) human platelets supplemented with human or murine fibrinogen; (B)
murine platelets supplemented with murine or human fibrinogen. Error bars represent
standard deviation; n = 3 for human platelets, n = 3 for murine platelets with conjugated
fibrinogen and n = 2 for murine platelets with unconjugated fibrinogen.
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Figure 9. Analysis of gold conjugated-fibrinogen labeling on surface-activated platelets
by SEM. Well spread surface-activated human platelets were incubated with either goldconjugated human (A) or murine (B) fibrinogen. Representative micrographs of murine
surface-activated platelets labeled with human or murine conjugates are shown in (C) and
(D), respectively. Less typical murine platelets at advanced stages of surface activation
that more closely resemble human surface-activated platelets are shown labeled with
human (E) or murine (F) conjugates. The colloidal gold nanoparticles appear as bright
spheres in SEM; examples of the nanoparticles are indicated with arrows. Labels are
primarily observed near the center of each platelet. Areas of the platelet periphery that
have been cleared of labels through their centralization are indicated on some platelets
with an arrowhead. Size bars are 3 µm.
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Figure 9
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Figure 10. SEM analysis of platelets aggregated with colloidal gold-fibrinogen
conjugates. Left column, low voltage (1 kV), high resolution secondary electron (SE)
images that reveal fine surface detail. Right column, backscattered electron (BSE)
images of the same field of view as shown on the left. (A, B) demonstrate murine gelfiltered platelets supplemented with murine fibrinogen conjugates in the absence of
agonist. Representative micrographs showing murine gel-filtered platelets supplemented
with either murine or human fibrinogen conjugates and stimulated with 10 mM ADP are
shown in (C, D) and (E, F), respectively. Human gel-filtered platelets supplemented with
murine or human fibrinogen conjugates with ADP stimulation are shown similarly in (G,
H) and (I, J). Size bars are 5 µm.
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Figure 10
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Figure 11. TEM analysis of ultrathin sections of murine platelets aggregated with human
fibrinogen conjugated to colloidal gold nanoparticles. Fibrinogen-conjugated colloidal
gold is observed around the membrane of the platelet, in platelet/platelet junctions, and in
the OCS of some platelets. An area in which movement of conjugates into the OCS from
the platelet surface is indicated by white arrows in (A); the progression of the conjugates
deeper into the OCS is further indicated by arrowheads. The range of labeling intensity
observed in individual sections is demonstrated in (B) where a heavily labeled platelet
has interacted with a lightly labeled platelet. Fibrinogen conjugates can be observed at
the platelet/platelet junction. Size bars are 500 nm.
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Figure 12. Comparison of human fibrinogen binding to human platelets during and after
platelet aggregation. Micrographs of a human platelet aggregate aggregated with
colloidal gold conjugated fibrinogen and imaged in the SEM by backscattered electrons
or by TEM are shown in (A) and (B), respectively. Platelet aggregates produced with
unconjugated fibrinogen and then labeled post aggregation in competition with
unconjugated fibrinogen are shown in a backscattered electron micrograph (C) and TEM
micrograph (D). In all cases, fibrinogen conjugates are mostly observed within the
aggregates at platelet/platelet junctions (arrows) or within the OCS of individual platelets
(arrowheads). (E) demonstrates platelets aggregated in platelet-rich plasma and then
labeled with fibrinogen conjugates, allowing them to compete with plasma fibrinogen.
The outer edge of the aggregate is slightly to the right of the field of view. The number
of nanoparticle conjugates observed was reduced in platelets labeled after aggregation
with unconjugated fibrinogen when compared to platelets aggregated using the
conjugates as the sole source of non-platelet-derived fibrinogen. Size bars are 4 m for
(A) and (C), 1 m for (B), (D), and (E).
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Figure 12
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Figure 13. Fluorescent fibrinogen labeling of human platelets in a mixed population of
activated and unactivated platelets. Gel-filtered platelets labeled with AlexaFluor 488fibrinogen and streptavidin-TRITC shown are shown using DIC (A) and as an overlay of
FITC and TRITC fluorescence channels (B). The fluorescence channels of biotinylated,
unactivated platelets labeled with Alexa 488-fibrinogen and streptavidin-TRITC are
shown in (C) and (D), respectively. Fluorescence channels of platelets activated with
thrombin and labeled with AlexaFluor 488-fibrinogen and streptavidin-TRITC are shown
in (E) and (F). The biotinylated, unactivated platelets and thrombin-activated platelets
were mixed together and labeled with both fluorochromes. The resulting DIC image is
shown in (G) to demonstrate platelet morphologies, including some small platelet
aggregates (arrow). Overlaid FITC and TRITC fluorescence channels of mixed
unactivated, biotinylated and thrombin-activated platelets are shown in (H). (C) and (F)
include DIC images as insets to show platelets in the field of view. Size bar is 20 m for
all images.
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Figure 14. Flow cytometry analysis of biotinylated, unactivated platelets mixed with
thrombin-activated platelets. Histograms depicting single populations of unactivated
(filled); activated (thin black line); and unactivated, biotinylated (thick black line) are
shown in (A,B,C), activated, biotinylated (gray line) platelets are further shown in (A,C).
(A) shows binding of fibrinogen conjugated to AlexaFluor 488 to the platelet
populations. Avidin conjugated to PE staining is shown in (B). (C) demonstrates
staining for P-selectin (CD62P) using a PE-conjugated monoclonal antibody; the gate for
CD62P-positive platelets is shown. A dot plot of the mixed populations of biotinylated
and activated platelets stained together is shown in (D). The gates drawn in (D) represent
populations of platelets positive or negative for fibrinogen and positive or negative for
avidin derived using single label controls. Average percentage of platelets and standard
deviation in each gate over 3 experiments is given.
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Figure 15. Singly-labeled negative controls for selectivity of nanoparticle conjugates for
unactivated (A,B); unactivated, biotinylated (C,D); and thrombin-activated platelets
(E,F). SEM of human unactivated gel-filtered platelets labeled with fibrinogen
conjugated to 18 nm colloidal gold (FGN-Au), and streptavidin conjugated to 38 nm (SAAu) colloidal gold is shown in secondary (SE) (A) and backscattered electron (BSE) (B)
images. Unactivated biotinylated platelets labeled with fibrinogen conjugated to 18 nm
colloidal gold are shown in SE (C) and BSE (D) images. Activated platelets labeled with
streptavidin conjugate shown in SE (E) and BSE (F) imaging modes. No labeling over
background levels can be detected in any of these specimens. Size bar is 4 m for all
micrographs.
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Figure 16. Singly-labeled positive control for streptavidin-conjugated nanoparticle
binding to unactivated, biotinylated platelets. (A) shows a secondary electron
micrograph of biotinylated platelets with the morphology typically observed after the
biotinylation procedure. (B) demonstrates the same area imaged with backscattered
electrons. Streptavidin labels appear over the entire surface of the platelets including on
the short pseudopodial extensions. Size bar is 4 m for both micrographs.
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Figure 17. Thrombin-activated platelets labeled with fibrinogen conjugated to 18 nm
colloidal gold. (A) shows a secondary electron micrograph of several activated platelets.
(B) shows the backscattered electron micrograph in the same region showing labeling
localization. Two distinct labeling patterns are observed, with heavy labeling shown as
very bright platelets and moderate surface labeling showing distinct small nanoparticles
on the surface, indicated with arrows. Size bar is 4 m for both micrographs.
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Figure 18. Activated and biotinylated, unactivated platelets mixed together and labeled
with both fibrinogen conjugated to 18 nm colloidal gold and streptavidin conjugated to
38 nm colloidal gold. SE micrographs of two representative fields are shown in (A) and
(C). Corresponding BSE micrographs are shown in (B) and (D). The field shown in (A)
and (B) demonstrates all types of labeling observed in this sample. The top platelet is
thrombin-activated, distinguished by heavy fibrinogen labeling, including extensive
labeling of the platelet interior. The middle platelet demonstrates a thrombin-activated
platelet distinguished by moderate labeling with 18 nm colloidal gold conjugated to
fibrinogen covering nearly its entire surface. The bottom platelet is an unactivated,
biotinylated platlet, which is shown by binding of streptavidin conjugated to 38 nm
colloidal gold on the platelet surface and the lack of any surface or interior labeling with
18 nm fibrinogen labels. (C) and (D) show a typical field of platelets with two thrombinactivated platelets on the left and a single unactivated, biotinylated platelet on the right.
Size bar is 4 m for all micrographs.
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Abstract:

Magnetite nanoparticles are of interest in biological systems for a variety of applications.
We are interested in using magnetite nanoparticles to cause localized cellular
hyperthermia upon exposure to an external oscillating magnetic field. To successfully
target magnetite nanoparticles to cells it is necessary to functionalize them with a
targeting protein and stabilize them at physiological pH and salt concentrations. One
method of accomplishing these goals is to coat the magnetite with gold and then
conjugate protein to the gold surface. Gold-coated magnetite is most often described as a
core-shell structure, despite significant issues with the ability of gold to wet the surface of
magnetite. Here we examined the structure and composition of lab-produced gold-coated
magnetite, and found structures, different than core-shell structures, with exposed
magnetite surfaces. We examined the ability of these nanoparticles to be conjugated to
fibrinogen for both nanoparticle stability and specific targeting of human platelets. Goldcoated magnetite can be functionalized with fibrinogen, which stabilizes the
nanoparticles at physiologic pH and salt concentration. Fibrinogen-conjugated goldcoated nanoparticles can be targeted toward activated platelets in a manner similar to the
already established fibrinogen-conjugated colloidal gold system. The localization of
fibrinogen-conjugated gold-coated magnetite on platelets was directly compared to the
well established fibrinogen-conjugated colloidal gold labeling pattern and found to be
very similar. Fibrinogen-conjugated gold-coated magnetite labeling was examined in an
in vitro made artificial blood clot. Labeling was detectable, albeit at greatly reduced
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values. Labeling was greatly reduced in conditions that resemble a blood clot but
hyperthermia may still be possible.

Introduction:

Successful nanoparticle-based systems require a method to target cells and tissue and to
cause a desired effect at the target site. Our proposed system uses fibrinogen as the
targeting molecule to specifically target activated platelets within a blood clot. For
ischemic stroke applications, we are most interested in magnetic field-induced
hyperthermia (1-6) to disrupt occlusive thrombi. Combining the targeting and heating
requires magnetite nanoparticles to be conjugated to proteins, while retaining the abilities
of the protein to target specific cells. In this report, we focus on synthesis of magnetite
nanoparticles that are coated with gold to allow conjugation of fibrinogen to the
nanoparticle surface, thereby promoting the use of the nanoparticles in our specific
biological application of targeting platelets.

Magnetic iron oxide nanoparticles have been studied for a variety of applications in
biological systems including magnetic-assisted cell separation (7-9), MRI contrast (7,
10), drug delivery (2), and magnetic field-induced hyperthermia (1-6). The scientific
principle underlying the design is that applying an external magnetic field to the cellbound nanoparticles causes a significant temperature elevation and results in highly
localized damage to the cell membrane immediately surrounding the nanoparticles (11,
12). The simplest application of the technology is direct injection of ferrofluid into a
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tumor (4, 13) or nonspecfic cell uptake (phagocytosis) of nanoparticles (1, 6, 14),
followed by heating. This type of bulk heating in the absence of specific targeting can be
effective in destruction of a tumor site, but has serious limitations in that hyperthermia is
likely to cause nonspecific damage to surrounding tissues (5, 14). Therefore, targeting
the nanoparticles to specific cells or tissues is desirable. Tumor cell destruction by
magnetic field-induced hyperthermia using magnetic nanoparticles conjugated to tumorspecific targeting proteins has been previously reported (5, 11, 12). For targeted
disruption of arterial thrombi, nanoparticle localization through molecules with
specificity for activated, as opposed to resting, platelets is of most interest.

Procedures for the synthesis of magnetic iron oxide nanoparticles can, in general, be
placed in one of three categories: thermal decomposition (10, 15, 16), aqueous alkaline
precipitation (17-19), or microemulsion synthesis (20-23). Thermal decomposition
synthesis uses organometallic iron that is dissociated by heat and recombined into
magnetite in an organic solvent. The result is nanoparticles of uniform size and shape
(10, 16); however, these particles are difficult to use in biological applications due to
their inherent hydrophobicity and the presence of potentially toxic organic residues (24).
Aqueous alkaline precipitation uses dissolved iron salts that are oxidized by a strong
base, which causes the iron oxide to precipitate from solution into nanoparticles. These
nanoparticles are hydrophilic and can be readily suspended in solution by use of
surfactant to impact a negative charge on the nanoparticle surface. A major drawback to
aqueous methods is that they give imprecise control of the size of the resultant
nanoparticles. Microemulsion synthesis attempts to bridge the gap between organic and
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aqueous synthesis by using inverse micelles suspended in an organic medium. Iron salts
are precipitated within the inverse micelle, which creates a natural size barrier and
controls size of the nanoparticle. These particles have relatively homogenous size
distributions (23, 25) like many organically-derived nanoparticles, but were created in an
aqueous environment. They may exhibit either hydrophilic or hydrophobic behavior and
organic residue contamination can still limit their use in biological systems. The best
choice in type of synthesis method used depends directly on the ultimate application of
the nanoparticles.

Nanoparticles that exhibit good magnetic behavior, are hydrophilic, non-toxic, and can be
functionalized with a biologically-relevant targeting molecule are most desirable for
platelet-targeted hyperthermia. Magnetite synthesized by an aqueous method has very
strong magnetic behavior (26) and can be made between nm to m diameter size ranges.
Because these particles are synthesized in water, they have surfaces that are most
compatible with an aqueous environment, and the reaction by-products are relatively nontoxic. However, addition of a surfactant such as tetramethylammonium hydroxide
(TMAOH) is required for these nanoparticles to remain a colloid (2, 27). Even
surfactant-stabilized iron oxide nanoparticles are unstable at physiologic salt and pH
values (28, 29), and thus have limited biological utility in the absence of further surface
modification. Functionalization of the surfaces of nanoparticles with simple organic
molecules or proteins (19, 30, 31) or metal coatings (22, 27, 28, 32) can protect the iron
oxide from agglomerating under physiologic conditions, and provides a means to keep
the nanoparticles stable within a biological system.

119

Magnetic iron oxide nanoparticles with a gold coating have been developed to address
some of the disadvantages associated with iron oxide colloids for biological applications.
The gold coating improves stability of the iron oxide at physiologic conditions (28) and
provides a surface for functionalization with proteins (32-34) or nucleic acids (35, 36), or
for other well characterized gold surface modifications (9, 37, 38). These gold-magnetite
nanoparticles have often been described as having a core-shell morphology, with a
magnetite or maghemite core surrounded by a thin, uniform gold shell (27, 32, 37, 39).
The surface modifications do not impair the magnetic properties of the nanoparticles (9,
27, 40), making them appropriate for biological applications that depend on magnetic
susceptability.

There are conflicting accounts describing the structure of the nominal magnetite-gold
core-shell nanoparticles. Many successful syntheses of magnetite core-gold shell
nanoparticles by both aqueous and organic methods resulting in an iron oxide core and a
gold shell have been reported (27, 32, 34, 37, 39, 41, 42). However, a true core-shell
morphology is an unexpected outcome because metals typically do not wet the surfaces
of oxides well (43) due to a mismatch in surface energies. Instead, gold is expected to
grow in a Volmer-Weber pattern (44), creating three-dimensional islands on the
magnetite surface and leaving portions of the magnetite uncoated. Volmer-Weber growth
has been observed when gold is grown on the (100) and (111) surfaces of magnetite in
high vacuum (45, 46). However, growth conditions in an aqueous environment may be
different. While many of these core-shell studies have demonstrated by x-ray or electron
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diffraction that their products contain both a magnetic iron oxide and gold, evidence of
true core-shell structure has been largely indirect or lacking.

We hypothesize that coating magnetite nanoparticles with gold facilitates subsequent
functionalization with proteins by increasing repulsive forces between nanoparticles to
prevent the nanoparticles from agglomerating due to the magnetic and electrostatic forces
of attraction that occur at physiologic pH and salt concentration. Gold nanoparticle have
been used as markers in biological systems for over 30 years and provide a good model
on which to base the functionalization of magnetic nanoparticles for targeting to specific
cell types, such as through their conjugation with fibrinogen for targeting activated
platelets in the current study. Most proteins can be conjugated to gold surfaces by nonionic adsorption without loss of function (47, 48). Coating magnetite with gold is
expected to provide a surface for non-ionic protein adsorption very similar to pure gold
nanoparticles. We and others (49-54) have routinely used fibrinogen-conjugated gold
nanoparticle in our light and electron microscopy studies of platelet physiology.
Applying this technology to the specific targeting of activated platelets in thrombi with
fibrinogen conjugates of gold-coated magnetite, and disruption of the targeted thrombus
by hyperthermia, is a logical extension of the foundation established by previous work.

Here we describe the synthesis and characterization of gold-coated magnetite
nanoparticles produced using an aqueous alkaline coprecipitation method for synthesis of
magnetite nanoparticles and hydrazine reduction for coating the nanoparticles with gold.
The composition and morphology of the resultant nanoparticles were characterized. The
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structure was found to significantly differ from that of true core-shell nanoparticles. All
morphologies of gold-coated magnetite nanoparticles produced were assessed for their
ability to conjugate with protein by non-ionic adsorption. Lastly, the ability of
fibrinogen-conjugated gold-coated magnetite to target activated platelets was evaluated
and directly compared to targeting using fibrinogen-conjugated colloidal gold as
described previously (Chapter 2).

Materials and Methods:

Magnetite synthesis:
Magnetite nanoparticles were synthesized by an aqueous alkaline coprecipitation method
(17). Under argon, 5 mL of a solution of 0.64 M anhydrous FeCl3 and 0.32 M anhydrous
FeCl2 (both salts from Sigma-Aldrich, St. Louis, MO) in 0.4 M HCl was slowly added to
50 mL of 1.5 M NaOH in 32-38C degassed, double deionized H2O (ddH2O). The
nanoparticles were allowed to settle, then washed three times by centrifugation at 3,000 g
for 1 minute and resuspended in degassed ddH2O. A final wash in 0.1 M
tetramethylammonium hydroxide (TMAOH, Alfa Aesar, Ward Hill, MA) was performed
in the same manner. Magnetite nanoparticles were size fractionated by centrifugation at
6,000 g for 5 minutes in 0.1 M TMAOH. The nanoparticles in the supernatant were
characterized by TEM and were used in gold coating procedures. The desiccated weight
and average diameter of isolated, individual nanoparticles, along with a Fe3O4 density of
5.15 g/cm3, were used to calculate magnetite nanoparticle concentrations.
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Gold growth on magnetite:
Magnetite nanoparticles were coated with gold in a manner similar to that of previous
reports (27). Magnetite nanoparticles were aged at least 3 days at 4C in 0.1 M TMAOH
under an argon atmosphere, then diluted 100-fold in 0.00275% hydrazine hydrate
(Sigma-Aldrich). Gold growth on the surface of magnetite nanoparticles was initiated by
slow addition of 120 L 4% aqueous HAuCl4·3H2O (Sigma-Aldrich) per 100 mL of
dilute magnetite nanoparticles with stirring, resulting in a final concentration of 0.12 mM
Au3+. Growth of gold on the magnetite was assessed by UV-visible light spectroscopy
and visually by the color of the resultant colloid. Blue sols were discarded; red or purple
sols were stored under argon at room temperature until further testing. To determine the
concentration of isolated gold-coated magnetite nanoparticles, the sol was mixed with a
known concentration of 90 nm latex bead standard (Ted Pella, Redding, CA) and
aerosolized onto carbon-coated TEM grids (Electron Microscopy Sciences, Hatfield, PA).
The number of latex beads and Au-coated Fe3O4 nanoparticles in discrete dried droplets
was determined by direct counting. From these values, the droplet volume and
concentration of isolated gold-coated magnetite nanoparticles were calculated.

Electron microscopy of magnetite and gold-coated magnetite nanoparticles:
Both gold-coated and uncoated magnetite nanoparticle sols were air-dried from the
solution in which they were synthesized onto TEM grids coated with holey or ultra-thin
carbon films (Electron Microscopy Sciences) for TEM imaging and selected area
diffraction. Nanoparticles were imaged using a Hitachi H-600 TEM (Dallas, TX) at 75
kV for amplitude contrast brightfield imaging and selected area diffraction. Selected area
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electron diffraction and phase contrast high resolution TEM imaging were performed
using a Hitachi H9000-NAR (Dallas, TX) operating at 300 kV, by Eric Mattson under the
direction of Marija Gajdardziska-Josifovska at the University of Wisconsin – Milwaukee
Department of Physics. Histograms displaying nanoparticle diameter were generated by
measuring the longest axis of 500 isolated, individual nanoparticles using ImageJ
software (National Institute of Health, http://rsbweb.nih.gov/ij/). Lattice spacing and
angles were measured by fast Fourier transformation in Digital Micrograph (Gatan,
Pleasanton, CA).

Conjugation of proteins to gold-coated magnetite
Proteins were conjugated to gold-coated magnetite through a modified non-ionic
adsorption protocol (49). The pH of gold-coated magnetite was adjusted by addition of 1
M HEPES at the indicated pH to a final concentration of 10 mM. Conjugation was
performed at pH 6.8 for human fibrinogen (plasminogen-, von Willebrand factor-, and
fibronectin-depleted, Enzyme Research Laboratories, South Bend, IN), 7.0 for goat antimouse immunoglobulin G (IgG,  chain specific, Southern Biotech, Birmingham, AL),
and 5.1 for bovine serum albumin (BSA, heat shock treated, DNase-, RNase-, and
protease-free, Fisher Scientific, Pittsburgh, PA). Gold-coated nanoparticles were
immediately incubated for 5 minutes with protein at final concentrations of 16 g/mL
fibrinogen, 20 g/mL IgG, or 40 g/mL BSA. For platelet labeling experiments, the
nanoparticles were further stabilized with 0.004% polyethylene glycol (average MW
20,000, Sigma-Aldrich). Conjugated nanoparticles were separated from free protein by
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centrifugation at 16,000 x g for 5 minutes, and resuspended in either Tyrode’s buffer or
ddH2O. Colloidal gold conjugates were prepared as described previously (Chapter 2).

The stability of nanoparticle conjugates was tested by addition of 10 L saturated CaCl2
per 1 mL nanoparticle conjugate resuspended in ddH2O. Fully stabilized conjugates did
not exhibit an obvious change in the nanoparticle absorbance spectrum as assessed either
visually or using a Beckman Coulter DU 800 UV-Vis spectrophotometer. The magnetic
character of the gold-coated magnetite was similarly observed by assaying UV-Visible
absorbance of nanoparticles remaining in solution after the nanoparticles were allowed to
interact with a neodymium static magnet for 12 hours.

Fibrinogen-conjugated nanoparticle labeling of surface-activated platelets:
Gel-filtered surface-activated human platelets were prepared as described previously
(Chapter 2). Adherent platelets were labeled with fibrinogen conjugated to Au or Aucoated magnetite nanoparticles in the presence of 2 mM Ca2+ for 10 minutes at room
temperature. Samples were then washed three times in Ca2+-supplemented Tyrode’s
buffer to remove unbound nanoparticles. Grids were fixed in 1% glutaraldehyde for 30
minutes. Samples were not stained with any heavy metals except for SEM samples
comparing fibrinogen-conjugated gold to gold-coated magnetite on platelet surfaces,
which were postfixed in 0.05% OsO4 for 15 minutes. The samples were dehydrated
using a graded ethanol series and dried by the critical point procedure using a Balzers
CPD020 critical point dryer (Schalksmühle, Germany). Samples were stabilized with a
carbon coating applied in an EMItech 575 sputtercoater (Ashford, Kent, United
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Kingdom) using a carbon evaporation head, except for SEM samples comparing
fibrinogen-conjugated gold to gold-coated magnetite labeling which were sputtercoated
with 2 nm Ir.

Electron microscopy of gold-coated magnetite nanoparticle morphology before and after
protein conjugation, and on platelet surfaces:
Fibrinogen-conjugated gold and gold-coated magnetite nanoparticles were prepared for
electron microscopy by two separate methods. First, nanoparticles were air-dried onto
carbon-coated TEM grids and then directly imaged. Nanoparticles were also adhered to
carbon-coated TEM grids coated with poly-L-lysine (Sigma-Aldrich) according to the
manufacturer’s instructions. Non-adherent nanoparticles were removed with three, 5
minute washes accomplished by incubating the grids over successive 20 L drops of
ddH2O. The grids were stained with 1% uranyl acetate, dehydrated in a graded ethanol
series, and dried by the critical point procedure using a Balzers CPD020. Both
fibrinogen-conjugated nanoparticles and surface-activated platelets labeled with
functionalized nanoparticles were imaged using a Hitachi H-600 TEM at 75 kV for
brightfield studies. Secondary electron (SE) imaging SEM studies of labeled platelets
were carried out on a Hitachi S-4800 (Dallas, TX) operating at 1 kV and at 30 kV for SE
imaging of nanoparticles and for all backscattered electron (BSE) imaging, respectively.

Morphological analysis of gold-coated magnetite nanoparticles bound to surfaceactivated platelets was performed using montaged high magnification BSE micrographs
or single lower magnification TEM micrographs containing entire platelets. The

126
nanoparticles on the BSE micrographs were counted around the periphery of the platelet,
with the centeral area of the platelet, as defined by a circle one half the radius of the
platelet’s shortest axis, excluded in order to accurately assess the morphology of the
nanoparticles which are difficult to resolve over the internal areas of platelets. Magnetite
portions of nanoparticle aggregates were identified by their lower contrast in both TEM
and SEM. The number of isolated and aggregated nanoparticles before and after
conjugation, and on the platelet surface was compared by Chi-square analysis.

Platelet aggregation with fibrinogen-conjugated nanoparticles:
Gel-filtered platelets and platelet-rich plasma (PRP) were prepared as described earlier
(Chapter 2). Gel-filtered platelets at 200,000 platelets/L were supplemented with either
200 g/mL unconjugated or approximately 96 g/mL conjugated fibrinogen (see below),
and 2 mM Ca2+, and stimulated with 67 mM SFLLRN-NH2 (Bachem Americas,
Torrence, CA) to a final volume of 500 L. Aggregation data was obtained as previously
described (Chapter 2). The blanks used for 0% aggregation consisted of Tyrode’s buffer
with Ca2+ and either conjugated or unconjugated fibrinogen to account for nanoparticle
absorbance. A sample of PRP was aggregated similarly to show the maximum platelet
response obtainable each day.

Preformed platelet aggregates were produced using a Chronolog Dual Aggregometer
(Havertown, PA) using 500 L gel-filtered platelets (Chapter 2). Similarly, platelet-rich
plasma was supplemented with 2 mM Ca2+ and aggregated using either 67 M SFLLRNNH2 or 2 nM human thrombin (Haematolgoic Technologies, Essex Junction, VT) as the
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stimulus. After the platelets aggregated for 5 minutes, the aggregates were labeled with
the pooled soft pellet obtained from 6 mL of the fibrinogen and gold-coated magnetite
conjugation reaction mixture. Assuming 8 g/mL protein adsorption to the nanoparticle
this represents addition of 48 mg of fibrinogen to 500 L aggregation reaction or 96
g/mL fibrinogen conjugate in the presence of the pre-existing 200 g/mL unconjugated
fibrinogen.

For SEM analysis, the gel-filtered platelets were fixed in 1% glutaraldehyde in 0.1 M
HEPES for 30 minutes. The samples were collected onto 0.4 m Nuclepore®
membranes (General Electric, Fairfield, CT) and postfixed in 0.05% OsO4 for 15
minutes. Samples were dehydrated using a graded ethanol series and dried by the critical
point procedure in a Balzers CPD20. The filter membranes were mounted onto SEM
stubs using carbon tabs (Electron Microscopy Sciences) and sputter coated with 2 nm Ir
using an EMITech K575X sputter coater. Samples were imaged using a Hitachi S-4800
SEM at 1 kV for SE imaging and 30 kV for BSE imaging.

For TEM analysis, the gel-filtered platelets were fixed in 1% glutaraldehyde, 1% tannic
acid in 0.1 M HEPES, pH 7.3, for 30 minutes. Platelet-rich plasma aggregates were fixed
in 2% glutaraldehyde in 0.1 M HEPES, pH 7.3 for 10 minutes. Glutaraldehyde crosslinked plasma proteins were removed by centrifugation at 300 x g for 5 minutes, during
which the proteins formed a very soft pellet on top of the pelleted platelet aggregates.
Proteins were removed by gently removing the soft protein pellet above the platelets.
The samples were fixed a second time in 2% glutaraldehyde, 1% tannic acid in 0.1 M
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HEPES at room temperature for 1 hour and then 4o C overnight. Samples were washed
three times in HEPES and embedded into 1% agar (Difco, Detroit, MI) in 0.1 M HEPES
by combining warm agar and 4o C platelet samples in equal volume in small TEM
embedding molds. After the agar became dense at 4o C, samples were postfixed in 0.05%
OsO4 for 1 hour at room temperature, washed 3 times in ddH2O, and stained with 1%
uranyl acetate for 30 minutes. The samples were dehydrated in ethanol, transferred to
propylene oxide and then infiltrated with low viscosity Spurr’s resin (55) but substituting
the accelerant N,N-dimethylbenzylamine with 2(dimethylamino)ethanol (56) (Electron
Microscopy Sciences). Ultrathin silver or pale gold sections were cut on a RMC MT7000 ultramicrotome (Tucson, AZ), and stained with 1% uranyl acetate. Samples were
imaged using a Hitachi H-600 TEM at 75 kV.

Results

Magnetite synthesis and characterization:
Magnetite synthesis was performed by an aqueous co-precipitation method using FeCl2
and FeCl3 at a ratio of 1:2 to promote magnetite (Fe2+)(Fe3+)2O4 over maghemite (Fe3+)2O3 formation (17, 57). Precipitation and growth of the particles occurred almost
immediately on contact with sodium hydroxide solution. We verified which particular
iron oxide was synthesized by several different techniques. Selected area electron
diffraction was performed on groups of nanoparticles. Reflections consistent with
magnetite (Fe3O4) and maghemite (-Fe2O3) were observed (Figure 19A) (58).
Maghemitehas additional low intensity reflections that were not detected in our
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nanoparticles. Analysis of our synthesized product by infrared spectroscopy, electron
energy loss spectroscopy, and HRTEM with direct comparison to magnetite and
maghemite standards, further confirmed that the predominate iron oxide synthesized was
magnetite (59).

The temperature of the solution during synthesis was found to strongly influence the size
of the resultant nanoparticles. The optimal temperature for 7 nm (average diameter)
magnetite nanoparticles was found to be between 32o to 38o C. The synthesized
magnetite nanoparticles were analyzed by TEM. When the stock magnetite was air dried
onto TEM grids, the nanoparticles were very agglomerated with few isolated particles
(Figure 19B). However, diluting the nanoparticles 1:100 in 0.1 M TMAOH before
drying prevented this artifact and the dispersion of the nanoparticles increased greatly
(Figure 19C). Diluted nanoparticles appeared as isolated particles or in small aggregates.
The size distribution of the magnetite nanoparticles were determined to be 7 ± 3 nm with
a coefficient of variation of 42% (Figure 19D), indicative of a highly heterogeneous
population.

Gold-coated magnetite structure and characterization:
Magnetite nanoparticles were coated with gold by reduction of HAuCl4 with a low
concentration of hydrazine as the reducing agent under conditions that do not favor gold
nanoparticle nucleation. Successful production of gold-coated magnetite was assessed by
color, electron microscopy, and stability following protein conjugation. Gold-coated
magnetite of the desired size had a red to magenta color similar to that of colloidal gold;
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unsuccessful batches of nanoparticles had a blue, purple, or black appearance. The
unsuccessful batches of gold-coated magnetite were often unstable and precipitated
quickly. These unstable batches often had large clumps of bare magnetite with no gold
coating as observed by TEM (not shown).

Successful coating of the magnetite seed nanoparticles was dependent on the conditions
used for the synthesis and storage of the magnetite. Seeds of the appropriate size and
concentration were obtained when synthesis was conducted between 32-38o C.
Temperatures greater than 38oC appeared to favor smaller, more highly concentrated
magnetite nanoparticles. Temperatures lower than 32oC resulted in nanoparticle size and
concentration that was difficult to reproduce. Too few magnetite seeds produced
nanoparticles with an average diameter greater than 50 nm that were not susceptible to
manipulation with a static magnet. Too many seeds resulted in precipitation of the
“coated” nanoparticles, often within a day. Further, if the magnetite seeds were aged less
than 3 days in 0.1 M TMAOH, the gold coating procedure resulted in larger
nanoparticles, similar to that observed in samples with too few seeds.

Our synthesized gold-coated magnetite nanoparticles are a heterogeneous population.
Brightfield TEM analysis of the nanoparticles showed several distinct classes of particles.
Isolated rounded nanoparticles were the most commonly observed gold-coated magnetite
nanoparticle. Minority populations of isolated faceted particles with very sharply defined
edges, and aggregated nanoparticles consisting of a group of associated nanoparticles of
low and high contrast were also observed (Figures 20A, 20B). The isolated nanoparticles
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in three different batches of gold-coated magnetite nanoparticles were found to have
average diameters of 16, 19, and 22 nm, with coefficient of variations of 24%, 25%, and
27%, respectively, and a concentration of 3 * 1011 ± 1.3 * 1011 particles/mL. The size
increase following gold coating was large in all cases, going from an average of 7 nm to
16 nm diameter in the example shown in Figure 20C. Selected area electron diffraction
was performed on magnetite, colloidal gold, and gold-coated magnetite (Figure 20D).
Gold-coated magnetite contains high intensity reflections from gold {111} and {200} and
magnetite {220} and {311}. Gold {200} and magnetite {400} overlap, making their
reflections difficult to interpret in gold-coated magnetite diffraction.

HRTEM was used to examine localization of the magnetite on and within the gold-coated
magnetite nanoparticles. Isolated particles often had magnetite lattice fringes within the
nanoparticle but not necessarily in the center of the particle. The lattice images were
analyzed using Fourier filtering to determine the relative distribution of gold and
magnetite within the nanoparticles. Magnetite fringes occasionally extended outside the
gold fringes, demonstrating that some isolated nanoparticles have exposed magnetite
surfaces. These isolated gold-coated magnetite nanoparticles usually had relatively thick
gold coatings (not shown). A small population of faceted gold-coated magnetite had a
structure consisting of a single layer of magnetite {311} extending to the edge of the
nanoparticle and two sets of gold {111} fringes, both forming 62o angles with the
magnetite {311} fringes, (Figures 21A, 21B, 21C). Aggregated gold-coated magnetite
had large areas of uncoated magnetite, with gold growth occurring in Volmer-Weber
morphology on some magnetite surfaces (Figures 21D, 21E, 21F).
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Protein conjugation to gold-coated magnetite:
Gold-coated magnetite was conjugated to fibrinogen, goat anti-mouse IgG, or BSA by
non-ionic protein adsorption. Attempts to conjugate any protein to uncoated magnetite
were unsuccessful, as the magnetite quickly agglomerated when the pH was adjusted to
near neutral (7.0). Gold-coated magnetite is partially stabilized at physiologic pH by the
gold coating but is still unstable in physiologic salt solutions. Addition of saturated
CaCl2 to 1% (v/v) caused the particles to agglomerate, which resulted in a change in the
visible absorbance spectrum as shown in Figure 22A. Adjusting the pH of the
nanoparticles with a small volume of concentrated HEPES buffer, rather than the NaOH
or KCO3 that is commonly used for colloidal gold conjugations, greatly improved the
conjugation success rate. After conjugation, addition of CaCl2 did not cause the
conjugated nanoparticles to agglomerate, as shown in Figure 22B. Conjugated particles
were removed from solution via a static magnet as easily as unconjugated gold-coated
magnetite, nearly eliminating the absorbance of visible light by the supernatants (Figure
23A). The particles bound visually to the static magnet poles (Figures 23B, 23C),
demonstrating that the magnetic behavior of the nanoparticles is preserved after the
protein conjugation procedure.

Fibrinogen-conjugated, gold-coated nanoparticles were observed by electron microscopy.
Nanoparticles were air-dried on carbon-coated TEM grids, or incubated on poly-L-lysine
carbon-coated grids followed by drying by the critical point procedure. Conjugated goldcoated magnetite nanoparticles air-dried onto TEM grids had a uniform distribution but
lacked a characteristic protein halo indicative of protein coating (Figure 24A). Both
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isolated and aggregated particles appeared in the conjugated population but a loss of
aggregated particles from 12.5% aggregated particles in the stock to 6.4% in the
conjugated population occurred. Conjugated nanoparticles dried by the critical point
procedure demonstrated the presence of protein coating as observed by TEM and SEM.
The different morphologies of gold-coated magnetite could be clearly observed in SEM
using BSE imaging. Areas containing mostly gold had high contrast, appearing bright,
while areas that were predominately magnetite had lower contrast. Protein was observed
to completely encompass nanoparticles, even at exposed magnetite edges (Figure 24B).
Both gold and gold-coated magnetite fibrinogen conjugates clumped extensively when
they were adhered to poly-L-lysine coated grids. Although clumping obscures the
distinction between what were isolated and aggregated nanoparticles prior to sample
preparation, protein can be observed to coat all available surfaces (Figure 25).
Unconjugated gold-coated magnetite also appeared clumped, while unconjugated gold
nanoparticles remained isolated. This level of clumping was not observed in any samples
air-dried directly onto carbon-coated grids.

Platelet targeting with fibrinogen-conjugated gold-coated magnetite:
The morphologies of fibrinogen-conjugated, gold-coated magnetite nanoparticles bound
to surface-activated platelets were assessed by SEM and TEM. Samples were prepared
without use of any heavy metal fixation, staining, or heavy metal sputtering that could
mask the relatively low contrast of magnetite and impede its detection. High
magnification BSE micrographs of three platelets were taken and montaged to assemble
images of entire platelets as illustrated in Figures 26A, 26B, and 26C. The numbers of
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isolated and aggregated gold-coated magnetite nanoparticles was quantified on the
periphery of platelets. Nanoparticles near the granulomere and in the open canalicular
system (OCS) were excluded from SEM analysis to prevent ambiguous analysis of
internalized nanoparticles. Similar analysis of three labeled platelets was done using
TEM micrographs of surface-activated platelets, shown in Figure 26D. TEM analysis
allowed for more of the platelet area to be quantified but required small and very thinly
spread platelets. By both SEM and TEM, magnetite was detected as nanoparticles with
weak contrast whereas gold generated a strong signal (bright for BSE imaging, dark in
brightfield TEM). The percentage of aggregated gold-coated magnetite nanoparticles on
platelets determined by SEM BSE imaging was 2.7% and by TEM imaging was 3.0%.
The two quantification strategies produced data that was not significantly different. The
proportion of aggregates in the nanoparticle population decreased with successive steps,
the stock gold-coated magnetite nanoparticle contained 12.5% aggregated nanoparticles,
after conjugation the aggregated nanoparticle proportion was reduced to 6.4%, targeted
aggregated nanoparticles on the platelet surface were further reduced to 2.7% (SEM) or
3.0% (TEM). Chi-square analysis of the proportion of aggregated nanoparticles indicated
the loss in each step was significant (p < 0.001). The stock sol contained twice as many
aggregates as the protein conjugates. Further, half as many aggregates were found on the
platelet surface as in the fibrinogen conjugates demonstrating a significant drop in
aggregated fibrinogen-conjugated, gold-coated magnetite on the platelet surface.
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Biological activity of nanoparticle conjugates:
Surface-activated platelets were labeled with gold and gold-coated magnetite conjugated
to fibrinogen in order to compare labeling between the types of nanoparticles. TEM
analysis (Figure 27) showed similar labeling patterns using conjugates of gold and goldcoated magnetite nanoparticles. Platelet nanoparticle labeling was further characterized
by SEM (Figure 28) using both SE to image the platelet surface and BSE to determine
nanoparticle localization using the strong signal from gold in both types of nanoparticles.
Both types of nanoparticles were found centralized on the platelet membrane and cleared
away from the periphery, ultimately localized around the granulomere. This pattern has
been previously described using fibrinogen conjugated to colloidal gold (50, 60, 61) and
unconjugated fibrinogen (62, 63), indicative that fibrinogen function is preserved in the
gold-coated magnetite conjugates.

The biological activity of fibrinogen-conjugated, gold-coated magnetite nanoparticles
was further tested through their ability to support aggregation of gel-filtered platelets.
Their activity was directly compared to fibrinogen-conjugated gold nanoparticles as well
as to unconjugated fibrinogen. Platelet aggregation reactions were supplemented with
calcium and unconjugated fibrinogen, fibrinogen-conjugated to colloidal gold, or
fibrinogen-conjugated gold-coated magnetite and stimulated with a maximal dose of
SFLLRN-NH2. The various treatments produced overlapping aggregometer tracings
(Figure 29) indicating the three fibrinogen sources behave equally well. PRP
supplemented with calcium and stimulated with SFLLRN-NH2 aggregated to the
maximal possible extent, and served as a positive control. After 5 minutes, PRP
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aggregated 87%, gel-filtered platelets supplemented with unconjugated fibrinogen,
fibrinogen-conjugated to colloidal gold, and fibrinogen-conjugated, gold-coated
magnetite aggregated to 80%, 79%, and 78%, respectively.

Aggregates supported by unconjugated fibrinogen, gold conjugates, or gold-coated
magnetite conjugates were examined by SEM using both SE and BSE (Figure 30).
Samples produced with unconjugated fibrinogen were used as an indicator of normal
morphology and as a baseline for BSE brightness levels. The morphology of the
aggregates in the three groups was similar, with neighboring platelets strongly interacting
with one another. Gold and gold-coated magnetite samples had strong BSE signals
emanating from deep within the platelet aggregates, similar to signals observed in
aggregates labeled with colloidal gold nanoparticles described previously (Chapter 2).

Gel-filtered platelets aggregated with unconjugated fibrinogen and then labeled with
fibrinogen conjugated to gold or gold-coated magnetite were further characterized by
TEM, with particular attention to the nanoparticles localized in the aggregate interior
(Figure 31). The localization of fibrinogen-conjugated gold nanoparticles in preformed
platelet aggregates (Figure 31A) and fibrinogen-conjugated gold-coated magnetite
nanoparticles in preformed platelet aggregates (Figure 31B) was similar. Results were
also consistent with TEM analysis of platelet aggregates supplemented only with
fibrinogen conjugates described earlier (Chapter 2). Nanoparticle labeling was found
almost exclusively on the interior of the aggregates, with little labeling appearing on the
surface of the platelet aggregates. Nanoparticles were predominately found at
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platelet/platelet junctions and in the OCS. Fewer nanoparticles were typically observed
in ultrathin sections of platelet aggregates labeled with gold-coated magnetite when
compared to ultrathin sections of aggregates labeled with gold nanoparticles. Penetration
of the label appeared equal between samples, with nanoparticles present throughout the
entire aggregate but intensity was lower in gold-coated magnetite labeled aggregates
when compared to colloidal gold labeled aggregates.

Lastly, the ability of fibrinogen-conjugated gold-coated magnetite to penetrate into
platelet aggregates under in vivo-like conditions was tested. Platelet-rich plasma was
aggregated using 67 M SFLLRN-NH2 (a non-proteolytic peptide) or 2 nM thrombin as
agonists. Both agonists activate the same signaling pathway via the PAR1 receptor (6466), but thrombin also mediates the proteolytic conversion of fibrinogen to fibrin, a much
closer approximation of a true blood clot. After the platelet aggregates were formed, they
were incubated with fibrinogen conjugated to gold-coated magnetite. Samples were
analyzed by TEM to determine localization and relative density of labeling. Aggregates
produced using SFLLRN-NH2 (Figure 32A) had similar localization and extent of
labeling as the platelet-rich plasma aggregates labeled with fibrinogen-conjugated gold
nanoparticles previously described (Chapter 2). Nanoparticle labeling was observed
primarily at platelet/platelet junctions and in the platelet OCS. Platelet aggregates
created using thrombin had a different appearance. Large amounts of darkly stained
fibrin were found within the aggregate and surrounding it, platelet fixation was poorer,
and the interior of the aggregate was more difficult to interpret. Labeling in these
aggregates was much sparser when compared to platelet-rich plasma aggregated with
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SFLLRN-NH2 (Figure 32B). Labels were found within or near fibrin bundles and
between platelets.

Discussion

It is highly desirable to develop a magnetic nanoparticle that can be easily conjugated to
proteins for cell-specific nanoparticle targeting and hyperthermic applications. Here we
produced magnetite nanoparticles using a typical aqueous coprecipitation method and
reduced gold onto the magnetite surface in an attempt to produce nanoparticles that have
been previously described as “core-shell” structures (27). The resulting gold-coated
magnetite nanoparticles did not exhibit the expected “core-shell” morphology and many
had exposed magnetite on the nanoparticle surface. However, attempts to conjugate
protein to the surface of gold-coated magnetite demonstrated that a complete gold coating
over the entire magnetite surface is not required for protein adsorption. Further, these
protein-conjugated nanoparticles were able to target platelets similarly to proteinconjugated colloidal gold.

Nanoparticle synthesis:
Production of magnetite nanoparticles by aqueous synthesis produces highly magnetic
nanoparticles that are stable in an aqueous solution of TMAOH for up to one month. The
synthesis procedure is relatively simple compared to many inverse micelle or organic
synthesis procedures (20, 22, 38), but has the high degree of variability (21, 42). Typical
nanoparticle synthesis occurs in two distinct phases: a seeding step where very small
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nanocrystals are produced, followed by subsequent growth around the nanocrystal
nucleus (67, 68). Some syntheses will also include a capping step that prevents further
growth of nanoparticles after they reach a certain size/diameter/aspect ratio (69-71). In
aqueous magnetite synthesis, the pH, ionic strength of the solution, and temperature are
all critical parameters (18). It has further been suggested that the size of the iron salt
droplets added to the reaction during magnetite synthesis plays a critical role in the
nanoparticle size and distribution (72). In our synthesis, the strong NaOH base solution
causes both seeding and growth to occur simultaneously, resulting in a combination of
many small nanoparticles and larger magnetite structures. The larger structures were
subsequently removed by centrifugation in TMAOH. The small nanoparticles remaining
in the supernatant had a fairly broad size distribution as has been previously described for
aqueous coprecipitation techniques (42).

Attempting to grow gold on magnetite nanoparticles produced mixed results. During the
coating procedure, the color change of the sol created by the gold plasmon was the
primary method of gauging initial success. After coating, success was further
characterized by stability of the nanoparticle sol and the ability to conjugate the
nanoparticles with protein. Our magnetite coating procedure revealed that the
temperature of the coprecipitation reaction plays a critical role in obtaining nanoparticles
that support gold growth. The temperature likely affected the size distribution of the
nanoparticles, which in turn affects the concentration of the final product following
removal of the large magnetite structures. It is also possible that gold growth is best
supported by magnetite nanoparticles of a certain size range. Controlling the temperature
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during magnetite synthesis provided a more consistent concentration of magnetite seeds,
and considerably increased the coating success rate. Additionally, temperature control
during coprecipitation may also affect the crystallographic termination planes of
magnetite nanocrystals and may promote different subtle surface modifications.
Repeated production of gold-coated magnetite still produces variable results when
following the same procedure with the same reagents, demonstrating that some yet
unknown variables also affect gold coating. Regardless, the procedure can be used to
produce gold-coated magnetite nanoparticles in a relatively consistent manner. Our
current success rate is approximately 70% of magnetite batches that can be coated with
gold.

Gold-coated magnetite morphologies:
None of the gold-coated magnetite morphologies observed appeared as the commonly
described “core-shell” nanoparticle consisting of a magnetite core surrounded by a thin
uniform gold shell. The majority of the gold-coated magnetite nanoparticles produced
were isolated (single), with a round morphology similar in appearance to colloidal gold of
the same size. These isolated particles had a thick gold coating. Magnetite fringes could
be observed in any part of the nanoparticle including the edges. Isolated rounded goldcoated magnetite most closely resembled “core-shell” morphology, but exhibited some
clear differences. The magnetite was not centered in the “core” of the particle and was
sometimes exposed on the outside of the nanoparticle. The isolated particle morphology
can be explained by Volmer-Weber growth of gold on magnetite, where isolated islands
of gold grow until coalesced into a single thick coating (45, 46). A subset of faceted
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triangular particles had a different morphology consisting of two independent layers of
gold and a single layer of magnetite. The definitive arrangement of the gold and
magnetite planes cannot be determined by HRTEM due to the planes being in projection.
One possibility is that the faceted nanoparticles may have a sandwich-type morphology in
which the magnetite is fitted neatly between the layers of gold. This interpretation is
supported by the observation that the angle between both gold {111} planes and the
magnetite {311} plane have the same value. Additionally, the angle between the two
gold {111} planes (56o) cannot occur in a single crystal.

The aggregated gold-coated magnetite nanoparticles had exposed magnetite seeds with
small gold islands consistent with Volmer-Weber growth on some nanoparticle surfaces.
Gold growth on these surfaces may not have reached the point of coalescence as appeared
to occur with the isolated nanoparticles. We observed aggregated gold-coated magnetite
nanoparticles in nearly all preparations, however this type of particle has not been
described in other similar synthesis methods (27, 28, 39, 41).

The faceted nanoparticles appear to have a much more ordered gold growth mechanism.
Gold growth appears confined to the predefined magnetite plane and gold growth occurs
as a single crystal without the stacking faults observed in colloidal gold. Well oriented
faceted gold-coated nanoparticles are a minority of the population and were difficult to
study in this system. For future studies that attempt to elucidate the mechanism of gold
growth on magnetite, depositing gold on thin films of magnetite may be a useful tool.
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The exposed magnetite edges commonly observed run contrary to our prior assumptions
regarding the role of the gold coating in nanoparticle stability and ability to be
functionalized by non-ionic protein adsorption. At a bulk level, protein adsorption to the
surface of nanoparticles stabilizes the vast majority of the population at physiologic pH
and salt concentration. We further analyzed the nanoparticles at an individual level to
determine which morphologies of gold-coated magnetite were successfully conjugated to
fibrinogen, paying particular attention to exposed magnetite surfaces. Protein coating can
be observed around both isolated nanoparticles and on smaller aggregates. Somewhat
surprisingly, protein was observed coating apparently bare magnetite surfaces on goldcoated magnetite aggregates. However, when we quantified the population of aggregated
nanoparticles in stock and conjugated nanoparticles, we found that the aggregated
population was significantly reduced during the procedure. The largest gold-coated
magnetite aggregates were lost after centrifugation during the conjugation procedure,
indicating that the largest aggregates with the least gold coating were unstable during
protein conjugation. This supports our hypothesis that the gold surface is important for
non-ionic protein adsorption. The coating of bare magnetite surfaces with protein
demonstrates that protein conjugation to magnetite directly is possible, but it likely
requires neighboring gold to protect the magnetite from agglomeration at pH values
approaching neutral during the conjugation process.

Biological activity of nanoparticle conjugates:
The labeling of platelets by fibrinogen conjugated to either colloidal gold or gold-coated
magnetite were directly compared to one another. Labeling with the two types of
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nanoparticle conjugates produced the same pattern in both the surface-activated and
aggregated platelet systems. The localization of the labels was always consistent with
previously described fibrinogen labeling (49, 50, 54, 61). Labeling intensity was either
similar or somewhat lower with fibrinogen-conjugated, gold-coated magnetite
nanoparticles when compared to colloidal gold. Differences in labeling intensity are
most likely due to different nanoparticle concentrations in the conjugates, and may be
corrected for by adjusting the concentration prior to labeling. The localization of gold
and gold-coated magnetite nanoparticles validates the targeting methodologies
established previously (Chapter 2) using fibrinogen conjugates to select for activated
platelets.

Labeling platelets with fibrinogen-conjugated gold-coated magnetite under in vivo-like
conditions:
PRP aggregated with the non-proteolytic peptide SFLLRN-NH2 labeled with fibrinogenconjugated gold-coated magnetite in the interior of the platelet aggregates, similar to the
fibrinogen-conjugated colloidal gold nanoparticle labeling described previously (Chapter
2). The similar localization and number of fibrinogen conjugated gold-coated magnetite
and colloidal gold labels present in platelet-rich plasma aggregates further confirms that
the two types of nanoparticles behave in a similar manner. When platelet-rich plasma
was aggregated with thrombin, the resulting labeling was significantly reduced. The
TEM ultrathin sections contained a large amount of fibrin around platelets that were more
completely degranulated and contracted. The labeling was much sparser than in any
other labeling condition tested. The fibrin itself may act as a physical barrier preventing
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nanoparticles from reaching the activated platelet surface, where we propose their effect
on reopening occluded arteries will take place. However, it is possible that fibrinogenconjugated nanoparticle-fibrin interactions could result in damage to the fibrin network
could as a result of localized hyperthermia, in addition to the platelet damage we expect.
The presence of fibrin certainly complicates our analytical approach. In any case, the
labeling pattern suggests that targeting blood clots in vivo may be challenging, and will
likely require a high concentration of fibrinogen-conjugated nanoparticles to achieve
significant nanoparticle infiltration of an occlusive thrombus.
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Figures Legends and Figures:

Figure 19. TEM analysis of the synthesized iron oxide nanoparticles. Selected area
diffraction of a group of iron oxide nanoparticles is shown in (A). The reflections are
indexed to magnetite lattice parameters as indicated. (B) demonstrates that when the
prepared magnetite nanoparticles are dried onto a holey carbon grid, they appear nearly
exclusively clumped together. When the magnetite nanoparticles are diluted 1:100 in
TMAOH and dried in a similar manner, the nanoparticles remain mostly isolated or in
small groups, as shown in (C). The size distribution of 500 nanoparticles measured along
their longest axis is shown in (D).

Size bars are 1 nm-1 for (A) and 50 nm for (B, C).
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Figure 20. Brightfield TEM and selected area electron diffraction of gold-coated
magnetite nanoparticles. (A) demonstrates commonly observed gold-coated magnetite
morphology. White arrowheads show faceted nanoparticles, while black arrows indicate
rounded nanoparticles. In (B) a minority of nanoparticles that consist of low contrast and
high contrast particles aggregated together are indicated with black arrows. Size bars are
50 nm. A histogram of the size distribution of 500 magnetite particles (black squares)
and of 500 isolated gold-coated magnetite (gray diamonds) is shown in (C). A composite
image of selected area electron diffraction of gold, magnetite, and gold-coated magnetite
is shown in (D). The image is inverted to better show the diffraction patterns.
Reflections occurring from gold and uncoated magnetite nanoparticles are indexed as
indicated with white arrows. The gold-coated magnetite diffraction pattern contains
reflections from gold {111} and magnetite {220} and {311}. Gold {200} overlaps with
magnetite {400}.
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Figure 20
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Figure 21. HRTEM of isolated and aggregated gold-coated magnetite. (A-C) shows an
isolated gold-coated magnetite particle with three sets of lattice fringes present. Fast
Fourier transform filtering was performed to isolate fringes based on known lattice
parameters. (A) shows the original HRTEM image, (B) is filtered to show magnetite
{311} planes, (C) is similarly filtered to show gold {111} planes. The magnetite {311}
plane makes 62o angles with both gold {111} planes, and the gold {111} planes make a
52o angle with each other. An aggregate of gold-coated magnetite nanoparticles is shown
in (D-F). The original HRTEM image is shown in (D), the fast Fourier transform
filtering showing magnetite {111} and {311} planes is shown in (E) and gold {111}
planes are shown in (F). Arrows point in parallel with observed fringes. Size bars are 5
nm.
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Figure 21
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Figure 22. Visible light absorbance spectra of gold-coated magnetite nanoparticles. (A)
demonstrates the normal absorbance spectrum of stock gold-coated magnetite (black line)
and gold-coated magnetite nanoparticles that were agglomerated with salt (grey line).
Nanoparticles challenged with salt had a spectrum with reduced absorbance in the gold
plasmon near 520 nm, and an increase in absorption at longer wavelengths. Gold-coated
magnetite nanoparticles conjugated to fibrinogen (FGN, solid black line),
immunoglobulin G (IgG, dashed grey line), or bovine serum albumin (BSA, grey dotted
line) and challenged with salt are shown in (B). All conjugated nanoparticles retain the
spectral characteristics of stock nanoparticles with little absorbance in the longer
wavelengths despite the salt challenge.
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Figure 23. Magnetic behavior of gold-coated magnetite nanoparticles in response to a
static magnet. (A) shows the visible light absorbance spectra of gold-coated magnetite
nanoparticles (solid line), and conjugated (dotted line) or unconjugated (dashed line)
nanoparticles remaining in solution after exposure to a static magnet. Images of
conjugated gold-coated magnetite nanoparticles before and after exposure to a static
magnet are shown in (B) and (C), respectively. The majority of fibrinogen-conjugated
gold-coated nanoparticles are located on the poles of the static magnet, as indicated by
arrows in (C). The magnet is attached to the vial with blue tape. Note that the liquid
visible above the tape line in (C) has changed from the distinct red color seen in (B) to
nearly colorless.
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Figure 23
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Figure 24. Brightfield TEM analysis of fibrinogen-conjugated gold-coated magnetite.
(A) demonstrates a representative field of fibrinogen-conjugated, gold-coated magnetite
nanoparticles air-dried onto the grid. Both isolated and aggregated (arrows) nanoparticles
are observed. Nanoparticles adhered to a poly-L-lysine coated grid and dried by the
critical point procedure are shown in (B). The poly-L-lysine treatment caused clumping
of the conjugated nanoparticles. Low contrast protein halos are present around the entire
group of nanoparticles. Arrows point to areas areas of bare magnetite that are covered
with protein. Size bars are 100 nm.
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Figure 24
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Figure 25. SEM of nanoparticles adhered to poly-L-lysine carbon-coated grids and dried
by the critical point procedure. The left column shows secondary electron (SE)
micrographs; the right column shows the same areas using backscattered electron (BSE)
imaging. Unconjugated 18 nm colloidal gold (Au) is shown in (A) and (B). Fibrinogenconjugated colloidal gold (FGN-Au) clumped during sample preparation, as shown in (C)
and (D). Unconjugated gold-coated magnetite (Au-Fe3O4) also clumped during
preparation as shown in (E) and (F). In BSE analysis, gold is observed as high contrast
regions and magnetite as low contrast. Fibrinogen-conjugated gold-coated magnetite
(FGN-Au-Fe3O4) is shown in (G) and (H). Protein binding is visible in the SE
micrographs (C) and (G). Size bar is 100 nm for all images.
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Figure 26. Analysis of gold-coated magnetite morphologies on surface-activated
platelets. (A) demonstrates a low magnification BSE micrograph of a surface-activated
platelet labeled with fibrinogen-conjugated gold-coated magnetite. (B) demonstrates a
high magnification micrograph used to quantify particle morphologies. (C) shows a
reconstructed montage of the entire platelet using higher magnification micrographs. The
dotted line shows the region around the granulomere excluded from SEM analysis,
arrowheads show regions of open canalicular system (OCS) also excluded from analysis.
TEM of similarly labeled platelet is shown in (D). Arrows point to low contrast
aggregated gold-coated magnetite on the platelet surface for both SEM and TEM. Scale
bar is 1 m for all images.
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Figure 27. TEM analysis of whole mount surface-activated platelets labeled with
fibrinogen-conjugated gold or gold-coated magnetite. The typical labeling of fibrinogen
conjugated to 18 nm colloidal gold is shown in (A). (B) shows representative labeling
with fibrinogen conjugated to gold-coated magnetite on surface-activated platelets.
Insets are approximately 2.5x higher magnification micrographs of the white boxes to
better show nanoparticle localization and presence of aggregated gold-coated magnetite.
Scale bars are 1 m for both images.
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Figure 28. SEM analysis of surface-activated platelets labeled with gold or gold-coated
magnetite conjugated to fibrinogen. SE (A) and BSE (B) micrographs show surfaceactivated platelets labeled with fibrinogen conjugated to 18 nm colloidal gold (FGN-Au).
Similarly, SE (C) and BSE (D) electron micrographs of platelets labeled with fibrinogen
conjugated to gold-coated magnetite (FGN-Au-Fe3O4) are shown. Both fibrinogenconjugated gold and gold-coated magnetite nanoparticles have translocated on the surface
of the platelet membrane, and are found around the granulomere of well-spread platelets.
Scale bar is 2 m for all images.
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Figure 29. Aggregometer tracing of platelets stimulated with 67 M SFLLRN-NH2.
Gel-filtered platelets were supplemented with unconjugated fibrinogen (Fibrinogen,
blue), fibrinogen conjugated to colloidal gold (FGN-Au, purple), or fibrinogen
conjugated to gold-coated magnetite (FGN-Au-Fe3O4, green). Platelet-rich plasma was
similarly aggregated to show the maximal possible aggregation (red). Stimulation of
platelets was initiated at the 30 second time point, indicated by an arrow.
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Figure 30. SEM analysis of gel-filtered platelets supplemented with unconjugated
fibrinogen, aggregated, and then labeled with fibrinogen conjugated to colloidal gold or
gold-coated magnetite. The left column shows SE micrographs of platelet aggregates, the
right column shows the same field of view using BSE imaging. Unlabeled platelet
aggregates (FGN) (A,B) serve as controls. Platelet aggregates labeled with fibrinogen
conjugated to 18 nm colloidal gold (FGN-Au) are shown in (C) and (D). Platelet
aggregates labeled with fibrinogen conjugated to gold-coated magnetite (FGN-Au-Fe3O4)
are shown in (E) and (F). Note that extensive incorporation of nanoparticles has
occurred, even though the aggregates were formed prior to incubation with labels. Size
bar is 10 m for all images.
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Figure 30
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Figure 31. TEM images of ultrathin sections of platelet aggregates labeled with
fibrinogen conjugated to 18 nm colloidal gold or gold-coated magnetite. Typical labeling
observed using fibrinogen conjugated to gold nanoparticles is shown in (A); labeling is
primarily in the aggregate interior at platelet/platelet junctions (arrows) and in the OCS
(arrowheads). Labeling using fibrinogen conjugated to gold-coated magnetite is shown
in (B). The labeling pattern is similar, but the number of nanoparticles observed is
reduced. Size bar is 2 m for both images.
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Figure 32. TEM ultrathin sections of aggregated platelet-rich plasma labeled with
fibrinogen conjugated gold-coated magnetite. Platelet-rich plasma was aggregated with
either 67 M SFLLRN-NH2 (A) or 2 nM thrombin (B). Aggregation of platelet-rich
plasma with thrombin results in fibrin production, indicated by black arrowheads.
Thrombin-induced aggregates have significantly reduced incorporation of fibrinogenconjugated, gold-coated magnetite labels, as shown with white arrows. Size bars are 1
m.
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Figure 32
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Chapter 4:

Magnetic field-induced hyperthermia on platelets labeled with
fibrinogen-conjugated gold-coated magnetite
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Abstract

Hyperthermia has long been recognized as a therapeutic method to eliminate unwanted
cells or tissues. Nanoparticle mediated hyperthermia is the use of targeted nanoparticles
to target a cell type and then convert an external energy source to localized thermal
energy. There has been much interest in development of nanoparticle-mediated
hyperthermia for anti-cancer applications. Here we examine the use of nanoparticlemediated hyperthermia to cause damage to platelets with the intent of developing a novel
treatment for ischemic stroke. We developed a system using fibrinogen-conjugated goldcoated magnetite nanoparticles to cause localized hyperthermia on human platelets when
exposed to an oscillating magnetic field. Scanning electron microscopy was utilized to
analyze hyperthermic damage to surface-activated platelets by directly observing intact
and fragmented platelets. Platelet aggregates, which better approximate in vivo platelets
in blood clots, were generated and treated with fibrinogen-conjugated gold-coated
magnetite and exposed to an oscillating magnetic field. Afterwards, the platelets were
analyzed by SEM and TEM. We developed a stereological method to estimate the extent
of hyperthermia damage to platelet aggregates by estimating the area covered by intact
platelets, damaged platelets and platelet-derived debris. Results indicate significantly
more dead platelets and debris were present in platelet aggregate samples exposed to the
fibrinogen-conjugated gold-coated magnetite than controls in both surface-activated and
aggregated platelet systems. Further studies used the aggregate quantification method to
optimize magnetic field exposure and dosages of nanoparticles to platelet aggregates.
When the damage was quantified it was found that significantly more damage occurred
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on platelets treated with fibrinogen-conjugated gold-coated magnetite with OMF
exposure than any other treatment. These results suggest that nanoparticle-mediated
hyperthermia has potential as an ischemic stroke treatment.

Introduction

Therapeutic hyperthermia is a method to disrupt cells of interest by increasing the cellular
temperature 3o C or more (1-4). Most hyperthermia treatments have been primarily
focused on the development of anti-cancer therapy. The effects of hyperthermia were
first characterized over 100 years ago in descriptions of cancer patients who experienced
high fever and subsequently recovered from cancer (5). Raising the temperature of a cell
can have effects on the metabolic balance (6, 7), lipid membrane dynamics and stability
(8, 9), and cytoskeletal arrangement of the cell (10, 11).

The outcome of hyperthermic treatment on cells is based on the ultimate temperature
reached (1, 12), the length of exposure (12, 13), and the cell type(s) exposed (14). A
variety of assays have been used to determine hyperthermia effects on cells, including
examining mitochondrial health using the 3-(4,5-dimethylthiazol)-2-diphenyltertrazolium
bromide (MTT) test (15), measuring apoptosis using the binding of annexin V to
phosphatidylserine (PS), staining with nuclear stains that are not permeable to intact
membranes (2), vital stains that measure cytoplasmic enzyme function (16), or by direct
observation using electron microscopy (4, 9, 13, 16, 17). In treatments using mild
hyperthermia, where cell temperatures are kept below approximately 46o C, cell death is
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primarily caused by apoptosis, which is thought to be triggered by a combination of
factors, including disruptions of nuclear function (2, 6, 18), metabolic stress (7), and
disruption of normal organelle structure (4, 19-21). Mild hyperthermia treatments were
observed to disrupt microtubule and actin cytoskeleton localization, causing changes in
cell shape (10). In some cancer lines, mild hyperthermic conditions can trigger a heat
shock response, leading to production of chaperone proteins such as HSP 70 (3). These
chaperone proteins bind to proteins that are highly expressed in cancer cells. When some
of these cells die, they release the chaperone protein in complex with cancer proteins
which can lead to an increased immune response to the tumor (3, 22, 23). In
hyperthermic treatments greater than ~50o C, protein denaturation and membrane damage
become more prominent (2, 24). The damage leads to necrosis and can be directly
observed by TEM where damage to both cellular and organelle membranes is apparent
(25). Increasing the temperature in hyperthermic treatments leads to increased damage to
cancer cells, but at the expense of possibly damaging the surrounding normal tissue as
well.

Hyperthermia can be induced by a variety of methods ranging from relatively simple bulk
heating to quite complex targeted methods. The simplest method of inducing
hyperthermia is by increasing the systematic body temperature, which will cause effects
on every tissue. Systematic hyperthermia can be useful in treating cancer cells, as they
are less likely to tolerate mild temperature increases than normal cells (26, 27). Specific
regions of the body may be heated using heated fluid (28) or radio frequency (RF) tissue
heating (12, 29). However, these types of heating are rather crude and have limited
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applications, due to the aforementioned possibility of nonspecific heating of surrounding
tissues. It is therefore desirable to target a specific tissue, tumor, or cell type, which for
most applications requires a method to produce highly localized heating. Nanoparticlebased heating methods using specific targeting molecules to target a tissue or cell type
have been developed (10, 15, 20, 30, 31). These treatments utilize nanoparticles to
convert an external energy source into localized heat, creating hyperthermia only in the
areas containing nanoparticles. These nanoparticles can transfer energy to cells/tissue by
two different means: absorption of infrared light (32-34), or by conversion of RF electric
(35, 36) or magnetic fields (37, 38) to heat or kinetic energy.

Photothermal hyperthermia has been developed using gold nanoparticles that absorb light
in the near infrared range to generate localized heat. In order to absorb light in the nearinfrared range well, gold nanoparticles are synthesized in rod shapes (33), hollow sphere
shapes (39) or as SiO2-gold core-shell-like structures (40). An alternative strategy is to
cause typical spherical gold nanoparticles to agglomerate at the site of interest. The
nanoparticle aggregation causes an increases in near-infrared light absorption increasing
the energy absorbed per unit area (34, 41). Basic protein conjugation procedures, such as
non-ionic adsorption, can be used to functionalize the nanoparticles with cell targeting
molecules (32, 41). Photothermal therapies work well in vitro, but often have limitations
in vivo due to attenuation of the near-infrared light heating penetration by light scattering
and absorption within the tissue (42, 43).
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Magnetic induction based nanoparticle hyperthermia treatments have been developed for
anti-cancer therapy in which iron oxide nanoparticles are heated by an external magnetic
field (44-47). Of particular interest are systems that utilize superparamagnetic magnetite
or maghemite to convert an oscillating magnetic field (OMF) into localized thermal
energies using the Neel relaxation methodology of heating. The magnetic field used for
heating typically oscillates in the order of 100 kHz and has a magnetic field strength in
the 1-100 mT range (15, 48, 49). The frequency and power output of the OMF can be
produced using relatively simple circuitry, which makes the methodology attractive. For
specific cellular targeting, iron oxide nanoparticles may be functionalized with organic
molecules or proteins (15, 50-52), or the iron oxide can be coated with gold and then
conjugated with protein as discussed previously (Chapter 3).

We have already established a method to specifically target activated platelets using
fibrinogen conjugated nanoparticles (Chapters 2, 3). We hypothesize that these
nanoparticles can cause structural damage to platelets by localized hyperthermia.
Hyperthermic effects on platelets are relatively poorly understood. Platelet activation and
aggregation have been found to be inhibited by hyperthermia by decreasing platelet
inside-out signaling which prevents platelets from binding fibrinogen (53, 54). Further,
hyperthermia conditions inhibit platelet adhesion to surfaces (54), promote ectodomain
shedding of glycoprotein I (53), inhibit platelet -granule release (54), and cause PS
expression on the outer leaflet of the platelet membrane (53). Whole body hyperthermia
causes a reduction in platelet counts (55, 56) which has been attributed to platelet
aggregate formation and adhesion (55), which is peculiar in light of the reports of
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decreased platelet aggregation and adhesion following in vitro hyperthermia (53, 54).
These studies examined platelet hyperthermia as a pathological condition rather than a
possible treatment for ischemic stroke. Our interest is primarily in disrupting pre-existing
platelet structure to dissolve blood clots rather than producing systemic effects on platelet
aggregation and adhesion.

In these studies, we examine whether fibrinogen-based targeting previously described
(Chapter 2) using the gold-coated magnetite nanoparticles previously developed (Chapter
3) will cause structural damage to platelets by magnetic field-induced hyperthermia.
Differences between platelets and typical cancer cells may cause them to respond quite
differently to hyperthermic conditions. Mammalian platelets lack a nucleus and much of
the eukaryotic cellular machinery found in nucleated cells. Additionally, platelet
activation and apoptosis pathways are similar, both leading to PS expression on the outer
leaflet of the platelet membrane (57-59). For hyperthermia-mediated restoration of blood
flow following an ischemic stroke event, disruption of platelet integrity must occur in a
way in which the blood clot becomes structurally weakened and breaks apart. We
examined the effects of nanoparticle-mediated hyperthermia on two platelet systems.
First, we used the surface-activated platelet system to characterize hyperthermic damage
and quantify platelet damage. We then examined the aggregated platelet system to better
understand how hyperthermia is likely to affect blood clots in vivo.
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Materials and Methods:

Platelet preparation:
Whole blood was obtained from healthy adult volunteers in accordance with the
University of Wisconsin – Milwaukee Institutional Review Board. Gel-filtered platelets
were obtained as described previously (Chapter 2).

Fibrinogen-conjugated gold-coated magnetite synthesis:
Magnetite and gold-coated magnetite were synthesized and conjugated to fibrinogen as
previously described (Chapter 3). Colloidal gold was similarly synthesized and
conjugated to fibrinogen as previously described (Chapter 2).

Oscillating magnetic field device:
A custom made OMF device was built using a basic LC (resonant) circuit. The circuit
consists of a hand-wound inductor connected as an autotransformer paired with a set of
fixed capacitors in series and a parallel variable air dielectric capacitor. The system was
powered by an AG Series 1024 RF amplifier (T&C Power Conversion, Rochester, NY)
using the internal signal generator of the amplifier to produce a 500 kHz waveform using
internal power output control to reach the desired field amplitude.

The inductor was built by winding 3.175 mm diameter copper tubing (Phillips and
Johnston, Glen Ellyn, IL) around a 5 cm diameter glass cylinder for a total of 50 turns.
Several coils were produced using different methods of electrical insulation. Early coils
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utilized paper flags between each turn to prevent short circuiting. Later coils were coated
by a layer of Formvar in addition to paper flags. These coil insulations proved to be
vulnerable to high temperatures and were ultimately replaced by wrapping the copper in
vinyl tape. The coil was cooled by running cold tap water through the copper tubing,
preventing excessive heating of the inductor coil during operation.

The OMF circuit was tuned using a BK Precision 4017B signal generator (Yorba Linda,
CA) producing a 5 volt sinusoidal wave at 500 kHz. The voltage drop between the set of
capacitors was recorded as shown in Figure 33. The tap position for the autotransformer
was selected where the voltage drop was 50% when the variable capacitor was at 50%
maximal capacitance, giving the highest possible power transfer function. Tuning was
further refined by varying the variable capacitor when the circuit was powered by the RF
amplifier at 10 watt forward power. Optimal tuning was achieved when reflected power
could no longer be detected. The magnetic field produced by the OMF device was
measured using a 1 cm2 area wire placed within the coil. The potential across the wire
was measured with a BK Precision 2125A analog oscilloscope. The following equation
used to calculate the magnetic field:

Where B is the magnetic field produced, E is the potential across the copper loop, f is the
frequency of the OMF, and A is the area of the copper loop.
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Oscillating magnetic field heating:
The amount of heat generated by magnetite nanoparticles was measured by placing 100
L drops of a 100-fold concentrated magnetite nanoparticle stock solution into a
calorimeter. In a second chamber, a 100 L drop of ddH2O was placed to serve as a
control for non-specific heating. A calibrated T-type thermocouple was positioned in
each well, and an initial reading was taken with a CEN-TECH digital multimeter (Harbor
Freight, Camarillo, CA). The samples were exposed to a 500 kHz, 8 mT OMF for 3
minutes and a second temperature reading was taken. The OMF system produced too
much electronic noise to allow accurate heating measurements during operation. Goldcoated magnetite nanoparticles could not be sufficiently concentrated to accurately
measure nanoparticle heating.

Temperatures of the inductive coil and non-magnetic samples were measured using a
CEN-TECH infrared thermometer (Harbor Freight) pointed directly at the source being
measured during OMF operation. With cold tap water cooling the system, these
temperatures never exceeded 38oC, and therefore the OMF device was not considered to
contribute to nonspecific sample heating.

Surface-activated platelet hyperthermia:
Gel-filtered platelets were supplemented with 2 mM Ca2+ and allowed to adhere to 300
mesh Formvar coated nickle grids for 10 minutes. The surface-activated platelets were
labeled with fibrinogen-conjugated gold-coated magnetite or gold, or left unlabeled in
Tyrode’s buffer for 10 minutes. Unbound labels were washed away by dunking the grids
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in excess Ca2+-supplemented Tyrode’s buffer, then washed 3 times by incubating the
grids on successive 10 L drops of Tyrode’s buffer for 5 minutes. Samples exposed to
the OMF were floated on 20 L drops of Tyrode’s buffer and exposed to an 8 mT OMF
operating at 500 kHz for 5 x 2.5 minute cycles with 30 seconds between cycles. Negative
controls receiving no magnetic field exposure were kept away from the OMF. After
magnetic field exposure, samples were fixed in 1% glutaraldehyde in 0.1 M HEPES, pH
7.3 for 30 minutes. Samples were washed in HEPES and post-fixed in 0.05% OsO4 in
HEPES for 15 minutes. Samples were dehydrated in a graded ethanol series and brought
through the critical point drying process. The grids were mounted onto SEM stubs with
carbon tape and sputter coated with 2 nm Ir using an EMITech K575X sputter coater
(Ashford, Kent, United Kingdom).

Samples were analyzed using a Hitachi S-4800 SEM (Dallas, TX) operating at 1 kV for
secondary electron (SE) and 30 kV for backscattered electron (BSE) imaging. For
hyperthermia quantification studies of surface-activated platelets, 5 fields of platelets
centered between grid bars were imaged at randomly generated coordinates at 1,000 x
magnification for each sample. The number of intact and fragmented platelets was
determined for each field by examination of the structure of the platelets. Platelets with
continuous membranes displaying no holes and normal platelet morphology were scored
as intact. Platelets showing obvious structural damage or membranes with large tears
were scored as fragmented. The percent of fragmented platelets was calculated per field
and then averaged with the other fields of the sample. Significance between treatments
was determined by Student’s t-test comparing percent platelet fragmentation averaged
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from all fields in a sample from 7 experiments, which had 5 unique blood donors and 7
unique nanoparticle batches.

Aggregated platelet hyperthermia:
Gel-filtered platelets were adjusted to 200,000 platelets/L and supplemented with 2 mM
Ca2+ and 200 g/mL unconjugated fibrinogen. The platelets were aggregated using 67
M SFLLRN-NH2 in the 24-well microtiter plate system or in an aggrogometer as
described previously (Chapter 2). Samples were labeled for 5 minutes post-aggregation
with fibrinogen-conjugated, gold-coated magnetite or fibrinogen-conjugated colloidal
gold.

In most experiments, aggregated samples were exposed to a 500 kHz OMF at 8 mT for
30 minutes. In experiments analyzing the time of exposure to the magnetic field, samples
were treated between 0 and 60 minutes.

For TEM studies, samples were fixed in 1% glutaraldehyde, 1% tannic acid in 0.1 M
HEPES, pH 7.3 for 1 hour at room temperature and then at 4oC overnight. Samples were
washed three times in HEPES by centrifugation and embedded in a drop of 1% agar
(Difco, Detroit, MI) prepared in 0.1 M HEPES. Equal volumes of warm agar and cold
platelet samples were combined in small TEM embedding molds. Samples were
postfixed en bloc in 0.05% OsO4 for 30 minutes, washed 3 times in ddH2O, and en bloc
stained in 1% uranyl acetate for 1 hour. Samples were dehydrated in a graded ethanol
series and then transferred to propylene oxide. Samples were infiltrated with low
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viscosity Spurr’s resin (60) but substituting the accelerant N,N-dimethylbenzylamine
with 2(dimethylamino)ethanol (61). Ultrathin pale gold or silver sections were taken
using an RMC MT-7000 ultramicrotome and sections were stained with 1% uranyl
acetate. The sections were imaged at 75 kV using an Hitachi H-600 TEM (Dallas, TX).

For both qualitative and quantitative SEM studies, the aggregated samples were diluted
1:20 in 1% glutaraldehyde in 0.1 M HEPES, pH 7.3 and fixed for 30 minutes at room
temperature. Platelets were collected onto 0.4 m Nuclepore membranes and postfixed
in 0.05% OsO4 for 15 minutes. Samples were dehydrated in ethanol and brought through
the critical point drying process. Samples were sputter coated with 2 nm Ir using an
EMITech K575X sputter coater. Micrographs were taken using an Hitachi S-4800 SEM
operating at 1 kV for SE and 30 kV for BSE imaging.

For quantitative analysis of hyperthermic damage of platelet aggregates, 5 fields of
platelet aggregates on Nuclepore membranes were taken at 2000x magnification at
random coordinates. The following criteria were established for including a field in the
statistical analysis: 1) At least 50% of the field must contain platelets or platelet-derived
debris; 2) the field must be mostly free of non-platelet debris (e.g. plastic shavings); and
3) the field must not overlap with a previously examined field. Fields were analyzed by
point counting, with the estimated area covered by intact platelets, disrupted platelets,
and platelet-derived debris (i.e. debris that no longer resembles a platelet) scored
separately. To determine the number of sampling points required to accurately assess a
field of view the entire area of several micrographs were quantified at a single pixel level.
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The micrographs were then sampled using the point counting system, increasing the
number of sampling points until the accuracy of the stereological method did not
increase. It was found that 140 evenly distributed points counted on every field could
provide accurate estimates. Points per field were scored and summarized for each
treatment. The ratio of intact platelets to the sum of disrupted platelets and plateletderived debris from each field were combined into a single sample mean for each sample
which was used for statistical analysis. ANOVA, including models in which different
variables were tested for their contribution to overall significance by defining them as
fixed effects, was performed using the PROC MIXED procedure in SAS (SAS Institute,
Cary, NC).

Results

Oscillating magnetic field heating of magnetite nanoparticles:
The OMF device was evaluated for use in heating the magnetite nanoparticles previously
described (Chapter 3). Non-specific heating caused by electrical resistance in the
inductive coil was removed by running cold tap water through the hollow induction coils.
The temperature of the induction coil and nonmagnetic ddH2O was measured by infrared
thermometer, which could sample temperatures while the OMF was running, during a
typical 2.5 minute OMF cycle at 8 mT power (Figure 34A). Coil temperature never
exceeded 38o C. The sample temperature never exceeded 25oC under normal cooling
conditions. When the pressure of the cooling water was increased to water mains
pressure, the sample temperature was modestly reduced below normal cooling.
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Heating of magnetic samples was measured in a calorimeter consisting of two TEM
embedding wells with T-type thermocouples that was constructed in-house (Figure 34B).
Thermocouples measure temperatures of small volumes of liquid more accurately than an
infrared thermometer, but do not function well with the electrical noise generated during
OMF operation. Inductive heating of magnetite nanoparticles could be measured by
concentrating the magnetite 100-fold and placing 100 L in one well, while 100 L
ddH2O was placed in the other well as a control for non-specific heating. As described
previously (Chapter 3), batches of magnetite synthesized through aqueous coprecipitation
had variable properties. The level of OMF-induced inductive heating varied between
batches of magnetite and appeared correlated with the ability of those magnetite batches
to be coated with gold. Batches of magnetite that could be coated with gold typically
heated 5o to 10o C over the ddH2O control (Figure 34C). Magnetite samples that failed to
coat with colloidal gold displayed a much larger range of possible final temperatures.
Only magnetite that could be coated with gold was used for further evaluation of
hyperthermia.

Magnetic field-induced hyperthermia on surface-activated platelets:
Surface-activated platelets were used as an initial model to test fibrinogen-conjugated,
gold-coated magnetite hyperthermia treatments. Platelets were allowed to surface
activate on Formvar coated TEM grids, then were labeled with fibrinogen-conjugated
gold-coated magnetite. Negative control platelets were labeled with non-magnetic
fibrinogen-conjugated colloidal gold or buffer. Samples were exposed to the OMF or
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kept out of range of the OMF and then analyzed by SEM. Platelet controls labeled with
colloidal gold with or without OMF exposure displayed the typical morphology and
fibrinogen labeling pattern of surface-activated platelets observed previously (Chapters 2,
3) (Figures 35A, 35B). Similarly, platelets labeled with fibrinogen-conjugated goldcoated magnetite without OMF exposure displayed the same morphology and labeling
pattern (Figures 35C, 35D) observed previously (Chapter 3). Platelets labeled with
fibrinogen-conjugated, gold-coated magnetite nanoparticles and exposed to the OMF
showed markedly different morphology. Many platelets exhibited fragmentation where
the membrane of the platelet was significantly disrupted (Figure 36). In some damaged
platelets, pieces of cellular membrane remained while the majority of the intracellular
contents of the platelets appear to have leaked away leaving behind holey or noncontinuous cell membrane (Figure 36A, 36B). While many platelets were damaged,
other seemingly well-labeled, yet intact, platelets were often found near extremely
fragmented platelets (Figures 36C, 36D).

The amount of damage caused by hyperthermia was quantified by comparing the number
of intact healthy-looking platelets to that of fragmented platelets in low magnification
fields (Figures 37A, 37B). Scoring across multiple fields and multiple experiments (n =
7) revealed that all control samples had nearly the same level of platelet fragmentation,
which can be considered to represent a background level. Unlabeled platelets with or
without OMF exposure had 22 ± 6% and 23 ± 7% fragmentation, respectively,
demonstrating that exposure to the OMF has no effect independent of labeling (p = 0.31).
Colloidal gold-labeled platelets exhibited 23 ± 9% fragmentation when exposed to the
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OMF and 23 ± 6% in the absence of OMF exposure, demonstrating that labeling alone is
insufficient to produce an OMF effect (p = 0.84). However, labeling with gold-coated
magnetite and exposure to the OMF produced significantly more fragmented platelets (58
± 6%) than was seen in the absence of OMF exposure (23 ± 6%, p < 0.01). In fact, goldcoated magnetite plus OMF exposure produced significantly more platelet damage than
any other labeling/treatment combination tested (Figure 37C).

Magnetic field-induced hyperthermia on aggregated platelets:
The surface-activated platelet system provided a relatively simple method of analyzing
the effects of gold-coated magnetite labeling plus OMF exposure on platelets. However,
surface-activated platelets only represent a minority of the platelet population in an in
vivo blood clot. To better approximate the effect of fibrinogen-conjugated, gold-coated
magnetite nanoparticles on a blood clot, hyperthermia treatment was performed on
preformed platelet aggregates produced with unconjugated fibrinogen.

To form aggregates, gel-filtered platelets were supplemented with unconjugated
fibrinogen, stirred, and stimulated with 67 M SFLLRN-NH2, then labeled with
fibrinogen conjugates and exposed to the OMF. Control samples labeled with
fibrinogen-conjugated colloidal gold (Figure 38A) or fibrinogen-conjugated, gold-coated
magnetite (Figure 38B) without OMF exposure showed the typical morphology observed
with aggregated gel-filtered platelets (Chapter 2). Additional controls that were exposed
to the OMF after incubation with unconjugated fibrinogen (Figure 38C) or fibrinogenconjugated colloidal gold (Figure 38D) showed similar morphology to control samples
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that did not receive OMF exposure. All negative controls displayed little damage on the
surface of the platelet aggregate. However, platelet aggregates treated with fibrinogenconjugated, gold-coated magnetite and exposed to the OMF often displayed obvious
structural damage (Figures 38E, 38F). Platelets within the aggregate had disrupted
membranes with tears or holes present. Interestingly, other areas of the same platelet
aggregates often had a normal appearance, which demonstrated heterogeneous effects
caused by hyperthermia on the same platelet aggregate.

The damage caused by hyperthermia to platelet aggregates labeled with gold-coated
magnetite and exposed to the OMF was further examined by SEM at higher
magnification to better understand platelet damage and nanoparticle localization.
Aggregates with obvious structural damage were examined using SE imaging to
characterize damage (Figure 39A) and BSE imaging to localize gold-coated magnetite
(Figure 39B). Closer examination of damaged areas in platelet aggregates showed areas
where platelet membranes appeared ruptured and the internal contents of the platelets
were visible, including the cytoskeleton. Many apparently intact platelets found near the
obviously damaged platelets had more subtle membrane damage such as small holes
(Figure 39C) that were only visible at higher magnification. Large amounts of bound
gold-coated magnetite were observed in the areas where obvious damage occurred to the
platelet membranes.

The internal areas of treated platelet aggregates were examined by TEM to observe
damage in areas not easily analyzed by SEM. Platelet aggregates labeled with
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fibrinogen-conjugated colloidal gold in the absence (Figure 40A) or presence (Figure
40B) of OMF exposure displayed morphologies and labeling patterns similar to those
previously described (Chapters 2, 3). Platelet aggregates treated with fibrinogenconjugated, gold-coated magnetite but not exposed to the OMF displayed the same
labeling pattern and morphology as previously described (Chapter 3) (Figure 40C), and
appeared quite similar to the colloidal gold labeled aggregates. Platelet aggregates
labeled with fibrinogen-conjugated, gold-coated magnetite and exposed to the OMF often
had internal damage centered around areas with the highest nanoparticle concentration
(Figure 40D). The damaged areas have disrupted ultrastructure, making interpretation of
the damage difficult. It appears that the nanoparticles can disrupt the platelet membrane,
and by extension the open canalicular system (OCS) membrane. Disruption of the
membrane lead to areas where the cytoplasmic contents of the platelet were partially
released. In gold-coated magnetite labeled platelets exposed to the OMF, there were
areas within the platelet aggregate that had less nanoparticle labeling and appeared to
have normal ultrastructure similar to controls. TEM analysis was also performed on
string-like debris only observed in gold-coated magnetite labeled samples treated with the
OMF (Figure 41A, 41B). These membrane fragments appear to be derived from labeled
platelet membranes. The fragments were often heavily decorated with fibrinogenconjugated nanoparticles and appeared to still contain some associated material from the
cytoplasm (Figure 41B).
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Quantification of hyperthermic damage:
Quantification of hyperthermic damage in the aggregated platelet system presents a
unique challenge. Platelet aggregates are not discrete entities, but rather each consists of
many individual platelets, not all of which will be analyzed at one time by SEM. Initial
attempts to quantify damage to platelet aggregates were made using vital fluorescent
dyes, such as calcein-AM which measures esterase activity in the platelet cytoplasm.
These attempts were unsuccessful due to quenching of the fluorescent signal by colloidal
gold and gold-coated magnetite (not shown). It became necessary to develop a system to
quantify hyperthermic damage using a method that could directly observe the damage. A
system to quantify the area of intact platelets, fragmented platelets, and platelet-derived
debris was developed using SEM and a stereological point counting method. To validate
the method, a set of hyperthermic experiments were performed using platelets from three
blood donors. Platelets from each blood donor were treated with three different
preparations of gold-coated magnetite to examine the effects of OMF, blood donor, and
nanoparticle batch on hyperthermia. Multiple low magnification fields of platelets
labeled with fibrinogen-conjugated gold-coated magnetite, colloidal gold, or unlabeled
aggregates and exposed or unexposed to the OMF were imaged and quantified.
Examples of platelet aggregates labeled with fibrinogen-conjugated, gold-coated
magnetite with or without OMF exposure are shown in Figure 42A and Figure 42B,
respectively. Qualitatively, the gold-coated magnetite plus OMF sample exhibited
platelet damage and had large quantities of platelet-derived debris visible.
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Statistical analysis was performed on the assembled data set to test for the significance of
nanoparticle type, OMF exposure, gold-coated magnetite batch, and blood donor on
damage to platelet aggregates. Data were analyzed by defining either the points scored as
intact platelets, fragmented platelets, platelet-derived debris, (fragmented platelets +
debris), or the ratio of intact platelets over (fragmented platelets + debris) as dependent
variables. The ANOVA model that agreed best with the data generated in the surfaceactivated platelet system (Figure 37) used the ratio of intact platelets over (fragmented
platelets + debris) as the dependent variable (Table 1), showing differences due to the
type of label used (none, gold, gold-coated magnetite) and the OMF (present or absent),
but no significance due to the batch of gold-coated magnetite nanoparticles or blood
donor. For ease of comparison to the surface-activated platelet system, the ratio of intact
platelets over (fragmented platelets + debris) was converted to a percentage and plotted
(Figure 42C). A large increase in fragmented platelets and debris was observed in
aggregates treated with gold-coated magnetite and OMF exposure, as compared to all
other treatments, which did not show significant differences from one another.

Refinement of treatment parameters for platelet aggregate hyperthermia:
After validating the method to quantify hyperthermic damage to platelet aggregates, it
became possible to refine hyperthermia conditions. The effects of length of exposure to
the OMF were determined using the same quantification method, which used the ratio of
intact platelets to (fragmented platelets + debris) as the dependent variable for statistical
analysis. Samples were incubated for times ranging from 0 to 60 minutes in the OMF.
All samples were fixed after 60 minutes regardless of OMF exposure time. Increasing
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length of exposure to the OMF produced greater damage to platelets labeled with
fibrinogen-conjugated gold-coated magnetite (Figure 43A). OMF exposure to platelet
aggregates treated with fibrinogen-conjugated colloidal gold did not increase damage
above the background level observed in samples that were not exposed to the OMF.
Optimal treatment time appeared to be near the 30 minute exposure time point, with no
further significant increases in damage detected after 20 minutes.

Nanoparticle dosage was evaluated in a similar manner. Samples of 4 * 107 platelets
were aggregated and labeled with different amounts fibrinogen-conjugated, gold-coated
magnetite ranging from approximately 3.8 * 1010 nanoparticles (0.625% of the total
reaction volume) to 1.2 * 1012 nanoparticles (20% of the total reaction volume). The
resulting ratio of nanoparticles to platelets ranged from a minimum of approximately 950
nanoparticles/platelet to a maximum dose of 3 * 104 nanoparticles/platelet. As in
previous studies hyperthermic damage was observed only in samples treated with
fibrinogen-conjugated gold-coated magnetite and exposed to the OMF. Gold-coated
magnetite-treated samples without OMF exposure, samples labeled with fibrinogenconjugated colloidal gold with or without OMF exposure, and no label controls with or
without OMF exposure all displayed the same baseline level of platelet fragmentation.
Hyperthermic damage increased with increasing dosage of nanoparticles until a dose of 3
* 1011 nanoparticles (7.5 * 104 nanoparticles/platelet) was reached (Figure 43B). Further
increase in the nanoparticle dose did not produce a significant increase in observed
hyperthermic damage.
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Discussion

Fibrinogen-conjugated, gold-coated magnetite nanoparticles were evaluated for
hyperthermic based anti-platelet therapy. While hyperthermic effects on cancer cells have
been extensively studied, much less is known about platelet hyperthermia. We described
platelet hyperthermia, showing that it primarily affects the platelet membrane by causing
holes or tears, leaving internal areas of the platelet exposed. This was observed in both
the surface-activated and aggregated platelet systems. Hyperthermic damage was only
observed in platelets treated with targeted magnetite-containing nanoparticles and
exposed to an OMF. The hyperthermic damage was quantified using SEM to count the
damaged platelets or to estimate the sample area containing damaged platelets.
Quantification was later used to refine the hyperthermic conditions and increased
structural damage to platelets labeled with fibrinogen-conjugated gold-coated magnetite
and exposed to the OMF.

Basic hyperthermia components:
Magnetic field-induced hyperthermia would not be possible in our system without two
key components, an OMF generator and magnetic nanoparticles that can respond to the
OMF. Our lab-built OMF device was able to produce a 500 kHz, 8 mT magnetic field
while maintaining temperatures that will not cause non-specific hyperthermia. Specific
heating (i.e. temperature increase over the ddH2O control) of concentrated magnetite
nanoparticles that were capable of being coated with gold was between 5o to 10o C when
exposed to the OMF for 3 minutes. The temperature increase initially appears modest,
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but takes on greater significance when interpreted in the light of the fact that relatively
few nanoparticles are heating bulk water temperature. Nanoparticles in contact with a
cell surface are likely to transmit localized temperature increases far greater than what is
observed in bulk heating. For hyperthermic applications, only localized heating is
desired, and the heating we observed is expected to be sufficient.

Hyperthermic damage:
Hyperthermic damage was observed on surface-activated and aggregated platelets labeled
with fibrinogen-conjugated gold-coated magnetite and exposed to the OMF.
Interestingly, fragmented platelets were often found in the vicinity of healthy platelets.
These platelets did not display any hyperthermic damage despite being exposed to
identical conditions and residing mere m away from fragmented platelets. The healthy
platelets may not have bound as many nanoparticles or had different nanoparticle binding
patterns that did not efficiently promote damage. One possibility is that nanoparticles did
not become concentrated in the OCS of platelets that displayed little damage. Even in the
platelet surface-activated system, some platelet OCS often remains and becomes heavily
labeled with fibrinogen conjugated-nanoparticles (62, 63). A second possibility is that in
our gold-coated magnetite synthesis, a sub-population of gold-coated magnetite
nanoparticles is produced that is more capable of causing hyperthermia than rest of the
population. Only platelets that bound enough of the “high damage” nanoparticle
population would display significant damage, while other platelets are left intact. A third
possibility is that the intact platelets observed are damaged in a subtle manner that we
cannot easily detect by SEM. Hyperthermic membrane damage can appear subtle in
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other cell types (13). Irrespective of the intact platelet population, many fragmented
platelets were observed in the gold-coated magnetite with OMF treatment group,
confirming that this method can be used to destroy at least some appropriately labeled
platelets.

Hyperthermia primarily appeared to affect the integrity of the platelet membrane, leading
to bulk loss of membrane or development of holes. This fits well with expected damage
localization as every targeted gold-coated magnetite nanoparticle being heated is in close
vicinity to the platelet membrane, either on the surface of the platelet or within the OCS
which is still continuous with the outside of the platelet. In platelet aggregates, damage
observed by SEM was primarily on the surface of the aggregates, but was also seen in
internal portions of the aggregate by TEM. It is expected that much of the platelet
aggregate damage is unobserved by SEM because the majority of nanoparticles are
within the aggregate interior at platelet/platelet junctions or in the OCS.

Severe membrane damage had the secondary effect of causing cytoplasmic contents to
leak out and to expose the platelet cytoskeleton to the extracellular environment. The
loss of membrane integrity and weakening of cytoskeletal elements should reduce the
structural integrity of platelets in an aggregate or participating in a blood clot, which is
promising for the ultimate goal of disruption of a blood clot in an ischemic stroke.
However, the release of platelet cytoplasm, pieces of platelet membrane, and exposure of
polymerized actin filaments could increase inflammation levels at the blood clot site or
downstream from the newly cleared occlusion site (64-67). This could result in new
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occlusions, essentially causing another ischemic event. Further testing of the
prothrombotic molecules released by platelets during hyperthermia and testing the murine
in vivo system will help determine the levels of inflammation expected to arise as a
consequence of treatment.

Quantification of hyperthermic damage to platelets:
Platelets treated with nanoparticles present a difficult system for quantitative analysis of
cellular death due to a combination of platelet physiology and nanoparticle physics.
Many techniques used to study apoptosis or necrosis are ineffective at probing platelet
health. Mammalian platelets lack a nucleus, leading nuclear stains to only label the
mitochondria in platelets, limiting their potential utility. PS in most healthy cells is
confined to the inner leaflet of the cellular membrane, but moves to the outer leaflet
during apoptosis. However, PS is expressed on the platelet outer membrane leaflet
during activation. Our fibrinogen targeting methodology is designed to specifically target
activated, therefore PS-positive platelets, making PS detection an ineffective method to
quantify platelet damage. Perhaps the most confounding complication to analysis of
platelet death in our system is the ability of nanoparticles containing gold to quench
fluorescent signals both at the peak abosrption of gold nanoparticles (i.e. green
fluorochromes) and in areas where gold nanoparticles have weak absorption (i.e. red
fluorochromes). The quenching appeared to be caused by the sheer number of
nanoparticles binding to each platelet, effectively blocking the fluorescent signal. These
complications prevented us from using many commonly employed fluorescent assays for
apoptosis and necrosis.
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We addressed the difficulty in measuring platelet damage by directly observing the
treated samples using electron microscopy. The surface-activated platelet system was a
relatively simple analysis approach, as platelets could be individually counted as intact or
fragmented, making data collection fairly straightforward. The aggregated platelet
system was more difficult to analyze. Platelet aggregates are not discrete units, but
rather, are highly integrated collections of individual platelets, making quantitative
analysis of damage difficult. We found the best way to characterize the damage was by
estimating the area of the aggregated samples that contained intact platelets, fragmented
platelets, and platelet-derived debris by point counting images of the filter membranes.
Analyzing the effect of hyperthermia treatments on aggregated platelets using the ratio of
intact platelets to (fragmented platelets + debris) provided a number of advantages. This
ratio best accounted for the empty area of the membrane which was not otherwise
counted. The results of this analysis mirrored those of the surface-activated platelet
system, and also agreed well with the expectations based on our extensive experience
with human platelet aggregation and the performance of many batches of nanoparticles.
This method was validated by studying the effects of nanoparticle type, OMF exposure,
blood donor, and batch of gold-coated magnetite on the level of intact platelets,
fragmented platelets, and debris. The effects of nanoparticle type and OMF conditions
greatly affected platelet fragmentation. Blood donor and the batch of gold-coated
magnetite did not contribute significantly to the biological effect. However, their
contributions approached significance, suggesting they may have some effect on the
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trends observed for hyperthermia treatment. This is not surprising, given that both
parameters carry a great deal of inherent variability.

Improvements to hyperthermia treatment:
Aggregate quantification allowed us to refine the hyperthermia treatment in a quantifiable
manner. Optimal exposure time was found to be around 30 minutes, in agreement with
other hyperthermic studies on different cell types (10). Nanoparticles containing
magnetite likely gradually increase their temperature in response to the OMF until they
reach a maximum. This heat is transferred to the nearby membrane causing localized
damage to the cell. Heat transfer is cumulative, meaning nanoparticles in close proximity
to one another can probably create a higher temperature, more quickly at a specific
location than isolated nanoparticles. After that localized damage has occurred, further
damage to the cellular surface is unlikely, meaning longer exposures to the OMF will not
produce further damage. Hyperthermic damage to aggregated platelets was dependent on
the concentration of fibrinogen-conjugated, gold-coated nanoparticles. By varying the
dosage of nanoparticles per platelet through two orders of magnitude, it was possible to
observe a clear difference between low dosages and high dosages of nanoparticles. The
highest dose of nanoparticles tested approaches the estimated 4*104 copy number of
IIb3 present on platelet surfaces (68-70). This makes sense given the higher dosages
did not produce a significantly greater response, likely because the receptors were
saturated by both the nanoparticle conjugate and competing unconjugated fibrinogen in
solution.
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Implications for in vivo development:
Fibrinogen-conjugated gold-coated magnetite appears suitable for further development in
a murine in vivo model of arterial thrombosis. The nanoparticles in combination with the
OMF treatment were capable of causing structural damage to platelet aggregates in a
manner that may dissolve blood clots. Several important factors need to be considered
for in vivo development: first, no ferro- or ferri-magnetic objects may be in the coil
during operation, limiting options for murine temperature control. Further, dosing the
mouse with enough nanoparticles to cause therapeutic effects may be difficult. For the
maximum nanoparticle dose used in vitro, 20% of the entire reaction volume was the soft
pellet of nanoparticles. Injection of large amounts of conjugated nanoparticles into the
vasculature at once may cause inflammation or hemostatic problems, potentially
systemically. It is also likely that not all the nanoparticles will reach the blood clot.
Despite these concerns, tests of in vivo treatment to evaluate platelet hyperthermia as
potential ischemic stroke therapy should be pursued.
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Figures and Figure Legends:

Figure 33. Design of the oscillating magnetic field device. (A) shows the design of the
device as viewed from the side. The inductor coil is seen on the left size of the image
partially coated in vinyl tape. Coming off the inductor are copper conduction plates and
water cooling lines. A set of capacitors in series is in the middle of the device and is in
parallel with a variable capacitor on the right. The circuit is energized by the RF power
amplifier below the circuit. Tuning is performed using the indicated oscilloscope and
signal generator. During operation, the device is enclosed in a protective plexiglass box
(not shown). The circuit diagram for the device is shown in (B), arrows indicate where
the voltage drop is measured during tuning.
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Figure 33
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Figure 34. Temperature profiles of samples during OMF operation. (A) the localized
temperature of a non-magnetic sample during operation of the OMF under normal
cooling (squares), under maximum cooling (diamonds), and the measured temperature of
the inductive coil during OMF cycled operation (trigangles). Dashed lines indicate the
end of the on/off portion of the OMF cycle. (B) shows the calorimeter used to measure
nanoparticle heating within the OMF. The right well is loaded with magnetite
nanoparticles, the left well is loaded with ddH2O which acts as a non-specific heating
control. Thermocouples are visible leading into each well. A plot of the temperature
increase over ddH2O control of 23 batches of magnetite nanoparticles after 3 minutes of
OMF exposure is shown in (C). Magnetite nanoparticles that were successfully coated
with gold and subsequently produced platelet damage are indicated as diamonds.
Magnetite nanoparticles that failed to coat with gold or failed to produce platelet damage
are indicated as squares.
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Figure 34
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Figure 35. Controls for OMF-induced hyperthermia of fibrinogen-conjugated goldcoated magnetite-treated surface-activated platelets. A surface-activated platelet labeled
with fibrinogen conjugated to colloidal gold (FGN-Au) and not exposed to the OMF is
shown in (A). (B) shows a similarly labeled group of platelets that was exposed to the
OMF. (C) and (D) show platelets labeled with fibrinogen-conjugated gold-coated
magnetite (FGN-Au-Fe3O4), but not exposed to the OMF. All platelets display the
expected morphology and show minimal damage to their surface. Size bar is 2 m for all
images.
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Figure 36. OMF induced hyperthermia of fibrinogen-conjugated gold-coated magnetitetreated surface-activated platelets. All micrographs depict the typical types of damage
observed when surface-activated platelets are treated with fibrinogen-conjugated goldcoated magnetite nanoparticles and exposed to the OMF. Fragmented platelets show
damaged surfaces with much of the cellular membrane missing, shown in (A, B).
Remnants of the platelet membrane and internal platelet structures are often observed.
Well-labeled, intact platelets can often be observed in the vicinity of highly fragmented
platelets (arrowheads) in (C, D). Size bars are 5 m.
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Figure 37. Quantification of hyperthermic damage to surface-activated platelets. (A) and
(B) show typical low magnification fields used to quantify intact and fragmented
platelets. (A) demonstrates a field that was treated with fibrinogen-conjugated, goldcoated magnetite not exposed to the OMF, (B) shows a similarly labeled sample that was
exposed to the OMF. Arrows indicate examples of fragmented platelets. Many more
fragmented platelets are observed in platelets labeled with gold-coated magnetite and
exposured to the OMF. Size bar is 50 m for both images. Percent of fragmented
platelets found among platelets labeled with gold-coated magnetite, gold, or with no label
and either exposed to the OMF (dark bars) or unexposed (light bars) is shown in (C).
Only the platelet samples labeled with gold-coated magnetite and exposed to the OMF
demonstrated significantly levels of platelet fragmentation. Error bars show standard
deviation, * indicates p < 0.05 (n = 7).
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Figure 38. The effect of OMF exposure on platelet aggregates produced with
unconjugated fibrinogen, then labeled with fibrinogen-conjugated nanoparticles. Control
platelet aggregates that did not receive OMF exposure following labeling with
fibrinogen-conjugated colloidal gold or fibrinogen-conjugated, gold-coated magnetite are
shown in (A) and (B), respectively. Platelet aggregates exposed to the OMF after
incubation with unconjugated fibrinogen (C) or fibrinogen-conjugated colloidal gold (D)
have a similar appearance to aggregates that were not exposed to the OMF. Platelet
aggregates treated with fibrinogen-conjugated gold-coated magnetite and exposed to the
OMF had obvious structural damage, shown in two differently sized aggregates (E, F).
Areas where the membrane integrity of platelets in the aggregate is compromised are
indicated with arrows, demonstrating large holes or membranes with a "shredded"
appearance. Size bars are 5 m.

213

Figure 38
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Figure 39. Characterization of hyperthermic damage observed on a platelet aggregate.
An example of a gold-coated magnetite-labeled platelet aggregate treated with the OMF
is shown using both SE imaging (A) and BSE imaging (B). (C) depicts the area
highlighted in by the box in (A) using secondary electron imaging at a higher
magnification. Arrows indicate areas where the platelet membrane has been significantly
disrupted. The damaged area encompassed by the box in (C) is shown at higher
magnification using backscattered electron imaging in (D). The damaged area is clearly
very strongly labeled with gold coated magnetite, observed as bright regions in the BSE
image. Size bars are 5 m for (A,B) and 1 m for (C,D).
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Figure 40. TEM analysis of hyperthermic damage in platelets labeled with gold-coated
magnetite plus OMF exposure and control samples. Negative control platelet aggregates
labeled with fibrinogen-conjugated colloidal gold without OMF exposure (A) or with
OMF exposure (B). A platelet aggregate labeled with fibrinogen-conjugated gold-coated
magnetite but not exposed to the OMF is shown in (C). Hyperthermic damage to platelet
aggregates treated with fibrinogen-conjugated gold-coated magnetite and exposed to the
OMF is shown in (D). The lower portion of the aggregate is labeled heavily with goldcoated magnetite and the platelet ultrastructure is extremely damaged. Areas with less
labeling such as the top half of (D) show little to no damage similar to (C). Size bars are
2 m.
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Figure 40
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Figure 41. Platelet-derived membrane fragmentation observed by TEM after
hyperthermia. The string-like platelet membrane fragments depicted in (A, B) were
observed in ultrathin sections of platelet aggregates treated with fibrinogen-conjugated
gold-coated magnetite and exposed to the OMF, but not in any of the negative controls.
A higher magnification of the boxed area in (A) is shown in (B). The membrane
fragments are still decorated with nanoparticles (arrows) and other membrane associated
structures (arrowheads). Size bars are 1 m.
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Figure 41
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Figure 42. Quantification of hyperthermic damage to platelet aggregates. Typical fields
of platelets treated with fibrinogen-conjugated gold-coated magnetite without OMF
exposure (A) or with OMF exposure (B). The crosses indicate the exaggerated sampling
points used to quantify the area of intact and fragmented platelets as well as plateletderived debris. Size bar is 20 m for (A, B). The percent of the sample covered by
fragmented platelets plus debris for platelet aggregates labeled with gold-coated
magnetite, gold, or with no label (buffer) and either exposed or not exposed to the OMF
is shown in (C). Error bars show standard deviation, * indicates p < 0.01, n = 9 for goldcoated magnetite groups, n = 3 for colloidal gold and buffer controls.
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Figure 43. Quantification of aggregate damage under different OMF conditions. The
percent fragmentation and platelet debris in platelet aggregates labeled with fibrinogenconjugated gold-coated magnetite (diamonds) or fibrinogen-conjugated colloidal gold
(squares) and exposed to the OMF for varying lengths of time is depicted in (A). Platelet
aggregates were labeled with differing amounts of fibrinogen-conjugated, gold-coated
magnetite and exposed to the OMF for 30 minutes in (B). Error bars are standard
deviation, letters indicate groups that are at the same level of significance, n =3.

222

Figure 43
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Tables

Table 1. ANOVA analysis of the effects of hyperthermia on aggregated platelets using
different models in the SAS PROC MIXED procedure. Models based on point counting
of intact platelets, fragmented platelets, platelet-derived debris, and the ratio of intact
platelets to (fragmented platelets + debris) were used as dependent variables. The
significance of 4 independent variables, the type of nanoparticle, the specific batch of
gold-coated magnetite used, OMF exposure, and the blood donor, was determined for
each dependent variable. The amount of intact platelets was significantly affected by the
OMF and the blood donor, but not by nanoparticle type or batch of gold-coated
magnetite. When fragmented platelets were used as the dependent variable, nanoparticle
type, OMF exposure, and the blood donor were significant. Platelet-derived debris was
significantly affected by the nanoparticle type, batch of gold-coated magnetite, and the
OMF. The ratio of intact platelets to (fragmented platelets + debris) demonstrated
significance in nanoparticle type and OMF exposure, but not to gold-coated magnetite
batch or blood donor. n = 30, sample means derived from 150 fields of view.

224
References:

1.

Roti Roti, J. L. 2008. Cellular responses to hyperthermia (40-46 C): Cell killing
and molecular events. Int. J. Hyperthermia 24:3-15.

2.

Li, S., S. Chien, and P. I. Brånemark. 1999. Heat shock-induced necrosis and
apoptosis in osteoblasts. J. Orthop. Res. 17:891-899.

3.

Ito, A., H. Honda, and T. Kobayashi. 2006. Cancer immunotherapy based on
intracellular hyperthermia using magnetite nanoparticles: A novel concept of
"heat-controlled necrosis" with heat shock protein expression. Cancer Immunol.
Immunother. 55:320-328.

4.

Harmon, B. V., Y. S. Takano, C. M. Winterford, and G. C. Gobé. 1991. The role
of apoptosis in the response of cells and tumours to mild hyperthermia. Int. J.
Radiat. Biol. 59:489-501.

5.

Busch, W. 1866. Uber den Einfluss weichen Hefttigere Erysipelen zuweilen auf
Organisierte Neubildugen Ausuken Verhandl. Naturh. Ver. Preuss. Rheinl. 23:2830.

6.

Vidair, C. A., and W. C. Dewey. 1988. Two distinct modes of hyperthermic cell
death. Radiat. Res. 116:157-171.

7.

Vaupel, P. W., and D. K. Kelleher. 2010. Pathophysiological and vascular
characteristics of tumours and their importance for hyperthermia: Heterogeneity is
the key issue. Int. J. Hyperthermia 26:211-223.

8.

Konings, A. 1988. Membranes as targets for hyperthermic cell killing. In
Preclinical Hyperthermia. W. Hinkelbein, G. Bruggmoser, R. Englhardt, and M.
Wannenmacher, eds. Springer, Berlin. 9-21.

9.

Mulcahy, R., M. Gould, E. Hidvergi, C. Elson, and M. Yatvin. 1981.
Hyperthermia and surface morphology of P388 ascites tumour cells: Effects of
membrane modifications. Int. J. Radiat. Biol. Stud. Phys. Chem. Med. 39:95-106.

10.

Prasad, N., K. Rathinasamy, D. Panda, and D. Bahadur. 2007. Mechanism of cell
death induced by magnetic hyperthermia with nanoparticles of γ-MnxFe2− xO3
synthesized by a single step proces. J. Mater. Chem. 17:5042-5051.

11.

Coss, R. A., W. C. Dewey, and J. R. Bamburg. 1982. Effects of hyperthermia on
dividing chinese hamster ovary cells and on microtubules in vitro. Cancer Res.
42:1059-1071.

225
12.

Storm, F. K., W. H. Harrison, R. S. Elliott, and D. L. Morton. 1980. Hyperthermic
therapy for human neoplasms: Thermal death time. Cancer 46:1849-1854.

13.

Asin, L., M. R. Ibarra, A. Tres, and G. F. Goya. 2012. Controlled cell death by
magnetic hyperthermia: Effects of exposure time, field amplitude, and
nanoparticle concentration. Pharm. Res. 29:1319-1327.

14.

Jordan, A., R. Scholz, K. Maier-Hauff, M. Johannsen, P. Wust, J. Nadobny, H.
Schirra, H. Schmidt, S. Deger, S. Loening, W. Lanksch, and R. Felix. 2001.
Presentation of a new magnetic field therapy system for the treatment of human
solid tumors with magnetic fluid hyperthermia. J. Magn. Magn. Mater. 225:118126.

15.

Sonvico, F., S. Mornet, S. Vasseur, C. Dubernet, D. Jaillard, J. Degrouard, J.
Hoebeke, E. Duguet, P. Colombo, and P. Couvreur. 2005. Folate-conjugated iron
oxide nanoparticles for solid tumor targeting as potential specific magnetic
hyperthermia mediators: Synthesis, physicochemical characterization, and in vitro
experiments. Bioconjugate Chem. 16:1181-1188.

16.

Krystofiak, E. S., V. Z. Matson, D. A. Steeber, and J. A. Oliver. 2012.
Elimination of tumor cells using folate receptor targeting by antibody-conjugated,
gold-coated magnetite nanoparticles in a murine breast cancer model. J. Nanomat.
2012:431012.

17.

Kaiser, M., J. Heintz, I. Kandela, and R. Albrecht. 2007. Tumor cell death
induced by membrane melting via immunotargeted, inductively heated core/shell
nanoparticles. Microsc. Microanal. 13:18-19.

18.

Nikfarjam, M., V. Muralidharan, C. Malcontenti-Wilson, and C. Christophi. 2005.
The apoptotic response of liver and colorectal liver metastases to focal
hyperthermic injury. Anticancer Res. 25:1413-1419.

19.

Vlad, M., C. Şerboiu, A. T. Ispas, I. Giuvărăşteanu, E. Ungureanu, and N.
Ionescu. 2013. Electron microscopy of the morphological changes in rat viscera
during experimental hyperthermic shock. J. Med. Life 6:55-60.

20.

Chu, M., Y. Shao, J. Peng, X. Dai, H. Li, Q. Wu, and D. Shi. 2013. Near-infrared
laser light mediated cancer therapy by photothermal effect of Fe3O4 magnetic
nanoparticles. Biomaterials 34:4078-4088.

21.

Guardia, P., R. Di Corato, L. Lartigue, C. Wilhelm, A. Espinosa, M. GarciaHernandez, F. Gazeau, L. Manna, and T. Pellegrino. 2012. Water-soluble iron
oxide nanocubes with high values of specific absorption rate for cancer cell
hyperthermia treatment. ACS Nano 6:3080-3091.

226
22.

Kobayashi, T. 2011. Cancer hyperthermia using magnetic nanoparticles.
Biotechnol. J. 6:1342-1347.

23.

Srivastava, P. K., A. Menoret, S. Basu, R. J. Binder, and K. L. McQuade. 1998.
Heat shock proteins come of age: Primitive functions acquire new roles in an
adaptive world. Immunity 8:657-665.

24.

Huff, T. B., L. Tong, Y. Zhao, M. N. Hansen, J. X. Cheng, and A. Wei. 2007.
Hyperthermic effects of gold nanorods on tumor cells. Nanomedicine (Lond)
2:125-132.

25.

DeNardo, S. J., G. L. DeNardo, A. Natarajan, L. A. Miers, A. R. Foreman, C.
Gruettner, G. N. Adamson, and R. Ivkov. 2007. Thermal dosimetry predictive of
efficacy of 111In-ChL6 nanoparticle AMF–induced thermoablative therapy for
human breast cancer in mice. J. Nucl. Med. 48:437-444.

26.

Muckle, D. S., and J. A. Dickson. 1971. The selective inhibitory effect of
hyperthermia on the metabolism and growth of malignant cells. Br. J. Cancer
25:771-778.

27.

Shinkai, M., M. Yanase, H. Honda, T. Wakabayashi, J. Yoshida, and T.
Kobayashi. 1996. Intracellular hyperthermia for cancer using magnetite cationic
liposomes: in vitro study. Jpn. J. Cancer Res. 87:1179-1183.

28.

Shiu, M. H., and J. G. Fortner. 1980. Intraperitoneal hyperthermic treatment of
implanted peritoneal cancer in rats. Cancer Res. 40:4081-4084.

29.

Storm, F. K., W. H. Harrison, R. S. Elliott, and D. L. Morton. 1979. Normal tissue
and solid tumor effects of hyperthermia in animal models and clinical trials.
Cancer Res. 39:2245-2251.

30.

Mazzucchelli, S., M. Colombo, C. De Palma, A. Salvade, P. Verderio, M. D.
Coghi, E. Clementi, P. Tortora, F. Corsi, and D. Prosperi. 2010. Single-domain
protein A-engineered magnetic nanoparticles: Toward a universal strategy to sitespecific labeling of antibodies for targeted detection of tumor cells. ACS Nano
4:5693-5702.

31.

Gupta, A. K., and M. Gupta. 2005. Synthesis and surface engineering of iron
oxide nanoparticles for biomedical applications. Biomaterials 26:3995-4021.

32.

Huang, X., P. K. Jain, I. H. El-Sayed, and M. A. El-Sayed. 2006. Determination
of the minimum temperature required for selective photothermal destruction of
cancer cells with the use of immunotargeted gold nanoparticles. Photochem.
Photobiol. 82:412-417.

227
33.

Goodrich, G. P., L. Bao, K. Gill-Sharp, K. L. Sang, J. Wang, and J. D. Payne.
2010. Photothermal therapy in a murine colon cancer model using near-infrared
absorbing gold nanorods. J. Biomed. Opt. 15:018001-018001.

34.

Zharov, V. P., E. N. Galitovskaya, C. Johnson, and T. Kelly. 2005. Synergistic
enhancement of selective nanophotothermolysis with gold nanoclusters: Potential
for cancer therapy. Lasers Surg. Med. 37:219-226.

35.

Gannon, C. J., C. R. Patra, R. Bhattacharya, P. Mukherjee, and S. A. Curley.
2008. Intracellular gold nanoparticles enhance non-invasive radiofrequency
thermal destruction of human gastrointestinal cancer cells. J. Nanobiotechnology
6:2.

36.

Moran, C. H., S. M. Wainerdi, T. K. Cherukuri, C. Kittrell, B. J. Wiley, N. W.
Nicholas, S. A. Curley, J. S. Kanzius, and P. Cherukuri. 2009. Size-dependent
joule heating of gold nanoparticles using capacitively coupled radiofrequency
fields. Nano. Res. 2:400-405.

37.

Rudolf, H., D. Silvio, M. Robert, and Z. Matthias. 2006. Magnetic particle
hyperthermia: Nanoparticle magnetism and materials development for cancer
therapy. J. Phys: Condens. Matter 18:S2919.

38.

Laurent, S., S. Dutz, U. O. Häfeli, and M. Mahmoudi. 2011. Magnetic fluid
hyperthermia: Focus on superparamagnetic iron oxide nanoparticles. Adv. Colloid
Interface Sci. 166:8-23.

39.

Prevo, B. G., S. A. Esakoff, A. Mikhailovsky, and J. A. Zasadzinski. 2008.
Scalable routes to gold nanoshells with tunable sizes and response to near-infrared
pulsed-laser irradiation. Small 4:1183-1195.

40.

Cole, J. R., N. A. Mirin, M. W. Knight, G. P. Goodrich, and N. J. Halas. 2009.
Photothermal efficiencies of nanoshells and nanorods for clinical therapeutic
applications. J. Phys. Chem. C 113:12090-12094.

41.

Huang, X., W. Qian, I. H. El-Sayed, and M. A. El-Sayed. 2007. The potential use
of the enhanced nonlinear properties of gold nanospheres in photothermal cancer
therapy. Lasers Surg. Med. 39:747-753.

42.

Hirsch, L. R., R. J. Stafford, J. A. Bankson, S. R. Sershen, B. Rivera, R. E. Price,
J. D. Hazle, N. J. Halas, and J. L. West. 2003. Nanoshell-mediated near-infrared
thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad.
Sci. USA 100:13549-13554.

43.

Vera, J., and Y. Bayazitoglu. 2009. A note on laser penetration in nanoshell
deposited tissue. Int. J. Heat Mass Transfer 52:3402-3406.

228
44.

Gordon, R. T., J. R. Hines, and D. Gordon. 1979. Intracellular hyperthermia. A
biophysical approach to cancer treatment via intracellular temperature and
biophysical alterations. Med. Hypotheses 5:83-102.

45.

Fortin, J. P., F. Gazeau, and C. Wilhelm. 2008. Intracellular heating of living cells
through Neel relaxation of magnetic nanoparticles. Eur. Biophys. J. 37:223-228.

46.

Strohbehn, J. W., and E. B. Douple. 1984. Hyperthermia and cancer therapy: A
review of biomedical engineering contributions and challenges. IEEE Trans.
Biomed. Eng. 31:779-787.

47.

Pankhurst, Q. A., J. Connolly, S. K. Jones, and J. Dobson. 2003. Applications of
magnetic nanoparticles in biomedicine. J. Phys D: Appl. Phys. 36:R167.

48.

Hilger, I., R. Hiergeist, R. Hergt, K. Winnefeld, H. Schubert, and W. A. Kaiser.
2002. Thermal ablation of tumors using magnetic nanoparticles: An in vivo
feasibility study. Invest. Radiol. 37:580-586.

49.

Johannsen, M., B. Thiesen, A. Jordan, K. Taymoorian, U. Gneveckow, N.
Waldöfner, R. Scholz, M. Koch, M. Lein, K. Jung, and S. A. Loening. 2005.
Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in the
orthotopic Dunning R3327 rat model. Prostate 64:283-292.

50.

Lattuada, M., and T. A. Hatton. 2006. Functionalization of monodisperse
magnetic nanoparticles. Langmuir 23:2158-2168.

51.

Mornet, S., J. Portier, and E. Duguet. 2005. A method for synthesis and
functionalization of ultrasmall superparamagnetic covalent carriers based on
maghemite and dextran. J. Magn. Magn. Mater. 293:127-134.

52.

Hu, F. Q., L. Wei, Z. Zhou, Y. L. Ran, Z. Li, and M. Y. Gao. 2006. Preparation of
biocompatible magnetite nanocrystals for in vivo magnetic resonance detection of
cancer. Adv. Mater. 18:2553-2556.

53.

Wang, Z., Q. Shi, S. Li, J. Du, J. Liu, and K. Dai. 2010. Hyperthermia induces
platelet apoptosis and glycoprotein Ibα ectodomain shedding. Platelets 21:229237.

54.

Etulain, J., M. J. Lapponi, S. J. Patrucchi, M. A. Romaniuk, R. Benzadón, G. L.
Klement, S. Negrotto, and M. Schattner. 2011. Hyperthermia inhibits platelet
hemostatic functions and selectively regulates the release of alpha-granule
proteins. J. Thromb. Haemost. 9:1562-1571.

55.

Nakayama, T., and W. Nakamura. 1984. Platelet aggregation induced in mice by
whole-body hyperthermia. Radiat. Res. 98:583-590.

229
56.

Strother, S. V., J. M. Bull, and S. A. Branham. 1986. Activation of coagulation
during therapeutic whole body hyperthermia. Thromb. Res. 43:353-360.

57.

Bevers, E. M., P. Comfurius, and R. F. Zwaal. 1983. Changes in membrane
phospholipid distribution during platelet activation. Biochim. Biophys. Acta
736:57-66.

58.

Leytin, V., D. J. Allen, E. Lyubimov, and J. Freedman. 2007. Higher thrombin
concentrations are required to induce platelet apoptosis than to induce platelet
activation. Br. J. Haematol. 136:762-764.

59.

Vanags, D. M., S. Orrenius, and M. Aguilar-Santelises. 1997. Alterations in Bcl2/Bax protein levels in platelets form part of an ionomycin-induced process that
resembles apoptosis. Br. J. Haematol. 99:824-831.

60.

Ellis, E. A. 2006. Solutions to the problem of substitution of ERL 4221 for vinyl
cyclohexene dioxide in spurr low viscoity embedding formulations. Microsc.
Today 14:32-33.

61.

Holdorf, M. M., H. A. Owen, S. R. Lieber, L. Yuan, N. Adams, C. Dabney-Smith,
and C. A. Makaroff. 2012. Arabidopsis ETHE1 encodes a sulfur dioxygenase that
is essential for embryo and endosperm development. Plant Physiol. 160:226-236.

62.

Simmons, S. R., and R. M. Albrecht. 1996. Self-association of bound fibrinogen
on platelet surfaces. J. Lab. Clin. Med. 128:39-50.

63.

Escolar, G., E. Leistikow, and J. G. White. 1989. The fate of the open canalicular
system in surface and suspension-activated platelets. Blood 74:1983-1988.

64.

Ginsberg, M. H., F. Kozin, M. O'Malley, and D. J. McCarty. 1977. Release of
platelet constituents by monosodium urate crystals. J. Clin. Invest. 60:999-1007.

65.

Ahrens, S., S. Zelenay, D. Sancho, P. Hanč, S. Kjaer, C. Feest, G. Fletcher, C.
Durkin, A. Postigo, M. Skehel, F. Batista, B. Thompson, M. Way, C. Reis e
Sousa, and O. Schulz. 2012. F-actin is an evolutionarily conserved damageassociated molecular pattern recognized by DNGR-1, a receptor for dead cells.
Immunity 36:635-645.

66.

Blair, P., and R. Flaumenhaft. 2009. Platelet α-granules: Basic biology and
clinical correlates. Blood Rev. 23:177-189.

67.

McNicol, A., and S. J. Israels. 1999. Platelet dense granules: Structure, function
and implications for haemostasis. Thromb. Res. 95:1-18.

230
68.

Marguerie, G. A., E. F. Plow, and T. S. Edgington. 1979. Human platelets possess
an inducible and saturable receptor specific for fibrinogen. J. Biol. Chem.
254:5357-5363.

69.

Bennett, J. S., and G. Vilaire. 1979. Exposure of platelet fibrinogen receptors by
ADP and epinephrine. J. Clin. Invest. 64:1393-1401.

70.

McEver, R. P., N. L. Baenziger, and P. W. Majerus. 1980. Isolation and
quantitation of the platelet membrane glycoprotein deficient in thrombasthenia
using a monoclonal hybridoma antibody. J. Clin. Invest. 66:1311-1318.

231

Chapter 5: Conclusions

232

Fibrinogen targeting to select for activated platelets:
Targeting platelets through their fibrinogen receptor, the integrin IIb3, has been
recognized as a powerful tool for anti-platelet therapy (1). This integrin is present at high
copy number on each platelet (2-4) and its competency to bind fibrinogen is tightly
controlled through distinct conformational changes in the integrin (5). Ligand crosslinked IIb3 centralizes along the platelet membrane, concentrating the bound fibrinogen
(6, 7). This can be exploited to concentrate fibrinogen conjugates to increase therapeutic
effects such as localized hyperthermia. We built upon earlier studies to show that
fibrinogen-conjugated nanoparticles will selectively bind to an activated platelet
population. Antibody treatments, such as abciximab, that do not discriminate well
between populations of activated and quiescent platelets, are associated with increased
bleeding risk (8). The capacity of fibrinogen to select for the activated population of
platelets provides a powerful tool to directly target platelets involved in a thrombus while
leaving circulating platelets unaffected, and is therefore expected to deliver significant
therapeutic benefit.

Fibrinogen-based targeting, however, has some complications that must be considered.
In both the murine and human in vivo systems, activated platelets will be bathed in
unconjugated free fibrinogen from the blood. Fibrinogen from blood binds to unoccupied
IIb3 receptors. Once these IIb3 receptors are occupied, the targeted fibrinogen
conjugate will no longer be able to bind to that site. In our studies we observed reduced
conjugate binding when we labeled preformed aggregates in the presence of
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unconjugated fibrinogen as compared to gel-filtered platelets aggregated with fibrinogen
conjugates as the only source of supplemental fibrinogen. Similarly, labeling with
fibrinogen-conjugated colloidal gold or gold-coated magnetite was further reduced in
aggregated platelet-rich plasma. While the number of bound nanoparticles was reduced
when compared to aggregates produced using conjugated nanoparticles, the labeling was
still at a fairly high density. Nanoparticle labeling was inhibited even further in blood
clot-like platelet aggregates that contained fibrin, the polymerized product of thrombincleaved fibrinogen, as observed in platelet-rich plasma samples aggregated with
thrombin. The reduction in binding is likely caused by binding of plasma fibrinogen to
the platelets in combination with steric hindrance from the fibrin within the platelet
aggregate. A true blood clot would likely have similar labeling to thrombin-aggregated
platelet-rich plasma.

The reduction in binding may be dealt with by modifications to the original targeting
strategy. Many ligand-induced binding site monoclonal antibodies have been developed
against IIb3 (9-12). These antibodies select for the activated conformation of IIb3
which is only present on activated platelets. Careful selection or development of a new
antibody that recognizes the active conformation of IIb3 and is not sterically hindered
by fibrinogen bound to IIb3 would allow for the same IIb3 targeting methodology we
employed. However, the antibody would alleviate the problem of unconjugated
fibrinogen limiting the number of binding sites. Penetration of the conjugate into the clot
may still be problematic, although we expect the normal movement of cross-linked
receptors to at least partially address this issue.
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Fibrin within blood clots can likely impair conjugates, fibrinogen- or antibody-based,
from binding to the activated platelets through steric hindrance. This may be dealt with
in future studies in two different ways, first, nanoparticles could be conjugated with
fragments of fibrinogen rather than the entire molecules, this will reduce the hydrated
nanoparticle diameter causing less steric hindrance. Second, the therapy could include
co-administration of tPA along with conjugated nanoparticles. The tPA will lyse the
fibrin within the blood clot causing a reduction in the structural integrity of the blood
clot. tPA will have the added benefit in this situation of reducing the amount of fibrin
around the blood clot, allowing the nanoparticles to more easily reach their targets and
cause their desired effect. Further, with or without tPA, fibrinogen conjugates may
integrate into the fibrin network in a blood clot and may be able to promote clot release
by causing hyperthermia to the fibrin network thereby directly, providing a second
method to help dissolve the blood clot.

Hyperthermia on platelets labeled with gold-coated magnetite in the presence of a
magnetic field:
The effects of hyperthermia on cancer are well represented in the literature (13-18). The
effects of hyperthermia on platelets are poorly understood and even contain some
apparent contradictory claims of both impairing platelet aggregation and adhesion, and
causing them (19-21). We examined the effects of localized hyperthermia on platelets by
use of fibrinogen-conjugated gold-coated magnetite that was exposed to an oscillating
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magnetic field. The primary effect of hyperthermia on platelets was disruption of the
platelet membrane. Surface-activated platelets lost a large portion of their membrane and
associated structure during hyperthermic treatments. Similarly, aggregated platelets often
displayed areas of the aggregate containing holes that revealed apparent internal
cytoskeletal elements. The extent of damage observed is expected to be sufficient to
cause a reduction in the structural integrity of the platelets, weakening a potential blood
clot.

In all experiments where fibrinogen-conjugated, gold-coated magnetite-labeled platelets
were exposed to the OMF, some platelets appeared unaffected by hyperthermia. It is
possible we were unable to detect more subtle damage to the platelets using electron
microscopy, but it is also unlikely that damage so subtle that it is beyond the resolution of
electron microscopy would structurally weaken the platelets enough to have any
significant biological effect. Alternatively, the intact platelet may not have experienced
the same hyperthermic conditions as the neighboring fragmented platelets due to
differences in labeling intensity or localization. Nanoparticles localized close together on
the platelet membrane will cause a greater temperature rise at that site than if they were
evenly dispersed. A second possibility is that the different morphologies of gold-coated
magnetite have different abilities to cause hyperthermic damage. Platelets that bind a
large amount of one particular nanoparticle morphology may experience greater localized
hyperthermia, causing those platelets to fragment while others do not. These
morphologies include the isolated and aggregated nanoparticles described here, but may
also include yet uncharacterized morphologies. Modulation of the length of exposure to
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the OMF and dosage of nanoparticles to platelets demonstrates that optimization of the
hyperthermic protocol increases the level of platelet fragmentation. Additional iterations
of optimization may produce even more dramatic results.

Further improvements to platelet hyperthermia may come from adjustment of the
oscillation frequency of the magnetic field. These studies utilized a 500 kHz oscillation
that was previously described for hyperthermic applications using gold-coated magnetite
nanoparticles (22). Because superparamagnetic nanoparticles may be heated at lower
frequencies below 500 kHz (18, 23-25), it is possible that our gold-coated magnetite may
heat more efficiently at lower frequencies. The existing design of the OMF device makes
it difficult to vary the frequency of the OMF in a time efficient manner, and essentially
requires the entire circuit to be rebuilt and retuned. Replacing the capacitive elements
with an impedance matching network would allow real time frequency modifications
without causing reflective power. Refinements in the OMF frequency could result in
hyperthermic treatments that are more effective and shorter in duration.

Implications for in vivo treatment in a murine model:
The next logical step for evaluation of fibrinogen-conjugated gold-coated magnetite for
use as a platelet targeted ischemic stroke treatment is in vivo testing using a murine
model of carotid artery thrombosis. We already examined the use of conjugated human
fibrinogen in a murine system and found that its targeting ability was similar to that of
conjugated murine fibrinogen. We have further examined the use of conjugates in
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systems that approximate an in vivo blood clot as closely as possible in an in vitro system
and found that nanoparticle binding does occur. Future studies will use the ferric
chloride injury model to produce platelet-rich thrombi in murine carotid arteries. The
occlusive clots formed with this method closely resemble those seen in human stroke
patients (26, 27). Fibrinogen-conjugated gold-coated nanoparticles would be
administered and either the entire mouse, or the anterior one-half to one-third of the
animal, treated within the OMF. The treatment could be monitored by measuring blood
flow through the artery by use of an ultrasonic probe. After the treatment is complete the
success of the treatment can be assessed by electron microscopy. The entire procedure
would be technically challenging. Microsurgery exposing the carotid artery of an
anesthetized mouse must be performed in a manner that minimizes damage to the vessel
and surrounding tissue. Our studies into the effect of nanoparticle dose on platelet
hyperthermia showed a strong correlation between dose and level of platelet disruption.
For the murine studies, it will be essential to deliver as many nanoparticles to the blood
clot as possible. Effective delivery of fibrinogen-conjugated gold-coated magnetite
nanoparticles to the blood clot will not be trivial. The best possible delivery method is to
administer the nanoparticles by catheter to the site of the blood clot, but would be
technically challenging due to the size of the murine vasculature and the fact that
catheterizing an artery can often cause thrombotic events in itself. Alternatively,
nanoparticles could be administered at the highest possible levels by tail vein injection
and use normal blood circulation to distribute the nanoparticles to the activated platelets
at the occlusion site. Blood flow at the site of occlusion is severely restricted which
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might prevent nanoparticles from reaching the occlusion site when administered in this
manner.

While technically challenging, the results of our evaluation of fibrinogen-conjugated
gold-coated magnetite for anti-platelet therapy suggest that murine feasibility studies
should be pursued in an effort to further develop this ischemic stroke treatment.
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